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Recently, two separate high-throughput screens (HTS) identified itraconazole 
(ITZ), a well-known antifungal agent, as both an inhibitor of the hedgehog (Hh) pathway 
and angiogenesis (IC50 = 690 nM and 160 nM, respectively).  Dysregulation of both the 
Hh pathway and angiogenesis are implemented in the growth and metastasis of various 
types of cancer.  Aberrant Hh signaling may lead to cell proliferation and tumor growth 
most notably associated with basal cell carcinoma (BCC) and medulloblastoma (MB).  
Currently, there are a few Hh pathway inhibitors that are FDA approved for the 
treatment of BCC.  However, there has been an emergence of resistance towards these 
compounds highlighting the need for novel Hh pathway inhibitors. The ITZ scaffold has 
not been thoroughly explored in terms of Hh pathway inhibition.  As a result, four 
generations of ITZ analogues were designed, synthesized, and evaluated for Hh 
pathway inhibitory activity.  Structure-activity relationship (SAR) studies indicated that 
the triazole moiety is not necessary for potent Hh pathway inhibition and removal of this 
functionality also abolishes coordination with CYP3A4.  While the stereochemistry of the 
sec-butyl side chain region was not important, stereochemistry at the 4-position of the 
dioxolane ring proved to be crucial.  In terms of the triazolone/side-chain region of the 
scaffold, truncation of the side-chain region to the free triazolone and truncation of the 
triazolone to smaller moieties (–NO2 and –NH2) maintain potency.  Amide functionality 
in replacement of the triazolone/side-chain region is tolerated with preference to polar 
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substituents at the meta- position of the phenyl ring.  Early evidence suggests that cyclic 
functionality is not necessary within the triazolone region indicating that acyclic 
functionalities could be explored for Hh pathway inhibitory activity.  A subset of ITZ 
analogues was evaluated in two additional assays to explore angiogenesis inhibitory 
activity.  Results indicated that the triazole region of ITZ seems to be important for 
angiogenesis inhibition.  Overall, a total of 60 analogues were designed, synthesized, 
and evaluated to thoroughly explore the ITZ scaffold in terms of these novel biological 
activities.  In addition to these medicinal chemistry efforts, a preliminary ITZ liposome 
formulation was designed and evaluated in vitro for Hh pathway inhibition. 
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CHAPTER I: Repurposing Itraconazole as an Anticancer Chemotherapeutic 
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1. Introduction 
1.1 Drug Repurposing 
 Drug development is a long and expensive process; on average it takes about 
13-15 years and $2-3 billion for a drug to become clinically approved.1 To bypass this 
route, it is becoming increasingly popular to explore FDA-approved or clinical stage 
compounds for novel biological activities.  Applying an existing therapeutic towards a 
novel biological indication can be described as drug repurposing or drug repositioning.1 
FDA-approved compounds have already been deemed safe in phase I clinical trials and 
as a result, many of these drugs can immediately enter phase II clinical trials for new 
disease indications.  It has been estimated to cost $300 million and take 6.5 years to 
repurpose a clinically approved drug for a novel ailment (Figure 1).2 Drug repurposing 
may also help improve Eroom’s Law which can be described as the efficiency of 
research and development of new drugs in the United States; on average, this number 
is said to be cut in half every nine years. 1,2  
Figure 1. Drug Discovery Pipeline2 
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 Although there are clear benefits from drug repurposing, most successes to date 
have been serendipitous (Figure 2).1 Some of these successes include repurposing 
sildenafil, a phosphodiesterase inhibitor designed for angina, which is now marketed as 
Viagra to treat erectile dysfunction.1,3  The antibiotic erythromycin has been repurposed 
for impaired gastric motility.  Finally, even drugs with detrimental side effects have been 
successfully repurposed for novel indications.  Thalidomide, originally an antiemetic, is 
now approved for the treatment of multiple myeloma.3 Side effects such as 
teratogenicity may be acceptable for treatment of a life-threatening disease but are not 
ideal for treatment of a chronic disease such as nausea.3 It is important to consider the 
risk versus reward aspect when repurposing a drug.1,2  Drug repurposing is especially 
advantageous during disease epidemics when there is not enough time for a novel 
therapeutic to go through the drug development pipeline.4 For example, the global 
outbreaks of both the Ebola and Zika viruses affected a large population of our world 
and there is still an immediate need for better treatment and/or prevention.  High 
throughput screening efforts of FDA-approved and clinical stage drugs have been 
performed for both of these disease indications.5,6 
 
Figure 2. Structures of Representative Repurposed Drugs 
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 In addition to the plethora of benefits, there are also a few downfalls to this drug 
repurposing strategy.  First, if the dose or mode of administration is significantly different 
from the original indication, the compound will have to be entered into phase I safety 
clinical trials.1–3 As drug repurposing is based upon improving time and cost efficiency, 
this raises a huge argument.  In addition, it is difficult to obtain the rights to explore 
novel compounds for new indications.1–3 Generally, pharmaceutical companies are 
going to explore potential secondary indications before other pharmaceutical 
competitors or academia can obtain them.1 Overall, drug repurposing is a promising 
form of drug development but there are still challenges associated with bypassing 
clinical stages and maintaining time/cost efficacy.1,3 
 Modern drug discovery focuses on the development of a drug candidate that has 
high selectivity and potency for one target.  “Promiscuous drugs” or “dirty drugs”, which 
have multiple biological activities and target sites, tend to have a negative reputation 
due to their presumed increase in side effects.7 However, this idea of one drug having 
multiple activities, known as polypharmacology, is gaining a renewed appreciation.7 
When a single-target drug is being used, cells may acquire resistance or decrease their 
dependence on that specific target.  For instance, in diseases such as cancer, there is 
generally a high rate of genetic mutations, which may lead to certain populations of 
cancer cells that are drug resistant; this ultimately results in treatment failure.7 Drugs 
that are able to treat a variety of different diseases may be beneficial in drug 
development as well as drug repurposing.  It is also advantageous to develop one drug 
that has multiple different biological activities as opposed to using combination therapy.7 
The use of drug cocktails complicates and inconveniences patients, increases the 
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prevalence of acute and delayed toxicities, and results in unpredictable pharmacokinetic 
properties.  It is more appealing and cost efficient to develop single-molecule drugs with 
multiple activities rather than administering multiple drug combinations within a single 
cocktail.7 
1.2 Itraconazole 
 
Figure 3. Structures and Regions of Itraconazole 
Itraconazole (ITZ) is a clinically efficacious antifungal agent that was FDA 
approved in 1992 (Figure 3).8 Recently, two separate high-throughput screens have 
determined that ITZ inhibits both the hedgehog (Hh) pathway and angiogenesis.9,10  
Both of these screens were performed at Johns Hopkins University School of Medicine 
and consisted of ~2,400 FDA-approved and post-phase I drugs.9,10  Preclinical in vitro 
assays have concluded that ITZ has anticancer activity and may serve as a potential 
chemotherapeutic.  There have been a variety of pilot studies to determine the 
anticancer effects of ITZ in humans.11 Clinical trials range from phase 0 to phase 2 and 
include patients suffering from leukemia, prostate cancer, non-small cell lung cancer 
(NSCLC), basal cell carcinoma (BCC), ovarian clear cell carcinoma, breast cancer, 
pancreatic cancer, and T-cell lymphoma (Table 1).11,12 
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Table 1. Itraconazole Clinical Trials 
Clinical Trial Clinical Status Cancer Type Reference 
NCT01787331 
NCT02357836 
NCT02120677 
NCT02354261 
NCT02366884 
Phase II 
Phase 0 
Phase 0 
Phase II 
Phase II 
Prostate 
NSCLC 
BCC 
BCCNS 
All cancer 
types 
[11, 12] 
[11, 12] 
[11, 12] 
[11, 12] 
[11,12] 
 
ITZ is a member of the well-known azole antifungal class.  It is considered to be 
a small molecule despite its large size (MW = 705.64 g/mol).  ITZ is a lipophilic drug 
with a LogP of 5.66 and as a result, has poor solubility in H2O (1 ng/mL).13 ITZ has three 
stereocenters and has the potential to exist as eight distinct stereoisomers.  However, 
ITZ is clinically administered as a mixture of 1:1:1:1 cis-racemates as this orientation 
predominantly forms during synthesis.14 ITZ has a complex scaffold highlighted by its 
triazole moiety and phenyl-piperazine-phenyl linker region.  As an antifungal agent, ITZ 
is generally well tolerated and causes minimal side effects.15 ITZ has been well studied 
in terms of its antifungal activity as well as its novel anticancer and antiviral activities.16 
Table 2. Properties of Itraconazole 13 
Property Value 
Molecular Weight 705.64 g/mol 
H-bond Donor 0 
H-bond Acceptor 9 
Rotatable Bond Count 11 
pKa 3.7 
LogP 5.66 
Melting Point 166.2°C 
Solubility in H2O pH = 7 1 ng/mL 
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1.2.1 Antifungal Activity of ITZ 
 The first report of an azole exhibiting antifungal activity was in 1944 with 
benzimidazole.8   In 1958, the first topical azole antifungal, chlormidazole, sparked an 
interest which lead to more topical azole antifungal agents: clotrimazole, miconazole, 
and econazole. In 1981, ketaconazole was FDA-approved for systemic fungal 
infections.8 Ketaconazole remained the standard for treatment and the only orally 
bioavailable agent for the next decade.  However, due to poor toxicity and recurring 
fungal infections, a second generation of azole derivatives were discovered which 
included terconazole, fluconazole, and eventually itraconazole.8 Throughout the 1990s, 
resistance to azole antifungals was uncommon. 8,17  However, this acquired resistance 
has become more prevalent as fluconazole is used in immunosuppressed and critically 
ill patients. Janssen Pharmaceuticals developed itraconazole and it became FDA 
approved in the United States in 1992.8,17 ITZ was developed to combat fluconazole-
acquired resistance.  It is less toxic and can be used to treat a broad range of fungal 
infections including Candida, Aspergillus, Cryptococcus neoformans, Coccidioides 
immitis, Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides 
brasiliensis, Sporothrix schenekii, and some phaeohyphomycetes.8,17  ITZ began to be 
utilized as the standard form of treatment for non-meningeal, non-life threatening cases 
of histoplasmosis, blastomycosis, and paracoccidioidomycosis.  Despite ITZ’s 
advantageous activity in aspergillosis and sporotrichosis, fluconazole has a more 
favorable pharmacological and toxicity profile.8,17 
   ITZ is more lipid-soluble than fluconazole and this poses issues with drug 
formulation and absorption.8 Originally formulated into a capsule, ITZ was not very 
		 	 		
 8		
effective due to low blood concentrations (< 500 ng/mL).  In 1997, an oral solution was 
FDA-approved and utilized the excipient hydroxypropyl-β-cyclodextrin to aide in 
solubility.8 Eventually, an intravenous formulation was approved and this allowed for a 
more flexible use of ITZ; steady-state plasma concentrations could be obtained in 2-3 
days as opposed to 1-2 weeks with ITZ capsules.  This was crucial for patients that had 
advanced HIV or were in intensive care.8 
ITZ exhibits its antifungal activity by inhibiting the enzyme cytochrome P450 14-
α-demethylase (14LDM).  This enzyme represents an intermediate step in the 
conversion of lanosterol to ergosterol (Scheme 1).8 Ergosterol is required for cell wall 
synthesis and disruption of this biosynthesis results in cell death.  It is essential for 
aerobic growth of most fungi.  It is important to point out that ergosterol is the major 
product of sterol biosynthesis in fungi, whereas mammalian systems synthesize 
cholesterol as the major membrane lipid.13,18,19 
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Scheme 1. Biosynthetic Pathway to Ergosterol 19,20 
Cytochrome P450 contains an iron protoporphyrin moiety, which is located at the 
active site.14,18 Azole antifungals bind to the iron atom via a nitrogen atom in the 
imidazole/triazole ring.  The remainder of the azole molecule binds to the apoprotein in 
a manner dependent on the individual azole’s structure.14,18  The exact confirmation of 
the active site differs between fungal species and amongst the many mammalian P450 
mono-oxygenases.14,18 For ITZ specifically, the N4 of the triazole ring moiety interacts 
O
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with the heme group of 14LDM, preventing coordination of the molecular oxygen 
required to initiate oxidation (Figure 4).14 
 
Figure 4. Mechanism of Action: Antifungal Activity 
While ITZ is FDA-approved and has been studied for many years, it still contains 
a few properties that are not considered to be “drug-like”.  While important for its 
antifungal activity, the triazole moiety of ITZ is able to coordinate with CYP3A4, which 
leads to drug-drug reactions and adverse side effects.21 If ITZ is going to be repurposed 
for a disease such as cancer, there should be minimal side effects/drug-drug 
interactions as cancer patients are often on a multi-drug treatment regimen to both treat 
the cancer and maintain comfort.  Second, ITZ is a rather large compound with a 
molecular weight over the typical threshold of small molecule therapeutic agents (< 500 
g/mol).  Lastly, ITZ is poorly soluble with a solubility of 1 ng/mL in H2O at pH 7.22,23,24  If 
ITZ is going to be utilized as an anticancer chemotherapeutic agent, it must be 
evaluated and deemed safe in cancer patients. 
1.2.2 Repurposing Screen Results 
 A library of ~2,400 FDA-approved and post-phase I drugs was screened for Hh 
pathway inhibition.9 This screen utilized a reporter cell line Shh-light which contains a 
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stably integrated Gli-luciferase reporter that responds to stimulation by ShhN, the active 
form of sonic hedgehog (SHH) signaling protein.  This screen yielded a few hits 
including microtubule inhibitors (vinca alkaloids), which are cytotoxic and were not 
further explored.9 In addition, ITZ inhibited the Hh pathway (IC50 = ~690 nM) and as a 
result, a few more azole antifungals were evaluated for this novel biological activity.  
Results concluded that the azole antifungals as a class did not inhibit the Hh pathway 
(Table 3).9 
 A library of 2,604 FDA-approved and phase II compounds were screened in an 
endothelial cell proliferation assay to explore potential angiogenesis inhibitors.10 This 
assay was performed in a 96 well plate with human umbilical vein endothelial cells 
(HUVECs) with a final drug concentration of 10 µM.  Cells were incubated for 36h and 
proliferation was measured with [3H]-thymidine for the final 8h of incubation.10 
Preliminary screen results identified 210 drugs with at least 50% inhibition at 10 µM.  
Some hits were excluded due to cytotoxicity and some were excluded due to being 
topical agents.10 ITZ inhibited VEGF-induced proliferation (IC50 = 0.16 µM) and as a 
result, a few more azole antifungals were explored for this novel biological activity.  
Results concluded that the azole antifungals as a class did not inhibit angiogenesis 
(Table 3).10 
Table 3. Results from High Throughput Screens9,10 
Azole IC50 Hh Pathway IC50 Angiogenesis 
Itraconazole 0.69 µM 0.16 µM 
Ketoconazole 9.2 µM 10.4 µM 
Miconazole 12.0 µM 2.47 µM 
Fluconazole > 100 µM > 100 µM 
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2. Hedgehog (Hh) Pathway 
 The Hh pathway is an embryonic developmental cell-signaling cascade that plays 
a role in cell differentiation, tissue growth, and tissue patterning (Figure 5).25 While the 
pathway is generally quiescent in healthy adults, it is required for the homeostasis of 
stem cell populations in the skin and the central nervous system (CNS).  Aberrant 
regulation of the Hh pathway leads to constitutive activation which results in abnormal 
cell proliferation and tumor growth most notably associated with basal cell carcinoma 
(BCC) and medulloblastoma (MB).25 
 
Figure 5. (A) Inactive and (B) active form of the Hh pathway25 
Reused with permission from John Wiley and Sons 
 
 
 The Hh pathway is regulated by the 12-transmembrane (TM) cell surface 
receptor, Patched (Ptch) and the 7-TM G-protein coupled receptor (GPCR)-like protein, 
Smoothened (Smo).  In the absence of Hh ligand, Ptch suppresses Smo through a 
complicated mechanism that is not well understood (Figure 5A).  In this state, a 
heteroprotein complex is formed between Suppressor of Fused (Sufu) and the glioma 
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(Gli)-associated oncogene family of zinc-finger transcription factors.26–28 This complex 
remains in the cytosol where Sufu serves as a negative regulator of Gli by promoting a 
series of phosphorylation events (PKA, GSK-, and CK1) leading to the proteosomal 
cleavage of Gli to the N-terminal truncated form (GliR).  Sufu confiscates the 
unprocessed cytosolic Gli and only the inactive transcriptional repressors Hh target 
genes are able to travel to the nucleus.26–28  
 In the presence of Hh ligand (Sonic Hh [SHh], Indian Hh [IHh], and Desert Hh 
[DHh], Ptch removes its suppression on Smo (Figure 5B).  Smo is then able to migrate 
to the primary cilium where it inhibits the phosphorylation of the Gli-Sufu complex.26–28 
This allows for the formation of full length GliA proteins that travel to the nucleus and 
induce the transcription of Hh target genes. Typical Hh target genes include: PTCH, 
GLI1, Cyclin D, Cyclin E, Wnt, N-Myc, VEGF, BCL2, SNAIL, ELK1, MSX2, osteopontin, 
BMI1, and NANOG.26–28  
2.1 The Hedgehog Pathway and Cancer 
 Aberrant Hh pathway activity may lead to unwanted cell proliferation and tumor 
growth most commonly seen in basal cell carcinoma (BCC) and medulloblastoma (MB). 
Hh pathway dysregulation arises from mutations in Ptch, Smo, or Sufu.  For instance, in 
sporadic BCC cases, mutations include Ptch1 (~75%), Smo (10%), and Sufu 
(~5%).26,29,30 Cancers resulting from Hh pathway dysregulation have been categorized 
by either being Hh ligand independent or Hh ligand dependent (Type I and Type II 
cancer, respectively).  Ligand independent aberrant Hh activity can be attributed to loss-
of-function mutations in Ptch or Sufu and/or gain-of-function mutations in Smo.26,27  Ptch 
mutations include deletions, insertions, or nonsense mutations, which result in loss of 
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function.  Ptch loss of function results in aberrant up-regulation of the Hh pathway, as 
Smo is no longer repressed even in the “off-state”.  Loss of function Ptch mutations are 
commonly seen in Gorlin Syndrome, which predisposes a patient to cancers such as 
BCC, MB, and rhabdomyosarcoma.26,27  Smo mutations result in gain of function; Active 
Smo would result in up-regulation of the Hh pathway as it can continuously generate 
active forms of Gli leading to increased transcription of Hh target genes.  Smo gain of 
function mutations are typically associated with sporadic BCC and other skin 
abnormalities.26,27   
Cancers can also result from aberrant Hh pathway activity that arises from 
abnormalities regarding Hh ligand.  Constitutive pathway activation results from a 
continuous receiving of Hh ligand.26,27  This phenomenon can be divided into three 
different models: autocrine-juxtacrine model, paracrine model, and reverse paracrine 
model.  The autocrine-juxtacrine model involves Hh ligand being secreted and absorbed 
by the same or adjacent tumor cells; this leads to tumor growth.26,27  The paracrine 
model involves Hh ligand being secreted from tumor cells and interacting with normal 
cells; this leads to angiogenesis and metastasis.  Lastly, the reverse-paracrine model 
involves Hh ligand being excreted from normal cells and interacting with cancer 
cells.26,27  
2.1.1 Basal Cell Carcinoma 
 Basal cell carcinoma (BCC) is the most common form of skin cancer affecting 4 
million US residents annually.31 This cancer arises from the basal layer of the epidermis 
and usually develops on skin that is exposed to the sun.  This skin cancer grows slowly 
and rarely spreads to other parts of the body.  If left untreated, BCC can grow wide and 
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deep resulting in destroyed skin, tissue and bone.31 Treatment options for BCC depend 
on the tumor’s size and location as well as the patient’s age and general health.  All 
treatment options are effective and include surgery (curettage + electrodessication, 
excision, and Mohs surgery), radiation therapy, cryotherapy, and chemotherapy 
(vismodegib and sonidegib).  With early diagnosis and treatment, recurrence-free cure 
rates are between 85-95%.31,32 
2.1.2 Medulloblastoma 
Medulloblastoma (MB) is a cancerous tumor also known as cerebellar primitive 
neuroectodermal tumor (PNET) that originates in the posterior fossa, the lower rear 
region of the brain (Figure 6).  These tumors rapidly grow in the cerebellum, a part of 
the brain that is important for balance, posture, and complex motor functions.33,34 MB 
tumors have the potential to spread to other regions of the brain or to the spinal cord.  It 
accounts for less than 2% of all primary brain tumors and 20% of childhood brain 
tumors.33,34 About 400 children are diagnosed with MB in the United States each year.  
It is the most common malignant brain tumor in children 4 and under and is the second 
most common malignant brain tumor in children between the ages of 5-14 years of 
age.33,34  It is slightly more common in males over females.  About 70% of all MBs are 
diagnosed in children under 10 and the median age of diagnosis is 7 years old.  MB is 
not common in adults and very few children under 1 receive a diagnosis.33,34  
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Figure 6. Location of MB Tumors in Brain 33 
 
Types of MB 
 MB is considered to be an “embryonal” cancer arising from immature cells.  
Embryonal tumors are typically pink/purple-gray masses.  MB tumors are not all the 
same and vary histologically.  While this is not necessarily important for prognosis, it is 
important to note that MB should not be considered a single disease but rather a group 
of different diseases.33,34 Classic MB tumors contain tissue that is densely packed and 
have small round cells with large dark nuclei.  Desmoplastic nodular medulloblastoma 
contains scattered densely packed tumor cells mixed with looser-packed cells.  MB with 
extensive nodularity is similar to desmoplastic nodular MB but has more pronounced 
nodularity.  Large-cell MB consists of tumor cells with large round nuclei.33,34 Anaplastic 
MB contains tumor cells with increased proliferation and abnormally shaped nuclei.  It is 
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important to make note that sometimes these histological variants co-exist (Figure 
7).33,34  
 
Figure 7. Histological MB Types35  
Reused with permission from Nature Publishing Group 
 
 Genetic subtypes of MB will eventually be important as oncologists predict this 
will declare route of treatment.  MB treatment may become more targeted based on 
what genetic abnormality is resulting in tumor growth.33,34 There are currently four 
different subtypes of MB: WNT, SHH, Group 3, and Group 4.  Each subgroup targets a 
different age of children/adults and may have a different prognosis and survival rate 
(Figure 8).33,34  WNT and SHH subtypes are named specifically for the cellular pathway 
that affects the tumor; Group 3 and Group 4 are more broadly labeled as a distinct 
pathway has not been found to cause tumor growth to date.33,34  
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 The first group of MB is termed WNT.  About 10-15% of patients suffer from this 
subgroup of MB.  The average age of diagnosis is 10 years of age and it is the only 
subgroup that is more common in girls than boys.33,34  Tumors typically are located in 
the fourth ventricle of the posterior fossa.  Tumors have been found to accumulate a 
protein, β-catenin, in the nucleus; this results in the activation of the WNT pathway.33,34  
The WNT pathway is a cell-signaling cascade that has been found to play a role in 
tumor growth.  Patients with this subtype of MB have an excellent outcome.34,33 
 The second type of MB is named SHH and affects about 25% of MB patients. It 
is more prominent in children under 5 years of age and over 16 years of age.  This 
subtype is typically caused by aberrant Hh pathway activity.33,34  Tumors are generally 
located in the body of the cerebellum and the tumor can grow on the sides of the organ.  
Survival rate for this subtype depends on the metastatic rate at time of diagnosis, 
histology type of tumor, and age of patient at diagnosis.33,34  
 An increased copy of the growth gene MYC generally categorizes group 3 MB.  
Like SHH, it affects 25% of MB cases.  It primarily affects children between the ages of 
1-10 years of age and is almost never seen in adults.33,34  There is often metastasis at 
the time of diagnosis and the tumor is generally located in the fourth ventricle like WNT 
subtype MB.  The histology type is most commonly large cell/anaplastic.33,34  Group 3 
subtypes have the worst survival rate among all of the MBs; this survival rate depends 
on the metastatic state at time of diagnosis and the age of patient at diagnosis.33,34  
 Group 4 is the most common subtype of MB accounting for 35-40% of cases.  It 
occurs in all ages but is most prevalent during mid-childhood.  Tumors are located in the 
fourth ventricle similarly to Group 3 and WNT subtypes.33,34  The hallmark of this 
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subtype is abnormalities in chromosome 17.  If the cancer does not spread, 5-year 
survival rates with standard therapy are 80% however, with metastasis this drops to 
60%.33,34  
 
Figure 8. MB Subgroup Prevalence35 
Reused with permission from Nature Publishing Group 
 
Current Treatment of MB 
 Current treatment for MB consists of surgery followed by high-dose 
chemotherapy and radiation.  Treatment plans are individualized based on the risk of 
tumor occurrence.33,34  This risk is based on the amount of metastasis and the amount 
of tumor remaining post-surgery.  For instance, in pediatric MB, “high” risk patients are 
less than 3 years of age, have a tumor volume of 1.5 cm2 post-surgery, and have 
metastasis.34,33 
 Surgically removing the tumor is an important part of treating MB.  The obvious 
goal is to remove the entirety of the tumor, but sometimes this is not possible as a result 
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of where the tumor has grown.33,34  In a third of MB patients, the tumor grows into the 
brain stem; attempted removal of this tumor type would result in neurological damage.  
The goals of this initial surgery are to remove as much of the tumor as possible without 
causing neurological damage, to obtain a tissue sample for diagnosis, and to relieve 
cerebrospinal fluid buildup caused by tumor growth and swelling.33,34  
Glucocorticosteroids (decadron, dexamethasone) are used before and during surgery to 
reduce swelling in the tumor.  Technological advances have aided in this step of treating 
MB.  MRI scanning and computer-aided navigation tools help with mapping the tumor 
removal before surgery.33,34  High powered microscopes, ultrasounds, and gentle 
suction devices are necessary for tumor removal.  MRI scanning is either performed 
right after surgery or days after surgery to determine how much tumor was resected.33,34  
 After surgery, MB is treated with radiation therapy.  Even after removal of the 
tumor, cancer cells remain in the surrounding brain tissue.  If not killed with radiation, 
these cells can spread and lead to cancer regrowth.33,34  Radiation to the brain/spinal 
cord can damage a developing brain and this is important to consider, as MB patients 
are typically children.  Therefore, this form of therapy is not used in children under the 
age of 3 and caution is used in patients between the ages of 3-7 as they are at the 
highest risk of neurocognitive defects as a result of radiation.33,34  On average, radiation 
therapy is given 5 days a week for 6 weeks.  Extra radiation is given to the site where 
the tumor was removed due to increased risk of tumor growth.33,34  
 Chemotherapy is described as the use of powerful chemicals to kill cancer cells 
after surgery and radiation therapy.  These drugs halt tumor regrowth and the spread of 
cancer metastatically.33,34  MB patients fare better with radiation but some children that 
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are too young to get radiation rely on chemotherapy alone.  Chemotherapy generally 
consists of a cocktail of drugs that target cell death at different cycles of cell growth.  
The drugs that are mainly used for MB are vincristine, cisplatin, carboplatin, 
cyclophosphamide, and lomustine (Figure 9).33,34  These drugs are administered in 
cycles with each cycle differing between 3-4 weeks; this allowed the body to recover 
after being administered these harsh chemicals.  The cycle length and amount of cycles 
depends on the severity of the cancer and the age of the patient.33,34 
 
Figure 9. Structures of Common Chemotherapeutic Agents 
Side Effects 
 Unfortunately, side effects are evident due to this harsh treatment regimen 
combining major surgery, radiation, and chemotherapy.  In terms of surgery, about 25% 
of children experience loss/delay of speech 6-24 hours after waking up; this is referred 
to as “posterior fossa mutism syndrome.”33,34  A small percentage of children have 
abnormal speech and unsteadiness years after surgery.  Radiation short-term side 
effects include: fatigue, loss of appetite, nausea, sore throat, difficulty swallowing, and 
hair loss.33,34  Long-term side effects include: lower intellectual ability, attention deficit, 
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and memory loss.  Younger children are more prone to these long-term side effects as 
their brains are still developing.  Radiation can also affect the hypothalamus and 
pituitary gland, which regulate hormones for bodily function and growth.33,34  This can 
lead to issues with obesity and hypothyroidism.  Generally, children can be treated with 
growth hormone replacement therapy.  Radiation can also cause short stature and 
scoliosis as the spinal cord is very close to the site of tumor growth.  In terms of 
chemotherapy, short-term side effects are very similar to those of radiation: hair loss, 
nausea, vomiting, fatigue, and weakness.33,34  Long-term side effects include early 
onset lung, heart, and kidney disease as well as the development of secondary cancers 
such as leukemia.  Hearing loss is a direct side effect of the chemotherapeutic agent 
cisplatin; as this drug is crucial towards MB treatment, additional drugs are currently in 
development for administration with cisplatin to limit hearing loss.33,34  
2.2 Established Smo Antagonists 
Smo became a popular drug target after the discovery of the first Smo inhibitor, 
cyclopamine, a naturally occurring alkaloid.  While cyclopamine exhibited poor 
pharmacokinetic properties, it was utilized in the exploration of Hh pathway function and 
subsequent tumor growth.36  To date, Smo has been identified as the most druggable 
target for the development of small molecule Hh pathway inhibitors; each of the Hh 
pathway inhibitors that have advanced into clinical trials is a direct Smo antagonist 
(Figure 10).28 Curis and Genentech co-developed the first small molecule Smo 
antagonist to enter clinical trials and ultimately gain FDA approval for the treatment of 
advanced basal cell carcinoma, vismodegib (GDC-0449/Erivedge™).  
Erismodegib/Sonidegib (NVP-LDE225) was originally identified and developed at the 
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Novartis Institute for Biomedical Research and has recently been FDA-approved for 
locally advanced basal cell carcinoma.11,37  A medicinal chemistry program at Pfizer 
resulted in the identification and development of PF-04449913 as a potent Smo 
antagonist that exhibits favorable pharmacological and pharmacokinetic (PK) properties 
in vitro and in vivo.38 PF-04449913 is currently being evaluated in multiple Phase I and 
Phase II studies for the treatment of both acute myeloid leukemia and myelodysplastic 
syndrome.11 Exelixis and Bristol-Myers Squibb collaborated to develop XL-139/BMS-
833923, which has been studied in Phase I and II trials as both a single agent and in 
combination regimens (Dasatinib, carboplatin, cisplatin, etoposide, and more) for the 
treatment of a variety of human cancers including chromic myeloid leukemia and 
extensive small cell lung cancer.11,39 Eli Lilly has also advanced a small molecule Smo 
antagonist, LY2940680 (Taladegib) into Phase I and II trials for pediatric 
medulloblastoma, rhabdomyosarcoma, and small cell lung cancer; it is also in phase II 
clinical trials in combination with paclitaxel, carboplatin, and radiation.11,40 Due to the 
well-established nature of these compounds as Hh pathway inhibitors, each of them has 
been extensively reviewed elsewhere and their path to clinical candidacy will not be 
detailed further.41,26,27,42,43 
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Figure 10. Structures of Established Smo Antagonists 
 
Table 4. Clinically Relevant Synthetic Smo Inhibitors.26 
Compound 
IC50 
Wild-Type 
Smo 
IC50 
D473H Smo 
Development 
Status References 
GDC-0449 
NVP-LDE225 
PF-04449913 
BMS-833923 
LY294068 
3-22 nM** 
2.5 nM 
5 nM 
21 nM 
2.4 nM 
Loss of activity 
Loss of activity 
ND 
ND 
Active* 
Clinically approved 
Clinically approved 
Clinical (Phase II) 
Clinical (Phase II) 
Clinical (Phase II) 
[11, 44] 
[11,37,45] 
[11, 38] 
[11, 46 ] 
[11, 47] 
 
ND: Not determined/reported 
*Specific IC50 values were not provided 
**Dependent on cellular assay 
 
 
 
 A major challenge for the continued advancement of small molecule Hh pathway 
inhibitors towards clinical efficacy is the development of multiple mechanisms of 
resistance to these Smo antagonists.48 An unsuccessful clinical trial for vismodegib in 
an MB patient resulted in the discovery of a clinically relevant Smo mutant (D473H) 
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(Table 4).  This point mutation in Smo rendered the patient insensitive to further 
treatment with vismodegib.49,50,51  Additional point mutations in Smo have been 
identified (H231R, W281C,Q477E, V386A, V321M, I408V, C469Y, T241M) to confer 
resistance in patients receiving vismodegib for the treatment of advanced BCC.52,53,54 
Half of the vismodegib-treated patients that experienced a relapse in BCC were found to 
have a Smo mutation.  Similar Smo mutations that result in constitutive pathway 
activation were identified in a preclinical Hh-dependent MB murine model upon 
treatment with sonidegib.55 Other mechanisms of Smo antagonist resistance include 
direct activation of Gli downstream, induced expression of p-glycoprotein, and 
chromosomal amplification of GLI2 and SUFU.53,54,55,56,57,48 These results highlight a 
therapeutic need to determine small molecule Hh pathway inhibitors that maintain 
potent inhibitory activity in the presence of wild-type Smo and mutant forms of Smo. 
 While many universities and industrial laboratories are searching for Smo-wild 
type and Smo-mutant antagonists, there are many other drug targets within the Hh 
pathway that are less popular in the drug discovery community.  The focus on targeting 
Smo has offered some information regarding limitations.58 First, Smo inhibitors are 
characterized by their structural moieties.  If one compound succumbs to resistance, the 
whole class of compounds may result in resistance.  Second, there is evidence 
emerging that the downstream components in the Hh pathway may be compensating 
for upstream inhibition.  There are many oncogenic-cell signaling pathways that interact 
with the Hh pathway: TGF- β, RAS/RAF/MEK/EK, and PI3K/AKT/Mtor.58 Gli 
transcription factors are regulated by other pathways such as TGF-β.58 Therefore, if 
vismodegib is inhibiting Smo, Gli transcription activity can still take place if another 
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pathway is simultaneously producing Gli transcription factors.  This crosstalk between 
Hh pathway and other oncogenic signaling pathways exemplifies an additional need for 
the exploration of downstream Hh inhibitors.58 
2.3 Recently Disclosed Smo Antagonists 
The emergence of resistance towards vismodegib influenced Novartis to identify 
a series of pyridazines as second-generation Hh inhibitors that remain potent in the 
presence of Smo mutant D473H. The most active compound identified through this 
process, NVP-LEQ506, inhibits Hh signaling in vitro against both wild-type and mutant 
Smo (IC50 values = 1 and 96 nM, respectively) (Figure 9).59 NVP-LEQ506 reduced Gli 
mRNA expression and promoted tumor regression in a murine Hh-dependent MB 
allograft following oral administration (10-40 mg/kg, q.d. dosing).59 Preclinical in vivo PK 
studies for NVP-LEQ506 resulted in a good bioavailability profile, low clearance, and the 
ability to cross the blood-brain barrier.59  
 The Scripps Research Institute, Novartis, and Harvard University collaborated on 
efforts to identify Hh inhibitors that maintain activity in the presence of wild-type and 
mutant forms of Smo.60 Both ALLO-1 and ALLO-2 were discovered via a high-
throughput screen of ~50,000 compounds from Maybridge and ChemDiv libraries 
(Figure 11).  Both ALLO-1 and ALLO-2 inhibit Hh signaling in Smo agonist (Hh-Ag1.5) 
stimulated TM3-Gli-Luc cells, a stable clone of mouse TM3 cells expressing the Gli-luc 
reporter construct (IC50= 50 nM and 6 nM, respectively).60  This Hh inhibition was further 
confirmed in a secondary Gli-luciferase reporter assay utilizing TM3-Gli-Luc cells 
stimulated with recombinant ligand ShhN (ALLO-1 IC50= 320 nM and ALLO-2 IC50= 39 
nM) as well as in a mouse Gli1 expression assay that utilized both human HEPM and 
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NIH3T3 cells (ALLO-1 IC50= 805 nM and ALLO-2 IC50= 40 nM.)60  Both compounds 
inhibited cell proliferation in ShhN stimulated mouse cerebella granule neuron 
progenitors (CGNPs) (ALLO-1 IC50= 410 nM and ALLO-2 IC50= 22 nM) and Ptch1+/-p53-
/- mouse medulloblastoma cells (IC50= 0.47 µM and 0.12 µM, respectively).60 Due to 
structural similarity to several kinase inhibitors, ALLO-2 was screened for inhibitory 
activity against a panel of kinases.  ALLO-2 did not show inhibitory activity in the 
presence of these kinases indicating its specificity for the Hh pathway.  A multitude of in 
vitro assays were utilized to try and determine a mechanism of action for both ALLO-1 
and ALLO-2.60  Neither compound inhibited the Hh pathway following treatment with 
Sufu-specific siRNA confirming that ALLO-1 and ALLO-2 act upstream within the Hh 
signaling cascade.  Both compounds successfully competed with BODIPY-cyclopamine 
for binding to murine Smo over-expressed in CHO-K1 cells, indicating that they form 
direct binding interactions with Smo (ALLO-1, IC50 = 140 nM and ALLO-2, IC50 = 2.8 
nM).60 Interestingly, while ALLO-2 demonstrated competitive characteristics with 
[3H]cyclopamine at concentrations comparable to its displacement of BODIPY-Cyc in 
reporter assays, ALLO-1 did not compete with [3H]cyclopamine. These results suggest 
that the binding site of ALLO-1 might reside in a pocket adjacent to the Cyc binding site 
where the BODIPY interacts with Smo.60  Finally, both ALLO-1 (IC50 = 1 µM) and ALLO-
2 (IC50 = 83 nM) were capable of inhibiting the murine homolog of Smo D473H (D477G) 
overexpressed in the TM3-Gli-Luc cell line with only a slight reduction in potency 
compared to wild-type Smo.60   
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Figure 11. Smo Antagonists 
 
 Utilizing a cell based screen, researchers at the University of Texas 
Southwestern Medical Center identified a series of small molecule Hh pathway 
inhibitors.61 Several compounds were identified as potent inhibitors of the Hh signaling 
pathway (IHR-1 – IHR-7) with IC50 values ranging from 7.6 – 200 nM 62 (Figure 11).  In a 
competition assay with BODIPY-Cyc utilizing Smo over-expressed Cos-7 cells, all IHR 
compounds demonstrated binding to Smo.  The most potent of these compounds, IHR-
1 (IC50 = 8.9 nM) further demonstrated the ability to prevent translocation of Smo to the 
primary cilia and also exhibited down-regulation of endogenous expression of Gli mRNA 
in PTCH1-/- cells.61  Interestingly, IHR-1 was significantly less active in the presence of 
SAG, a small molecule Smo agonist (IC50 > 10 µM).  Follow-up studies demonstrated 
that IHR-1 is cell impermeable and is unable to compete with SAG for Smo binding 
when the receptor is within the cell. An acetylated version of IHR-1, IHR-NAc, 
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demonstrated enhanced cell permeability and was significantly more active against Hh 
signaling when the pathway is upregulated with SAG (IC50 = 19 nM).61 These results 
strongly suggest that Smo antagonists may not be exhibiting maximum results due to 
potential cell impermeability and subsequent inability to reach all cellular Smo 
populations.61         
 Researchers at the Centre National de la Recherche Scientifique utilized a 
combined molecular modeling and virtual screening approach to design, synthesize, 
and evaluate multiple generations of Smo antagonists consisting of acylureas, 
acylthioureas, and acylguanidines.63,64 After comprehensive medicinal chemistry of 
these molecular scaffolds, acylguanidine MRT-83 was identified as a potent Hh pathway 
inhibitor (IC50 value = 15 nM), with the ability to displace BODIPY-Cyc from Smo (IC50 = 
5 nM).64 Molecular docking studies of MRT-83 with several conformations of murine 
Smo suggested that MRT-83 bound to a cleft-opened conformation of Smo and that 
further extension of the biaryl moiety would provide enhanced interactions between the 
scaffold and binding pocket.65 Based on these computational results, a series of 
elongated MRT-83 derivatives were synthesized and evaluated for Hh pathway activity. 
The most potent of these analogues, MRT-92, is a potent inhibiter of Hh signaling (IC50 
= 6 nM) (Figure 11), prevents Smo accumulation in the primary cilia, and displaces 
BODIPY-Cyc from human Smo in vitro. Binding studies with a tritiated analogue of 
MRT-92 demonstrated that the compound binds comparably to both wild type and 
mutant (D473H) Smo (Ki values for both forms of Smo = 0.7 nM).65 There have been 
extensive binding studies between several Smo antagonists (including MRT-92) and 
various Smo mutants, which account for its ability to retain binding affinity to Smo 
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D473H and potentially provide a new binding mechanism to be considered for the 
development of Smo antagonists.65   
2.4 Novel Smo Antagonist Scaffolds 
 
Combining structural features of ALLO-2, LDE-225, and BMS-833923 lead to a 
novel series of Smo antagonists consisting of the N-(2-pyrimidinylamino)benzamide 
scaffolds.  Researchers at Jiangsu Simcere Pharmaceutical designed this series by 
incorporating a 4-(trifluoromethoxy)phenyl moiety of LDE-225 and ALLO-2 (A), a 
pyrimidinylamino moiety of ALLO-2 (B) and a biaryl amide functionality of BMS-833923 
(C and D) into a single scaffold (Figure 12). An initial screen of these novel hybrid 
compounds identified compound 1 as a potent Hh pathway inhibitor (IC50 values = 1.3 
nM) (Figure 12).66 
 
Figure 12. Synthetic Smo Antagonists 
This novel scaffold was further explored in order to determine the optimal 
functionality for potent Hh pathway inhibition.  Each region of the scaffold (A-D) was 
modified to generate a series of N-(2-pyrimidinylamino)benzamide analogues that were 
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evaluated for their ability to inhibit Hh signaling in a luciferase assay utilizing NIH3T3 
cells stably transfected with Gli-reporter construct.66 Structure-activity relationship (SAR) 
results for region A suggested that a single electron-withdrawing substituent (-OCF3, -
CN, -F) in either the ortho- or para- position of a phenyl ring was important for optimal 
Hh inhibition. The incorporation of various heteroaryl functionalities was also well 
tolerated in this region.  SAR results for region B determined that small hydrophobic 
groups at either position 5 or 6 of the pyrimidinyl moiety retain potent activity.67 It is 
important to note that removal of the N-1 of the pyrimidinyl ring was detrimental to Hh 
inhibition. SAR studies for the benzamide phenyl ring, region D, demonstrated that a 
wide range of functionalities was tolerated in this portion of the scaffold; however, a 
basic amine was required to improve the PK properties of the overall scaffold.67  From 
this series, analogues 2a and 2b demonstrated potent inhibition of Hh signaling (IC50 
values = 0.53 and 0.73 nM, respectively) (Figure 12); however, both compounds 
demonstrated unfavorable PK parameters, presumably due to elevated lipophilicity 
values (2a, AlogP = 7.07 and 2b, AlogP = 7.37).67 Further structural modifications were 
made in an attempt to decrease lipophilicity and to improve the overall drug-like 
properties of the scaffold ultimately resulted in compound 3, which demonstrated potent 
inhibition of Hh signaling (IC50 = 1.3 nM) and more favorable PK parameters (AlogP = 
3.6) (Figure 12).67 Preliminary in vivo PK studies for compounds 2a, 2b, and 3 identified 
analogue 3 as having enhanced oral bioavailability. 
Researchers at Jiangsu also performed parallel optimization of the N-(2-
pyrimidinylamino)benzamide scaffold by replacing the pyrimidine ring (B) with a 
pyrrolo[2,1-f][1,2,4]triazine moiety.68 This substitution proved promising as the initial 
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compound in this series (compound 4) demonstrated potent Hh inhibitory activity with 
an IC50 value of 1.6 nM. A typical SAR approach was undertaken and a series of 
pyrrolo[2,1-f][1,2,4]triazine benzamide analogues was designed, synthesized, and 
evaluated.68 These compounds proved promising in terms of in vitro analysis (IC50 
values = 0.62-12.3 nM) and several of the most potent compounds were further 
analyzed in vivo to determine preliminary PK properties. Compound 5 contained the 
initial para-trifluoromethoxy aryl ring and a meta-morpholine moiety on ring D, had an 
IC50 value = 0.83 nM, demonstrated good serum concentration (Cmax = 4185 ng/mL), 
oral exposure (AUC = 1935 h ng/mL), and half-life (T1/2 = 8.34 h) (Figure 12).68 
Jiangsu further developed a third series of Hh inhibitors developed at Jiangsu 
that replace the pyridine ring functionality of vismodegib with an amide- or urea-linked 
phenyl ring.69 The addition of this spacer was hypothesized to enhance hydrogen-
bonding interactions with Smo. The initial compound in this series demonstrated modest 
inhibition of Hh signaling (IC50 = 300 nM) and thus further analogues were designed, 
synthesized, and evaluated.69 The most active compounds identified, 6a (IC50 = 100 
nM) and 6b (IC50 = 40 nM) were also capable of displacing BODIPY-Cyc from human 
Smo over-expressed in HEK-293T cells (Figure 13).  Compound 6b exhibited enhanced 
water solubility and was further evaluated in a variety of in vitro and in vivo model 
systems. Most importantly, compound 6b significantly decreased fluorescence 
associated with Gli-dependent RFP in a transgenic zebra fish model of Hh signaling.69  
		 	 		
 33		
 
Figure 13. Additional Synthetic Smo Antagonists 
 A group of researchers at the Chinese Academy of Sciences designed and 
synthesized a chimeric compound, NL-103, which contains the structural components of 
both vismodegib and the FDA-approved histone deacetylase enzyme (HDAC) inhibitor, 
vorinostat (Figure 13).70,71   This followed strong evidence that HDAC inhibitors 
exhibited anti-Hh pathway activity.  NL-103 potently inhibited Hh signaling in a Gli-
reporter cell line (IC50 = 19.7 nM) and was capable of displacing BODIPY-Cyc from 
human Smo overexpressed in HEK293T cells (KD = 79.6 nM).71 NL-103 also inhibited 
HADC1-3 at levels comparable to the FDA-approved vorinostat. Further in vitro 
evaluation was performed to distinguish vismodegib and vorinostat mediated Hh 
pathway inhibition.  Utilizing Hh-dependent cells, NL-103 was tested for its ability to 
regulate Gli1, Gli2, and Gli3 mRNA levels.71  At higher concentrations (1-10 µM) both 
NL-103 and vorinostat stimulated Gli1 but reduced Gli2 mRNA expression. By contrast, 
vismodegib demonstrated significant down-regulation of Gli1 at all concentrations 
evaluated but had minimal effects on Gli2 mRNA expression.71 These results suggest 
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that while NL-103 does bind Smo, this binding is non-selective; this scaffold retains 
significant cellular effects traditionally associated with vorinostat.71    
 
Figure 14. Vismodegib-based Smo Antagonists 
 
 Researchers at Soochow University utilized a scaffold hopping approach to 
design and optimize a series of Smo antagonists based on the combination of known 
Smo antagonist scaffolds.72,73,74  Previous reports suggested that the amide bonds of 
both vismodegib and NVL-LDE225 were not crucial for binding to Smo but where 
important for linking the aryl regions of these two molecules.73,74,75,76 It was 
hypothesized that replacing the amide bond of vismodegib with an alkyl or heteroalkyl 
ring would reduce planarity and rotatable bonds, resulting in increased solubility, 
absorption, and metabolic stability.72 This approach led to the development of two 
related series of compounds based on either a tetrahydroimidazo[1,2-a]pyrazine or 
tetrohydrothiazolo[5,4-c]pyridine scaffold.72,73   An extensive medicinal chemistry effort 
yielded a variety of substituents on the imidazopyridine moiety: alkyl esters, aryl esters, 
and amides. Phenyl amides that incorporated an electron withdrawing moiety at the 
meta- or para- position demonstrated the most potency.72 Short alkyl substituents, both 
straight chain and ring structures, were less active.  The most active analogues in this 
series, 7 and 8, inhibited pathway signaling (IC50 = 87 and 200 nM, respectively) (Figure 
14). For the closely related thiazolopyridine scaffold, the most potent compounds 
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evaluated either contained an ethyl side chain 9 (IC50 = 80 nM) or substituted piperidine 
10 (IC50 = 58 nM) as the substituent (Figure 14).73 Both of these compounds displaced 
BODIPY-Cyc from full length human Smo over-expressed in U2OS cells.  Preliminary in 
vivo studies for both 9 and 10 demonstrated promising PK properties similar to those 
exhibited by vismodegib.72,73  A comprehensive table of clinically relevant and novel 
Smo inhibitors is described below (Table 5). 
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Table 5. Key Synthetic Hh Pathway Inhibitors that Function via Smo. 
Compound 
IC50 
Wild-Type 
Smo 
IC50 
D473H Smo Reference 
NVP-LEQ506 
ALLO-1 
ALLO-2 
IHR-1 
IHR-NAc 
MRT-92 
1 
2a 
2b 
3 
4 
5 
6a 
6b 
NL-103 
7 
8 
9 
10 
1.0 nM 
410 nM 
41 nM 
0.01 µM 
0.0031 µM 
0.7 ± 0.1 nM 
1.3 nM 
0.53 nM 
0.73 nM 
1.3 nM 
1.6 nM 
0.83 nM 
100 nM 
40 nM 
19.7 nM 
87 nM 
200 nM 
80 nM 
58 nM 
96.0 nM 
1 µM 
83 nM 
ND 
ND 
0.7 ± 0.2 nM 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
Active* 
ND 
ND 
ND 
ND 
[59] 
[60] 
[60] 
[77] 
[77] 
[65] 
[66] 
[67] 
[67] 
[67] 
[68] 
[68] 
[69] 
[69] 
[71] 
[73] 
[73] 
[73] 
[73] 
 
ND: Not determined/reported 
*Specific IC50 values were not provided 
**Dependent on cellular assay 
 
2.5 ITZ and Hedgehog Signaling  
 The hedgehog (Hh) pathway is an embryonic cell-signaling pathway that is 
responsible for cell differentiation and tissue growth.  There are two main regulating 
proteins of this pathway: Patched (Ptch) and Smoothened (Smo). As ITZ has been 
determined to inhibit the Hh pathway, there have been various explorations into how ITZ 
mediates this anticancer activity.   ITZ exhibited similar in vitro results as cyclopamine 
and cyclopamine mimics including inhibition of Hh signaling in Ptch-/- cells, in cells 
treated with oxysterols, and in cells over expressing Smo.  Because of this, ITZ was 
originally hypothesized to bind to Smo.9  However, ITZ failed to compete with BODIPY-
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cyclopamine indicating that ITZ does not bind to Smo at the same position as 
cyclopamine.9  Additional experiments have been performed in the presence of Smo 
agonists (SAG) and antagonists (MRT-92); ITZ acts as a non-competitive inhibitor of 
SAG and is able to inhibit MRT-92 binding to Smo.65 This evidence suggests that ITZ 
may be binding to Smo in a distinct manner than other Smo inhibitors.  However, the 
binding mode and way in which ITZ is exhibiting Hh pathway inhibition has not been 
determined. 
 In addition to inhibiting the Hh pathway via Smo, ITZ was also found to inhibit the 
Hh pathway in the presence of vismodegib-resistant mutant SmoD477G.9,78  Since ITZ 
acts in a distinct manner from cyclopamine and cyclopamine mimics, it was predicted 
that ITZ may retain activity in the presence of mutant forms of Smo.  In ShhN stimulated 
Smo-/- mouse embryonic fibroblasts (MEFs) transfected with SmoWT or SmoD477G, ITZ 
exhibited inhibitory activity (IC50= 270-690 nM and 500 nM, respectively).9,78  In the 
presence of SmoWT or SmoD477G expressing MB tumors, ITZ retained similar inhibitory 
activity (SmoWT IC50= 55 nM and SmoD477G IC50= 62 nM).   ITZ was also determined to 
remain active in the presence of a variety of other Smo mutants (E522K, G457S, 
S391N, D388N, N223D, L225R).78 This ability to inhibit the Hh pathway in the presence 
of wild type Smo and mutant Smo makes ITZ a unique Hh pathway antagonist.  As a 
clinically approved drug, ITZ has a well-known safety profile and has been studied for 
many years.  Taken together, ITZ serves as a promising anticancer chemotherapeutic 
agent. 
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3. Angiogenesis 
Angiogenesis is described as the formation of new blood vessels.  Blood vessels, 
which are constructed of endothelial cells (ECs), are essential for the distribution of 
oxygen and nutrients throughout the body.  These blood vessels play a major role in 
embryonic organ growth and development.79,80  Adult blood vessels are necessary for 
wound healing, the menstrual cycle, and in the placenta during pregnancy.81,80 The 
dysregulation of angiogenesis is a hallmark in a variety of different diseases including 
cancer, psoriasis, arthritis, and blindness.79 Angiogenesis is one of the few biological 
functions that impact the well-being of many people across the world as its presence 
results in a multitude of ailments; about 500 million people would benefit from 
therapeutics that modulate angiogenesis.80 The process of angiogenesis remains 
complex and involves a large number of cytokines and associated receptors.  The step-
wise process of forming new blood vessels is thought to consist of multiple signaling 
pathways including the vascular endothelial growth factor (VEGF) pathway, the mTOR 
pathway, and the Notch pathway.  In healthy adults, a balance between pro-angiogenic 
and anti-angiogenic molecules tightly regulates angiogenesis.82,83  Any extreme shift in 
this equilibrium will lead to uncontrolled angiogenesis, which includes both vascular 
insufficiency and vascular overgrowth.  Various stimuli affect this “angiogenic switch” 
and include metabolic stress, mechanical stress, immune/inflammatory response, and 
genetic mutations.  In response to these stimuli, the cell releases pro-angiogenic factors 
and initiates the angiogenic switch.82,83 
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3.1 Pathways Involved in Angiogenesis 
 The vascular endothelial growth factor (VEGF) receptor family is the most 
studied in terms of angiogenesis and is responsible for regulating new blood vessel 
growth.  VEGF aids in proliferation and survival of ECs and enhancing vascular 
permeability.    This family includes VEGF A, B, C, D, E, and placental growth factor 1 
and 2 (PIGF-1 and PIGF-2).  VEGF molecules signal through tyrosine kinase receptors, 
vascular endothelial growth factor receptors (VEGFR1-3).84–86  Out of the three 
isoforms, VEGFR2 is responsible for effects that are directly related to angiogenesis.   
VEGF is produced by cancer cells and results in tumor metastasis seen in a number of 
different types of cancers. In cancer, VEGF is induced by a number of 
pathophysiological factors such as hypoxia, low oxygen tension.  After release of VEGF, 
it can trigger more cellular pathways such as JAK-STAT, Erk/MAPK, and PI3K/Akt, 
which are involved in DNA synthesis/cell growth and cell survival.62,84,85,86  
 Platelet derived growth factor (PDGF) is an essential protein for blood vessel 
maturation.  It plays a role in the development and differentiation of blood vessel walls.  
PDGF interacts with VEGF and it is believed that these pathways converge and exhibit 
activity such as the stabilization and formation of new blood vessels.84–86  It is also 
hypothesized that PDGF is activated to overcome resistance acquired from VEGF 
inhibition.  There are four isoforms of PDGF (A-D) and two isoforms of receptor PDGFR 
(a-b).  Ultimately, activation of the PDGF pathway leads to downstream signaling of the 
PI3K/Atk pathway and subsequent interactions with MAPK molecules, Src proteins, 
phospholipase C-gamma, Ras protein, STAT proteins, and guanine-5’-triphosphate 
(GTPase)-activating protein.62,84,86,85 
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 The fibroblast growth factor (FGF) pathway has been extensively studied as an 
embryogenesis pathway.  There are 23 isoforms of FGF protein and 5 receptor 
isoforms.  FGF receptors contain an extracellular immunoglobulin (Ig)-like domain and 
an intracellular tyrosine kinase domain.  Ligand binding to receptor causes a 
dimerization of receptors and an intracellular signaling cascade.85–87 This signaling 
cascade involves downstream proteins involved in the MAPK and PI3K/Akt cascades.  
FGF may also exhibit its angiogenesis activity alongside VEGF; there may also be 
some crosstalk with the Notch Pathway, which plays a role in cell patterning and 
differentiation. The Notch Pathway has also been found to play a significant role in 
angiogenesis regarding endothelial cell differentiation.62,87,86,85 
 Angiopoietin (Ang) exists as two isoforms (Ang-1 and Ang-2) and both may 
interact with Tie2 receptor to enhance new vessel production.85,86 Ang-1 acts via the 
Akt/survivin pathway to help stabilize new blood vessels.  Ang-2 acts alone or in 
combination with other pro-angiogenic factors such as VEGF to establish and enhance 
vasculature.85,86  Downstream signaling of the Ang/Tie2 receptor includes the PI3K/Akt 
pathway, Protein Kinase B, MAPK/Erk molecules, and Ras pathway molecules.  
Blocking the interaction between Ang/Tie2 leads to decreased sprouting and reduction 
in number of tumor vessels highlighting this pathways role in angiogenesis.62,85,86 
3.2 Angiogenesis and Cancer 
 Angiogenesis was first observed in malignant cancerous tumors over 100 years 
ago.  It was later proposed that tumor growth and metastasis are dependent on the 
formation of new blood vessels.88 Additional evidence demonstrated that cells in 
precancerous tissue develop angiogenic properties on their way to becoming 
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cancerous.89  The hypothesis was thus made that inhibition of angiogenesis would 
arrest tumor growth; the search began for the development of anti-angiogenic agents to 
be utilized as chemotherapeutic agents.82 There are a wide variety of pro-angiogenic 
molecules including the well-known vascular endothelial growth factor (VEGF) and 
basic fibroblast factor (bFGF).  The primary drivers of tumor angiogenesis are hypoxic 
cells.82,84,87 Hypoxia results from the distance between the tumor cells and the oxygen 
source.  This stimulus causes the cells to secrete pro-angiogenic factors, such as 
VEGF, which bind to endothelial cells (ECs).  Activation of ECs leads to blood vessel 
formation.  These newly formed blood vessels attach to the tumor mass and invade the 
local tumor environment leading to tumor growth, metastatic spread, and the 
pathogenesis of cancer (Figure 15). 84,82,87,62 
 
Figure 15. Tumor Angiogenesis 
3.3 Established Angiogenesis Inhibitors 
This link between angiogenesis and tumor growth provided another therapeutic 
route towards treating cancer.  A number of synthesized and naturally occurring 
compounds have been explored for angiogenesis inhibition. These angiogenesis 
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inhibitors would be used to indirectly arrest tumor growth by inhibiting the growth of 
blood vessels and depriving tumor cells of oxygen and nutrients.  Due to the complexity 
of angiogenesis, there are a variety of drug targets for inhibiting this biological function.  
As a result, there are a few different classes of angiogenesis antagonists such as 
compounds that target angiogenic growth factors and compounds that target endothelial 
cell (EC) migration/proliferation.  A few angiogenesis inhibitors have been approved by 
the FDA including bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), 
pazopanib (Votrient), and everolimus (Afinitor) (Figure 16).  Most of these approved 
agents are dual-action inhibitors targeting VEGFR/PDGFR and/or various pathways 
such as RAF/MEK/ERK and mTOR.90–94  Bevacizumab is a monoclonal antibody (anti-
VEGF) and serves as the only angiogenesis inhibitor that is not a small molecule.93  
While there has been a modestly positive outcome from angiogenesis antagonists in 
clinical trials, there has been no long-term survival benefits documented.83 In most 
cases, it has been determined that the combination of antiangiogenic agents and 
chemotherapeutic agents is more effective than either therapy alone.  In addition, while 
most chemotherapeutic agents are toxic and confer resistance, antiangiogenic agents 
have only shown mild side effects and there are not reported incidents of resistance.   
This combination of conventional methods and angiogenesis inhibitors provides a novel 
and safe approach for future cancer treatment.83,95 
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Figure 16. Small Molecule Angiogenesis Inhibitors 
 
3.4 Combination Therapies 
 As previously mentioned, angiogenesis inhibitors are not productive enough on 
their own to be administered as monotherapy; in addition, resistance is rapidly acquired, 
as there are many cellular pathways involved with angiogenesis.83,84  It is anticipated 
that the most productive way to utilize angiogenesis inhibitors is in combination with 
other chemotherapeutic agents.  Preclinical and clinical evidence suggest dual 
treatment with an angiogenesis inhibitor and cytotoxic agents/radiation therapy result in 
an additive antitumor effect.83,84 There are several preclinical and clinical trials exploring 
angiogenesis inhibitors with EGFr/Her2 inhibitors (cetuximab, erlotinib, trastuzumab); 
PDGFR/bcr-abl inhibitors (imatinib); proteosome inhibitors (bortezomib); and inhibitors 
of integrins (alphavbeta3 and alpha5beta1).83,84 While combination therapy seems 
possible, there are still debates on if this is a practical approach.  Paradoxically, an 
angiogenesis inhibitor may deteriorate blood vessels and blood flow, which would 
decrease the efficacy of chemotherapy and drug delivery to the tumor site.83,84  
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3.5 ITZ and Angiogenesis 
 Because angiogenesis is implicated in a variety of ailments, a therapeutic agent 
that targeted angiogenesis would be beneficial to many people.10 Johns Hopkins 
University screened 2,604 FDA approved drugs for antiangiogenic activity utilizing 
human umbilical vein endothelial cell (HUVEC) proliferation assays.  From these 
screens, ITZ was found to be a potent and selective inhibitor of VEFG-induced 
proliferation in HUVEC cells (IC50= 0.16 µM).10 Other azole antifungals were also 
screened for antiangiogenic activity.  All other azole antifungals were less potent than 
ITZ including ketoconazole and terconazole (IC50= 10.4 µM and 7.1 µM, 
respectively).10,96  
Clinically, ITZ is used as a 1:1:1:1 mixture of four diastereomers.14 Johns 
Hopkins further explored the antiangiogenic activity of all eight stereoisomers of ITZ.  
Stereochemistry minimally effected antiangiogenic activity.97 The most prominent effect 
was seen within the dioxolane region, where the cis-diastereomers were more potent 
than the trans-diastereomers.  The stereochemistry of the sec-butyl group was found to 
have little influence on the endothelial cell inhibitory activity.97 While the ITZ 
antiangiogenic mechanism is still being unraveled, Johns Hopkins University 
determined that ITZ inhibits cholesterol trafficking, the mTOR pathway, and VEGFR 
signaling in HUVECs.98,96  It has also been determined that ITZ inhibits the mTOR 
pathway and the ERK1/2 pathway in HMEC-1 cells, a primary cell line with a limited life 
span and variable characteristics due to multi-donor origins.99 
The antiangiogenic activity of ITZ can be attributed to its inhibition of the 
mechanistic Target of Rapamycin (mTOR) signaling pathway via the disruption of 
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cholesterol trafficking between the plasma membrane and late endosomes/lysosomes.98 
This activity is due to ITZ’s ability to inhibit both Niemann-Pick Type C (NPC1) and 
voltage-dependent anion channel 1 (VDAC1) which inhibit the mTOR pathway through 
distinct mechanisms.100,101  NPC1 inhibition prevents the release of cholesterol from the 
lysosome to the rest of the cell.  VDAC1 is a critical regulator of mitochondrial 
metabolism and its inhibition leads to a drop in cellular energy levels; VDAC1 is shown 
to be a novel target for modulation of the mTOR pathway (Figure 17).100,101 This 
anticancer activity can also be attributed to its ability to inhibit vascular endothelial 
growth factor receptor 2 (VEGFR2).96 Because of this, ITZ is currently in several clinical 
trials that represent a broad range of cancers: breast, prostate, and non-small cell 
lung.11   
 
Figure 17. ITZ Proposed Mechanism of Action:  Antiangiogenesis Activity101 
4. Conclusions  
 Exploring FDA-approved or clinical stage compounds for novel biological 
activities is becoming a popular way to expedite the long and expensive drug 
development process.2  There are many benefits to this approach such as decreased 
time and expense, however, there are also disadvantages associated with this form of 
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drug discovery.  Recently, two separate screening efforts found ITZ, a clinically 
efficacious antifungal agent, to inhibit both the Hh pathway and angiogenesis.9,10  While 
the Hh pathway has been studied for many years, the emergence of resistance 
highlights the therapeutic need for novel Hh pathway inhibitors.50  ITZ is of therapeutic 
promise due to its unique ability to inhibit the Hh pathway in the presence of both wild 
type Smo and mutant Smo.78  In addition, ITZ has been found to contain other biological 
activities, such as angiogenesis inhibition, that may aid in its anticancer properties.  
These biological activities all seem to act in distinct manners from one another.  It is 
possible that these activities may yield synergistic effects in anticancer treatment 
supporting the many clinical trials that ITZ is currently being studied. 
 The overall goal of this research project is to utilize the scaffold of the FDA-
approved antifungal agent, ITZ, for the treatment of SHH subtype MB.  To date, ITZ has 
not been thoroughly explored in terms of its novel anticancer properties.  More 
specifically, ITZ has not been studied as a potential anti-MB chemotherapeutic agent.  
In terms of its anti-Hh activity, only one SAR study has been reported which focuses on 
extending the side-chain region of the scaffold.  As there is currently not an FDA-
approved targeted treatment for MB, it is necessary to explore Hh inhibitors as an 
alternative option for therapy. The ITZ analogues presented herein will be focused on 
improving the general “drug-like” properties of this approved compound while also 
maintaining potent Hh pathway activity.  These analogues may be modified to have the 
optimal properties necessary to penetrate the blood brain barrier (BBB) and treat 
pediatric MB.  If optimal drug-like properties cannot be attained after considerable 
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structure-activity relationship (SAR) studies, drug formulation will be utilized to assist the 
most potent in vitro ITZ analogues to cross the BBB and reach the brain.  
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CHAPTER II: Structure-Activity Relationship Studies of Itraconazole Analogue 
Generations I and II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 	 		
 49		
1. Introduction 
 
 Recently, two separate high-throughput screens of FDA-approved compounds 
identified itraconazole (ITZ), a well-known antifungal agent, to be an inhibitor of both the 
Hh pathway and angiogenesis (IC50 = 690 nM and 160 nM, respectively).9,10  The 
potential to repurpose FDA-approved and clinical stage compounds with novel 
biological activities is an increasingly popular drug development strategy.2 While ITZ is 
now in various clinical trials for its anti-cancer potential, it contains some drug properties 
that would not make it an ideal chemotherapeutic agent.12,11  ITZ contains a triazole 
group, which is capable of coordinating with CYP3A4; this interaction leads to drug-drug 
interactions and adverse side effects.102 As cancer patients are often on a multi-drug 
regimen to both treat the cancer and manage the symptoms, these drug-drug 
interactions would be probable in the presence of ITZ.    
To date, the ITZ scaffold has been minimally explored in terms of its novel anti-
cancer properties. The ability for ITZ to inhibit angiogenesis, specifically through 
vascular-endothelial growth factor receptor 2 (VEGFR2), NPC1, and VDAC1 have been 
previously reported.96,101  However, thorough structure-activity relationship (SAR) 
studies have not been performed in regards to ITZ and its novel biological activities.  In 
terms of anti-Hh activity, the only structural component explored has been the side-
chain region.103 Thus, a series of ITZ analogues have been designed, synthesized, and 
evaluated to probe the ITZ scaffold for its anti-Hh and anti-angiogenic activities. 
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2. Design, Synthesis, and Evaluation of Generation I Analogues 
 
2.1 Analogue Design 
 
As previously mentioned, ITZ is a rather large compound that has a complex 
chemical structure, which is amendable to various modifications.  This first generation 
series of ITZ analogues designed, synthesized, and evaluated consists of conservative 
modifications to either the dioxolane region or the triazolone/side-chain region (Figure 
1).  The overall goal of this initial series of analogues is to determine if all the structural 
functionality of ITZ is necessary for its anticancer properties.  This first generation of 
analogues will provide preliminary data that suggests the favorable and unfavorable 
structural components of ITZ-mediated Hh inhibition and angiogenesis inhibition. 
 
 
 
Figure 1. Design of Generation I Analogues 
 
2.2 Synthetic Routes 
 
2.2.1 Synthesis towards Linker Region  
All of the first-generation ITZ analogues contain a central phenyl-piperazine-
phenyl linker region.  This moiety is initially constructed by coupling commercially 
available N-(4-methoxyphenyl)-piperazine (11) and 1-chloro-4-nitrobenzene (12).  The 
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nitro functionality (13) can then be reduced to the aniline (14) in the presence of 
hydrazine monohydrate and 10% palladium on charcoal.  The aniline then undergoes a 
series of two well-characterized transformations to the carbamate (15) and hydrazine 
carboxamide (16) intermediates before ultimately forming the triazolone ring (17) 
(Scheme 1).97 The methoxy- substituent in the commercially available starting material 
serves as a protecting group throughout this synthetic route; while other protecting 
groups have been used during this synthesis, such as methoxymethyl- (MOM-), we 
found that the methoxy- group proved more efficient in generating the triazolone 
intermediate.103 
Scheme 1. Synthesis towards Linker Region 
 
Reagents and conditions: (a) K2CO3, reflux, 12 h, 82%; (b) Pd/C, NH2NH2•H2O (10 eq), reflux, 
3.5 h, 71%; (c) Pyr (17 eq), ClCOOPh (1.1 eq), 3 h, 90%; (d) NH2NH2•H2O (5.5 eq), reflux, 3 h, 
quant; (e) formamidine acetate (4.5 eq), acetic acid, reflux, 3 h, 91%.	
 
The triazolone intermediate was alkylated (24-27) with either commercially 
available brominated alkyl chains (22,23) or alkyl brosylates (20,21) that were prepared 
from corresponding commercially available and stereochemically defined alcohols 
(18,19) (Scheme 2).97 The methoxy- group in the triazolone/side-chain intermediate was 
removed with 48% hydrobromic acid in toluene to afford various phenols (28-31).104 It is 
important to note that alkylation of the triazolone inverts the stereochemistry of the side 
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chain region, for example, (R)-brosylates generate (S)-intermediates.  The 
stereochemistry of the triazolone/side-chain regions was monitored throughout these 
reactions.  As enantiomers have similar physical properties such as melting points, 
densities, boiling points, and refractive indexes, a polarimeter was used to aid in 
determining the optical activity and corresponding orientation of the stereochemically-
defined intermediates.  If a substance is not optically active, the polarimeter output will 
read [α] = 0°.  However, if a compound is optically active, the plane of light will either be 
rotated clockwise or counter clockwise and the observer will read a (+) or (–) value.  It is 
important to note that a (+) or (–) value is not indicative of a particular isomer.105  These 
polarized values were used in combination with crystal structures to determine the (R) 
or (S) configurations of these stereochemically-defined intermediates.  
Scheme 2. Synthesis towards Phenol 
	
Reagents and conditions: (a) Et3N, BsCl (1.3 eq), RT, 3 h; 30-50%; (b) Cs2CO3, brosyl/bromo 
alkyl chain, RT, 12 h, 45-88% (c) 48% HBr, toluene, reflux, 12 h, 55-80%. 
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2.2.2 Synthesis towards Dioxolane Regions 
Dioxolane regions containing the triazole moiety could not be formed under 
standard ketalization conditions due to the basicity of the triazole ring.  For these 
intermediates, the triazole moiety was added to various halogenated ketones.  In 
parallel, tosylated glycerol was formed through standard tosylation of commercially 
available dioxolane and subsequent acid mediated hydrolysis (Scheme 3).106 Finally 
triazole-containing dioxolanes were prepared through a ketalization reaction utilizing 
tosylated glycerol, ketone intermediates, and triflic acid.107 Other attempts were made to 
add the triazole group directly to the dioxolane after the ring closing reaction, as this 
would be helpful in developing subsequent triazole-mimic analogues; however, this 
proved unsuccessful.  The des-triazole dioxolanes were synthesized utilizing standard 
ketalization conditions that make use of the Dean-Stark apparatus.108 Tosylated glycerol 
was used to ketalize 2,4-dichloroacetophenone and yield des-triazole dioxolane.97  
Scheme 3. Synthesis towards Dioxolane Region 
	
Reagents and conditions: (a) NaHCO3, toluene, reflux, 3h, 25-65%; (b) Pyr, TsCl, 0°C- RT, 12 
h, 71%; (c) MeOH, 0.5N HCl, reflux, 5 h, 89%; (d) Triflic acid (3-4 eq), toluene, RT, 60 h 10-
70%. 
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2.2.3 Synthesis towards Generation I Final Analogues 
 Tosylated dioxolane regions were coupled with the linker/triazolone/side-chain 
region phenols in anhydrous dimethyl sulfoxide (DMSO) with cesium carbonate 
(Cs2CO3) to yield final analogues (Scheme 4A).97 Truncated ITZ analogues were 
synthesized via a reversed synthetic route.  Unprotected linker region (44) was 
prepared in the same manner as methoxy-protected linker region.103 This intermediate 
was then coupled with the tosylated dioxolane region under standard coupling 
conditions to yield nitro intermediate (54).  This intermediate was then reduced to the 
aniline with palladium on charcoal in the presence of hydrazine monohydrate to yield 
aniline intermediate (55) (Scheme 4B).103 
Scheme 4. Synthesis towards Final Generation I Analogues 
	
Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 90ºC, 12 h, 45-88%; (b) Pd/C, 
NH2NH2•H2O (10 eq), reflux, 3.5 h, 60-70%. The functional groups represented by X, Y, and Z 
above can be found in Schemes 2 and 3. 
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2.3. Biological Evaluation 
 
Table 1. First Generation Series of ITZ Analogues 
 
	 	
Compound R1 R2 R3 
45, ITZ 
   
46 -CH3 
  
47 
   
48 
 
-CH3 
 
49 -CH3 -CH3 
 
50 
   
51 
   
52 
   
53 
   
54 
  
-NO2 
55 
  
-NH2 
 
 The first generation of ITZ analogues (Table 1) was evaluated for Hh pathway 
inhibitory activity by monitoring endogenous Gli1 mRNA levels in C3H10T1/2 (C3H) 
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cells, an Hh-dependent mouse embryonic fibroblast (MEF), at a single concentration 
(1µM).  This is a well-studied in vitro model system for evaluating small molecule 
inhibition of Hh signaling.  Addition of exogenous Hh agonist (recombinant Hh ligand or 
small molecule) results in a characteristic increase in Gli1 mRNA expression.109 
Combined treatment with Hh agonist and a pathway inhibitor reduces Gli1 expression.  
ITZ analogues that reduced Gli1 mRNA expression below 20% at 1µM were 
subsequently evaluated for their ability to reduce Gli1 mRNA expression levels in a 
concentration dependent fashion in both the C3H cell line and an Hh-dependent murine 
basal cell carcinoma cell line (ASZ-001).110,111  Finally, with the help of our collaborators 
at Sanford Burnham Prebys Medical Discovery Institute, several generation I analogues 
were also tested for their antiproliferative activity in primary Hh-dependent 
medulloblastoma cells isolated from conditional Patched knockout Math1-Cre-ER; Ptcfl/fl 
(MERP) mice.112,113,114  Only a small subset of analogues was evaluated due to the 
difficult nature of culturing primary MERP cells. 
 As ITZ was found to also inhibit angiogenesis, generation I analogues were 
screened for their ability to inhibit VEGF-induced proliferation of human umbilical vein 
endothelial cells (HUVECs).  Angiogenesis is dependent on endothelial cell proliferation 
and the inhibition of HUVEC proliferation is commonly utilized as an early stage in vitro 
model of antiangiogenic activity.97,103 
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Table 2. In Vitro Activity of First Generation ITZ Analogues 
Compound 
% Gli 
Expression 
(1 µM) b  
IC50 (µM) a 
C3H10T1/2 b          ASZ c 
GI50 (µM) a, d 
HUVEC 
GI50 (µM) a 
MERP 
MB c 
ITZ	   0.07 ± 0.02 0.14 ± 0.02 0.40 ± 0.03 0.44 ± 0.08 
45 1.7 ±	0.3 0.06 ± 0.003 0.17 ± 0.01 0.49 ± 0.09 0.6 ± 0.1 
46 17.8 ±	0.5 0.14 ± 0.04 0.17 ± 0.04 23.8 ± 6.7 ND 
47 13.1 ±	1.2 0.42 ± 0.2 0.45 ± 0.06 8.3 ± 0.7 ND 
48 61.4 ±	3.5 ND ND 18.4 ± 4.5 ND 
49 71.4 ±	5.5 ND ND >100 ND 
50 6.9 ±	3.1 0.16 ± 0.04 0.14 ± 0.01 2.5 ± 0.3 ND 
51 3.0 ±	0.9 0.14 ± 0.04 0.16 ± 0.02 1.7 ± 0.4 ND 
52 58.5 ±	6.4 ND ND 4.7 ± 0.3 ND 
53 1.1 ±	0.2 0.043 ± 0.02 0.12 ± 0.03 5.8 ± 0.8 ND 
54 1.5 ±	0.05 0.13 ± 0.03 0.09 ± 0.03 8.4 ± 0.7 ND 
55 6.1 ±	1.6 0.16 ± 0.06 0.12 ± 0.05 42.7 ± 4.4 0.9 ± 0.7 
30 45.7 ±	3.0 ND ND >100 ND 
aIC50 and GI50 values represent the Mean ± SEM of at least two separate experiments performed in 
triplicate. bAll analogues evaluated following 24 hr incubation. cAll analogues evaluated following 48 hr 
incubation. dAll analogues were evaluated following 72 hr incubation.  
  
Evaluation of the first generation of ITZ analogues (Table 2) yielded structural 
features that appear necessary for Hh pathway inhibition.  First, the stereochemistry at 
the 2’ position of the sec-butyl side-chain region does not appear to be important (50 
and 51 are equipotent in the MEF and ASZ cell lines).  Truncation to a propyl side-chain 
(52) significantly reduces the overall activity of the scaffold.  Interestingly, removal of the 
side-chain region to the free triazolone (53) and further truncation of the triazolone 
region to nitro or aniline substituents (54 and 55) maintained Hh pathway inhibition; all 
three of these analogues maintained potent IC50 values in the MEF and ASZ cell lines in 
relation to ITZ.  In terms of the modifications made to the dioxolane region, removal of 
the chlorine atoms of the phenyl ring (47) had minimal effects while truncation of the 
phenyl ring all together (48) resulted in significant loss of Hh pathway inhibition.  
Removal of the triazole moiety (46) maintained potent Hh pathway inhibition.  Not 
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surprisingly, removal of both the triazole and the phenyl functionality (49) or complete 
truncation to the phenol (30) significantly reduced Hh pathway inhibitory activity.  Our 
synthesized ITZ (45) demonstrated comparable activity to commercially available ITZ in 
both the MEF and ASZ cell lines.  Overall, these analogues were equipotent in their 
ability to down regulate Gli1 mRNA expression in both cell lines evaluated.  ITZ, 45, and 
55 were tested for their ability to inhibit proliferation of Hh-dependent murine MB cells 
and all three of these compounds had slightly reduced activity (Table 2).115  
 First generation analogues were also evaluated for their ability to inhibit VEGF-
induced anti-proliferation in HUVECs, a preliminary assay used to measure 
angiogenesis inhibitory potential (Table 2).  Commercially available ITZ and synthesized 
ITZ (45) demonstrated comparable antiproliferative activity (GI50 values = 0.40 and 0.49 
µM, respectively).  Other ITZ analogues were significantly less active compared to ITZ.  
Several analogues were moderately active (GI50 = 1.7 – 8.4 µM); however, there was no 
clear SAR pattern in terms of angiogenesis.  Finally, ITZ and des-triazole ITZ (46) were 
evaluated for their ability to inhibit CYP3A4 (IC50 values = 50.4 nM and >10 µM, 
respectively).  Removal of the triazole moiety results in potent Hh inhibition and 
abolishes CYP3A4 inhibition making compound (46) the lead analogue from this first 
generation of ITZ analogues (Figure 2).115  
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Figure 2. CYP3A4 Inhibition  
Calculated IC50 values (µM) for inhibition of CYP3A4 activity by the two compounds are as 
follows: ITZ (0.051 ± 0.01 µM) and des-triazole ITZ (>10 µM). 
 
 
3. Design, Synthesis, and Evaluation of Generation II Analogues 
3.1 Analogue Design 
 Formation of the cis-conformation around the dioxolane ring predominates during 
its synthesis and pharmaceutical preparations of ITZ are typically administered as a 
1:1:1:1 mixture of cis-diastereomers.115 For efficiency, the first generation of ITZ 
analogues was evaluated as mixtures of stereochemical isomers.  To probe more fully 
the absolute structural requirements of this scaffold for its novel biological activities, a 
second generation of analogues was designed, synthesized, and evaluated (Figure 3).  
This second generation contains the stereochemically-defined isomers of lead 
compound, des-triazole ITZ (46).  This generation of compounds will highlight if there is 
an optimal stereochemical orientation for either Hh pathway inhibition or angiogenesis 
inhibition.115  
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Figure 3. Design of Generation II Analogues 
 It is important to note the difference in nomenclature of the stereochemistry 
surrounding the dioxolane region differs between ITZ and des-triazole ITZ.  In terms of 
ITZ, the triazole moiety receives the priority within the dioxolane region; therefore, the 
cis- orientation is in reference to the triazole and ether linkage.  By contrast, removal of 
the triazole group shifts the priority to the phenyl ring and a cis-des-triazole analogue 
has the opposite absolute configuration between the phenyl ring and the ether linkage 
as ITZ (Figure 4).115  
	
Figure 4. (A) Representative cis-ITZ isomer, (B) cis- and (C) trans-des-triazole 
analogues 
 
3.2 Synthetic Routes 
3.2.1 Synthesis towards Stereochemically-Defined Dioxolane Regions 
 The stereochemically-defined des-triazole dioxolane regions were synthesized 
under standard ketalization reaction conditions utilizing a Dean-Stark apparatus.108 
Stereochemically-defined tosylated glycerols were prepared via the method described 
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previously only beginning with stereochemically-defined commercially available 
dioxolane (Scheme 5).106 Formation of the dioxolane ring predominately forms the 
trans- isomer and these isomers were best separated via preparative thin layer 
chromatography (TLC). 
Scheme 5. Synthesis towards Stereochemically Defined Dioxolanes 
	
Reagents and conditions: (a) p-TsOH (cat.), toluene, reflux (Dean Stark), 48h, 70-90%. 
 
3.2.2 Synthesis towards Final Stereochemically Defined Analogues 
 As previously described, tosylated dioxolane regions were coupled with the 
linker/triazolone/side-chain region phenols in anhydrous dimethyl sulfoxide with cesium 
carbonate to yield final analogues (Scheme 6).97 
Scheme 6. Synthesis towards Final Generation II Analogues 
 
Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 90ºC, 12h, 45-88% 
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3.3 Biological Evaluation 
Table 3. Second Generation ITZ Analogues 
 
	
Compound R1 R2 
Final 
Stereochemistry 
63 
  
Trans-2,4 
64 
  
Cis-2,4 
65 
  
Trans-2S,4S,2’S 
66 
  
Cis-2R,4S,2’S 
67 
  
Trans-2R,4R,2’S 
68 
  
Cis-2S,4R,2’S 
69 
  
Trans-2S,4S,2’R 
70 
  
Cis-2R,4S,2’R 
71 
  
Trans-2R,4R,2’R 
72 
  
Cis-2S,4R,2’R 
73 
  
Trans-2R,4R 
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74 
  
Cis-2S,4R 
75 
  
Trans-2S,4S 
76 
  
Cis-2R,4S 
 
Evaluation of our stereochemically defined analogues (Table 3) for their ability to 
inhibit Hh signaling in the C3H10T1/2 and ASZ cell lines provided both interesting and 
confounding results.  The majority of compounds evaluated were more active in the 
ASZ cells, with numerous analogues exhibiting 100- to 1000-fold improvement in activity 
when compared to C3H cells.    Several compounds that were “inactive” in the C3H 
cells (IC50 >10 µM) exhibited potent down-regulation of Gli (IC50 – 0.2-0.5 µM) in the 
ASZ cell line.  In addition, several other compounds with modest inhibitory effects in the 
MEF cell line (64, 68, 72) exhibited low nanomolar IC50 values in the ASZ cells (Table 
4).115  
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Table 4. In Vitro Activity of Second Generation ITZ Analogues  
Compound IC50 (µM) 
a 
C3H10T1/2 b                   ASZ c 
GI50 (µM) a, d 
HUVEC 
GI50 (µM) a 
MERP 
MB c 
63 0.091 ± 0.02 0.077 ± 0.01 3.32 ± 0.55 2.0 ± 1.3 
64 0.85 ± 0.1 0.071 ± 0.02 3.69 ± 1.1 2.9 ± 1.9 
65 1.1 ± 0.17 2.5 ± 0.7 7.7 ± 4.4 ND 
66 >10 0.55 ± 0.07 78.3 ± 17.3 ND 
67 0.47 ± 0.001 0.38 ± 0.07 18.3 ± 11.8 ND 
68 1.85 ± 0.09 0.15 ± 0.038 2.5 ± 0.7 0.39 ± 0.2 
69 0.54 ± 0.24 0.13 ± 0.04 12.1 ± 4.7 ND 
70 6.6 ± 0.3 2.8 ± 0.9 65.0 ± 11.5 ND 
71 0.19 ± 0.04 0.022 ± 0.01 53.2 ± 25.2 0.6 ± 0.2 
72 2.4 ± 0.6 0.024 ± 0.02 12.8 ± 2.9 1.0 ± 0.5 
73 4.1 ± 1.5 1.3 ± 0.65 26.5 ± 3.5 ND 
74 >10 1.4 ± 0.5 49.9 ± 15.9 ND 
75 >10 0.2 ± 0.08 84.1 ± 33.5 22.4 ± 12 
76 
PSZ 
>10 
0.14 ± 0.02 
0.54 ± 0.06 
0.54 ± 0.05 
24.9 ± 2.2 
1.6 ± 0.02 
ND 
1.5 ± 0.3 
aIC50 and GI50 values represent the Mean ± SEM of at least two separate experiments performed in 
triplicate. bAll analogues evaluated following 24 hr incubation. cAll analogues evaluated following 48 hr 
incubation. dAll analogues were evaluated following 72 hr incubation.  
  
Despite the conflicting results between cell lines, several interesting SAR 
developments with respect to optimal configuration were identified for the second 
generation of ITZ analogues (Table 4).  These results reiterated that the orientation of 
the sec-butyl side-chain substitution is not significant but the methyl group must be 
present.  Truncation to the propyl side-chain region abolishes Hh pathway activity.   
Compounds containing the propyl side-chain region were significantly less active than 
sec-butyl analogues containing the same dioxolane ring orientation.  Generation II 
analogues with the trans-orientation around the dioxolane ring were generally more 
potent than the cis-orientation throughout all cell lines evaluated.  Finally, compounds 
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containing the 4R configuration were generally more active than the 4S configuration; 
des-triazole analogues with the 2R,4R configuration demonstrated the most comparable 
activity between the two cell lines.115  
After evaluation of Hh pathway inhibitory activity in both the C3H10T1/2 and ASZ 
cells, select compounds were further evaluated in primary MB (MERP) cells (Table 
5).112,113,114  Analogues selected for the antiproliferative assay were chosen either 
because they exhibited potency in both cell lines (ASZ and MEF) or because they were 
significantly less active in the MEFs in comparison to the ASZs.  Testing the 
antiproliferative effects of these analogues in the Hh-dependent primary culture 
provided additional in vitro data for the most active trans-oriented compounds and also 
aided in determining discrepancies in the Hh pathway inhibitory activity across the two 
preliminary cell lines.  The mixtures containing trans- and cis- (63 and 64) 
stereoisomers were less active than the single stereochemically defined analogues.  
The most active analogue in this assay was analogue 68 (GI50 = 0.39 µM) which has the 
cis-2R,4R configuration around the dioxolane moiety.  Further, the reduced 
antiproliferative activity exhibited for analogue 75 further highlights the importance of the 
methyl group on the side chain region of Hh pathway inhibition.  Based on these 
antiproliferative results, several generation II analogues (68, 71, and 72) were evaluated 
for their ability to down regulate endogenous Gli1 mRNA expression in the MERP 
primary cell line.112–114 Each of these analogues, along with parent compound ITZ, 
demonstrated potent down-regulation of Gli1 mRNA expression in this assay.  In 
addition, the anti-Hh activity of these analogues in the MERP MB cells more closely 
correlated with the data obtained in the ASZ cells.  This suggests that the immortalized 
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BCC cell line may be a more appropriate early stage in vitro cellular model for Hh 
inhibition.  Specifically, this model should be utilized in testing compounds that contain 
the ITZ scaffold.115  
Table 5. Down-Regulation of Gli1 mRNA in MERP MB cells  
Compound IC50 (µM) a, b 
ITZ 0.39 ± 0.06 
68 0.26 ± 0.12 
71 0.19 ± 0.07 
72 0.29 ± 0.08 
aIC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. bAll 
analogues evaluated following 48 hr incubation.  
 
 Following the discovery of ITZ and its novel biological activities, the entire class 
of azole antifungals was screened for Hh-inhibitory activity.9 The only other compound 
to exhibit comparable activity to ITZ was posaconazole (PSZ), which interestingly has a 
very similar chemical structure; ITZ and PSZ share the same phenyl-piperazine-phenyl 
linker and differ in their dioxolane and furan rings, halogenated substituents, and side-
chain regions (Figure 5).  PSZ and the most active generation II analogue (71) share a 
similar orientation in terms of their dioxolane/furan rings.  Therefore, PSZ was evaluated 
for its ability to inhibit Gli1 expression in the C3H, ASZ, and MERP cell lines (Table 4).  
Due to its moderate activity in MERP cells, it was concluded that the dioxolane and 
hydrophobic side-chain region of ITZ may be more advantageous than the furan and 
hydroxylated side-chain region of PSZ.115  
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Figure 5. Structure of Posaconazole 
In terms of angiogenesis inhibition, results obtained from the HUVEC 
antiproliferation assay did not yield a clear SAR pattern that distinguished one 
stereoisomer to be more potent (Table 4).  The stereo-defined analogue that had the 
most potent activity against HUVEC proliferation was 68 (IC50 = 2.5 ± 0.7 µM), which 
contains the (R)-cis-dioxolane region and the (S)-sec-butyl side chain region.  When 
only the stereochemistry of the sec-butyl moiety is inverted (72), activity is weakened 
(IC50 = 12.8 ± 2.9 µM).  Overall, compounds containing the (S)-sec-butyl side chain 
region were more potent than compounds containing the (R)-sec-butyl side chain 
region; compounds containing the (R)-dioxolane region were more potent than the (S)-
dioxolane, specifically, the (R)-trans dioxolane region carried the most potent activity.  
These results differ from the SAR results for Hh pathway inhibition in that the 
stereochemistry of the sec-butyl side chain did not play a crucial role in achieving potent 
activity.  In terms of HUVEC antiproliferation, there is not one dioxolane region that can 
be determined as the most potent across the second generation of ITZ analogues.115  
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Figure 6. Representative fields from tube formation assay   
Treated cells were grown on Matrigel ® for 16h.  Phase contrast images were taken from 
multiple locations in each well (~8 images/well) on an inverted microscope: (A) DMSO treatment 
served as a negative control; (B) Suramin treatment served as a positive control; (C) ITZ 
treatment at 10 µM; (D) des-triazole ITZ treatment at 10 µM; (E) 69 treatment at 10 µM; (F) 72 
treatment at 10 µM. 
 
Due to this lack of clear SAR, a several of the generation II analogues were 
evaluated in a Matrigel® tube formation assay to further explore antiangiogenic 
properties of the ITZ scaffold (Figure 6).  Normally, HUVECs plated and grown on 
matrigel migrate toward each other, align, and form tubes that resemble in vivo capillary 
beds.  This type of assay is a more accurate model of angiogenesis as it takes into 
account several aspects of proper vessel formation: adhesion, migration, and tube 
formation.116  Compounds evaluated in this assay were chosen based on their overall 
structure and activity in antiproliferation assays in an attempt to provide the most 
relevant preliminary data in terms of generation II analogues and angiogenesis 
inhibition.  Inhibition of tube formation can be measured via two different parameters: 
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tube length and tube junctions.  Based on these parameters, inhibition of tube formation 
for both ITZ and des-triazole ITZ were comparable at 10 µM.  At lower concentrations, 
there was a decrease in activity seen in des-triazole ITZ (Figure 7).  This highlights the 
importance of the triazole moiety in terms of ITZ-mediated angiogenesis inhibition.  
Interestingly, the stereochemically defined analogues presented a decrease in activity 
even at high concentrations such as 10 µM (Figure 7).  Overall, there was minimal 
correlation between the HUVEC antiproliferation assay and the HUVEC tube formation 
assay.  For example the stereochemically-defined analogues were more potent than the 
des-triazole ITZ mixture in terms of inhibiting HUVEC proliferation, however showed 
opposite activity against HUVEC tube formation.  Taken together, these data suggest 
that the triazole group of ITZ is important for the antiangiogenic activity of the scaffold 
and future SAR studies into this region should be undertaken.115  
 
Figure 7. Comparison of (A) total tube length and (B) total tube junctions  
Phase contrast images were taken from multiple locations in each well (~ 8 images/well) on an 
inverted microscope and tube formation parameters (total tube length and total tube junctions) 
were quantified using ImageJ (NIH) software.  DMSO (negative control) was set to 100% tube 
formation for analysis purposes.  Suramin (10 µM) was used as the positive control for each 
experiment and its ability to inhibit total tube length (51.9 ± 7.8%) and tube junctions (57.6 ± 
6.1%) was consistent. 
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 In addition to exploring ITZ and its analogues for these novel biological activities, 
a few of these compounds were evaluated in pharmacokinetic (PK) assays.  These PK 
data helped determine if the structural changes made were advantageous to improving 
the overall drug-like properties of the ITZ scaffold (Table 6).  None of these compounds 
are substrates for BBB efflux proteins p-glycoprotein (P-gp) or breast cancer resistant 
protein (BCRP).  The trans-dioxolane improves solubility in comparison to the cis-
dioxolane analogue (Solubility = 1.56 and 0.8 µM, respectively).  Interestingly, the cis-
dioxolane analogue has a more optimal IC50 value against CYP3A4.  Compounds ITZ, 
71, and 72 were also screened for their ability to passively permeate membranes in a 
parallel artificial membrane permeability assay (PAMPA).  The des-triazole ITZ 
analogues have poor permeability in comparison to parent compound ITZ.  
Table 6. Pharmacokinetic Data for Generation II Analogues 
Compound Solubility (µM) BCRP P-gp PAMPA CYP3A4 IC50 (µM) 
ITZ 0.8 No No Moderate 0.4 
71 1.56 No No Poor 1.02 
72 0.8 No No Poor >20 
 
4. Conclusion 
 Analogue generations I and II provided interesting information regarding the ITZ 
scaffold and its novel anticancer activities.  First, the triazole moiety can be removed 
and still maintain Hh pathway inhibition.  This is important as removal of this triazole 
region decreases the overall size of the scaffold and abolishes coordination with 
CYP3A4.  Second, while the stereochemistry of the side-chain region does not play a 
significant role in Hh pathway inhibition, the stereochemistry of the dioxolane region 
proved to be important.115  SAR studies indicated that the most potent stereochemical 
		 	 		
 71		
orientation was the 2R,4R-trans-dioxolane region.  In terms of angiogenesis inhibitory 
activity, no clear SAR pattern was determined even after a tube formation assay on 
Matrigel®.  While the triazole region is less important for Hh inhibitory activity, this 
moiety seems to be necessary for angiogenesis inhibition, as ITZ remained the most 
potent compound in both the HUVEC proliferation assay and the tube formation 
assay.115  As future analogues will not contain the triazole region, angiogenesis will no 
longer be explored.  ITZ is a large compound and there are still regions and structural 
functionality to explore in terms of these novel biological activities.  The SAR studies of 
ITZ analogue generations I and II remain important for the design, synthesis, and 
evaluation of future des-triazole ITZ analogues.   
 
Thank you to Dr. Albert DeBerardinis for his assistance with the synthesis, purification, 
and preliminary evaluation of the des-triazole ITZ analogues. 
 
4.1 Experimental 
Purity Analysis of Final Analogues: It is important to note that generation I final ITZ 
analogues were synthesized and evaluated as stereoisomeric mixtures.  This initial 
series was not separated into individual isomers and the ratio between cis/trans was not 
determined after the dioxolane reaction.  The mixtures of these final analogues are 
reflected in the 1H and 13C NMR characterization data described below and the spectra 
provided in Appendix A.  Purity analysis for all final analogues was determined via one 
of the following methods. 
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Method A: ITZ analogues were dissolved in HPLC-grade MeCN and injected (20µL of a 
1mM solution) into an Agilent Manual FL-Injection Valve (600 bar) on an Agilent 
1100/1200 Series HPLC equipped with an Agilent Eclipse Plus C18 (4.6 x 100mm) 
column and Agilent 1100 Series Photodiode Array Detector.  The mobile phase 
consisted of 60% MeCN/40% H2O for analogues containing the triazole moiety and 70% 
MeCN/30% H2O for des-triazole ITZ analogues.  All analogues were run at a flow rate of 
1.0 mL/min for 20 min and purity was assessed at 254 nm. 
Method B: ITZ analogues were dissolved in HPLC-grade MeCN and injected (20µL of a 
1mM solution) into an Agilent HPLC system coupled to an Agilent ESI single quadrupole 
mass spectrometer equipped with a Kinetix C18 (150 x 4.6 mm) column and an Agilent 
G1315 diode array detector.  The mobile phase consisted of 70% MeCN/30% H2O for 
des-triazole ITZ analogues.  All analogues were run at a flow rate of 0.7 mL/min for 30 
min and purity was assessed at 254 nm. 
Previously Characterized Intermediates: Common ITZ linker region, dioxolane region, 
side chain, and coupled intermediates were prepared primarily as described previously 
for the ITZ scaffold with the minor modifications described in Appendix A. 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (46) . To a solution of 30 (50 mg, 0.127 mol) in DMSO (2 mL) was added 
dioxolane tosylate 43 (67 mg, 0.139 mmol) followed by Cs2CO3 (0.41 mg, 1.27 mmol). 
The mixture was warmed to 80 °C and stirred for 16 h. The mixture was cooled to RT 
and water was added slowly (6 mL) with vigorous stirring to form a precipitate. The 
precipitate was filtered, washed with water, and determined to be the product with only 
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DMOS as an impurity. The precipitate was dissolve in EtOAc (60 mL) and washed with 
water (50 mL). The aqueous layer was washed with EtOAc (1 X 50 mL) and the 
combined organic layers were dried (Na2SO4), filtered, and concentrated. The crude 
residue was purified by column chromatography (SiO2, 0-80% acetone in hexanes) and 
sonicated in pentanes to produce 46 as a white solid (62 mg, 69%). 1H NMR (500 MHz, 
CDCl3) δ 8.20 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 10.6 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.50 – 
7.39 (m, 3H), 7.06 – 6.99 (m, 2H), 6.94 (d, J = 9.1 Hz, 1H), 6.88 (d, J = 8.9 Hz, 1H), 
6.84 – 6.77 (m, 1H), 6.69 – 6.61 (m, 1H), 4.88 – 4.70 (m, 2H), 4.40 – 4.19 (m, 2H), 3.96 
– 3.87 (m, 1H), 3.85 – 3.76 (m, 2H), 3.54 – 3.44 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 
1.87 (m, 1H), 1.72 (m, 1H), 1.39 (dd, J = 6.7, 1.4 Hz, 3H), 0.91 (m, 3H). 13C NMR (126 
MHz, CDCl3) δ 152.52, 152.43, 151.94, 151.49, 151.31, 150.45, 145.94, 145.89, 
144.81, 144.60, 135.98, 135.70, 134.97, 133.97, 133.81, 133.04, 132.89, 131.35, 
131.06, 129.52, 129.42, 127.15, 126.98, 125.87, 123.46, 118.37, 118.27, 116.58, 
115.19, 115.08, 74.62, 67.57, 67.37, 54.30, 53.53, 52.58, 50.49, 49.15, 28.35, 19.17, 
10.70. DART-HRMS: m/z calcd. for C35H38Cl2N8O4 [MH]+, 705.2471; Found: 705.2474.  
IR (solid) vmax: 3125, 2966, 2832, 1698, 1585, 1551, 1510, 1450, 1379, 1228, 1184, 
1139, 1042, 976, 944, 824, 736. Purity: 98.0% (Method A). 
1-(sec-butyl)-4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (47). To a 
solution of 30 (64 mg, 0.163 mmol) in DMSO (10 mL) was added sodium hydride (1.14 
mmol). The mixture was warmed to 50° C and stirred for 2 h. To this solution was added 
57a (62 mg, 0.148 mmol in DMSO, 5 mL). The solution was warmed to 90° C and 
stirred for 12 h. The mixture was cooled to RT and H2O (30 mL) was added slowly with 
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vigorous stirring. The mixture was washed with EtOAc (3 X 100 mL), and the organic 
layers were combined, dried (Na2SO4), filtered, and concentrated. The crude residue 
was purified by column chromatography (SiO2, 0-5% MeOH in DCM) to afford 47 as a 
reddish-brown solid in modest yield (34%). A portion of 47 was dissolved in chloroform 
and slow evaporation provided off-white crystals that were utilized for the biological 
assays. 1H NMR (500 MHz, CDCl3) δ 7.66 – 7.59 (m, 2H), 7.46 – 7.36 (m, 3H), 7.21 (m, 
1H), 7.06 – 7.00 (m, 2H), 7.01 – 6.71 (m, 4H), 4.37 – 4.25 (m, 2H), 4.12 (m, 1H), 4.01 
(m, 1H), 3.96 (m, 1H), 3.79 (m, 1H), 3.36 (d, J = 6.2 Hz, 4H), 3.31 – 3.17 (m, 4H), 1.89 – 
1.82 (m, 1H), 1.82 (s, 3H), 1.78 (s, 1H), 1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.90 (t, J 
= 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.0, 150.5, 138.1, 134.5, 133.8, 132.8, 
131.1, 128.8, 128.5, 126.7, 126.6, 125.9, 123.5, 118.4, 116.6, 115.5, 109.0, 73.9, 69.2, 
66.9, 52.7, 50.6, 49.2, 28.4, 25.8, 25.7, 19.2, 10.7. DART-HRMS: m/z calcd. for 
C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2298.  IR (solid) vmax 2960, 2922, 2874, 
2850, 1696, 1552, 1509, 1462, 1449, 1376, 1226, 1192, 1149, 1076, 1034, 870, 734. 
Purity: 98.0% (Method A).   
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-phenyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-(sec-butyl)-1H-1,2,4-triazol-5(4H)-one 
(48). ITZ analogue 48 was prepared using the general method described above for 
analogue 46 utilizing the requisite linker/side chain and dioxolane intermediates (23 mg, 
47%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.91 (s, 1H), 7.61 (s, 1H), 7.57 – 7.51 
(m, 2H), 7.46 – 7.34 (m, 5H), 7.06 – 7.00 (m, 2H), 6.96 – 6.90 (m, 2H), 6.82 – 6.76 (m, 
2H), 4.54 (d, J = 1.6 Hz, 2H), 4.39 – 4.25 (m, 2H), 3.90 (dd, J = 8.4, 6.7 Hz, 1H), 3.77 
(m, 2H), 3.44 (m, 1H), 3.39 – 3.33 (m, 4H), 3.26 – 3.16 (m, 4H), 1.93 – 1.80 (m, 1H), 
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1.78 – 1.65 (m, 1H), 1.39 (d, J = 6.8 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 152.45, 151.61, 145.20, 139.21, 134.33, 129.63, 129.08, 126.23, 
123.97, 118.89, 117.09, 115.69, 74.96, 68.39, 67.73, 56.33, 53.09, 51.03, 49.65, 28.86, 
19.67, 11.21. DART-HRMS: m/z calcd. for C35H40N8O4 [MH]+, 637.3251; Found: 
637.3271.  IR (solid) vmax 3122, 3058, 2961, 2825, 1693, 1602, 1551, 1508, 1448, 
1388, 1327, 1296, 1226, 1180, 1135, 1939, 944, 823, 736, 701, 676. Purity: 97.1% 
(Method A). 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (49). ITZ analogue 49 was prepared using the general method described 
above for analogue 46 utilizing the requisite linker/side chain and dioxolane 
intermediates. (45%) 1H NMR (500 MHz, CDCl3) δ 8.30 – 8.10 (m, 1H), 7.94 (s, 1H), 
7.62 (s, 1H), 7.43 (d, J = 8.5 Hz, 2H), 7.03 (d, J = 8.9 Hz, 2H), 6.97 – 6.87 (m, 2H), 6.84 
(t, J = 9.9 Hz, 2H), 4.49 (t, J = 5.8 Hz, 1H), 4.39 (s, 1H), 4.36 – 4.24 (m, 2H), 4.15 (m, 
1H), 4.03 – 3.84 (m, 1H), 3.79 (m, 1H), 3.69 – 3.59 (m, 1H), 3.42 – 3.33 (m, 4H), 3.24 (t, 
J = 5.0 Hz, 4H), 1.92 – 1.81 (m, 1H), 1.72 (m, 1H), 1.44 (s, 1H), 1.43 – 1.36 (m, 5H), 
0.90 (t, J = 7.4 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 152.7, 152.0, 151.4, 150.5, 145.9, 
144.6, 133.9, 125.9, 123.5, 118.5, 118.4, 116.6, 115.3, 115.2, 108.0, 75.4, 74.8, 68.5, 
67.7, 67.5, 67.1, 55.7, 55.6, 52.6, 50.6, 49.2, 28.4, 23.5, 22.5, 19.2, 10.7.  IR (solid) 
vmax 3121, 3053, 2930, 2850, 2809, 1702, 1683, 1548, 1510, 1471, 1452, 1336, 1251, 
1134, 1106, 1068, 1050, 940, 883, 735.  DART-HRMS: m/z calcd. for C30H39N8O4 
[MH]+, 575.3094; Found: 575.3090. IR (solid) vmax: 2967, 2934, 2878, 2837, 1701, 
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1554, 1510, 1450, 1382, 1225, 1181, 1136, 1042, 1017, 942, 826, 784. Purity: 95.1% 
(Method A). 
1-(sec-butyl)-4-(4-(4-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-
1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (50). ITZ analogue 50 was prepared using the 
general method described above for analogue 47 utilizing the requisite linker/side chain 
and dioxolane intermediates. The crude residue was purified via column 
chromatography (SiO2, 0-5% MeOH in DCM) to afford 50 in modest yield (14 mg, 21%) 
1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 2H), 7.03 (d, 
J = 8.5 Hz, 2H), 6.94 (s, 1H), 6.89 (d, J = 8.4 Hz, 2H), 4.46 (m, 1H), 4.29 (m, 1H), 4.16 
(t, J = 7.4 Hz, 1H), 4.04 (m, 1H), 3.90 (m, 2H), 3.37 (s, 2H), 3.24 (s, 2H), 1.86 (m, 1H), 
1.71 (m, 1H), 1.46 (s, 3H), 1.39 (d, J = 7.8 Hz, 6H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 152.44, 134.28, 124.08, 123.96, 118.93, 117.14, 115.81, 110.13, 
74.49, 69.77, 67.32, 53.11, 51.11, 49.62, 33.08, 28.86, 27.22, 25.79, 19.66, 11.20. 
DART-HRMS: m/z calcd. for C28H37N5O4 [MH]+, 508.2924; Found: 508.2909.  IR (solid) 
vmax: 3126, 3060, 2967, 2926, 2878, 2828, 2212, 1681, 1584, 1556, 1510, 1452, 1380, 
1226, 1149, 1037, 941, 819, 736. Purity: 97.5% (Method B). 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((S)-sec-butyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (51). ITZ analogue 51 was prepared using the general method described 
above for analogue 46 utilizing the requisite linker/side chain and dioxolane 
intermediates (55%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.89 (s, 1H), 7.61 (s, 
1H), 7.57 (d, J = 8.3Hz, 1H), 7.47 (d, J = 2.1Hz, 1H), 7.43 (d, J = 8.9Hz, 2H), 7.03 (d, J 
= 9.0Hz, 2H), 6.94 (m, 2H), 6.80 (m, 2H), 4.80 (m, 2H), 4.36 (m, 1H), 4.28 (m, 1H), 3.92 
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(m, 1H), 3.81 (m, 2H), 3.48 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.72 (m, 
1H), 1.39 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
152.6, 151.4, 150.5, 146.0, 144.8, 136.0, 134.0, 133.8, 133.1, 131.4, 129.6, 127.2, 
125.9, 123.5, 118.4, 116.6, 115.2, 109.9, 107.6, 74.7, 67.6, 67.4, 53.6, 52.6, 50.5, 49.2, 
28.4, 19.2, 10.7.  DART-HRMS: m/z calcd. for C35H39Cl2N8O4 [MH]+, 705.2471; Found: 
705.2465. IR (solid) vmax: 2967, 2930, 2878, 1695, 1586, 1552, 1509, 1451, 1378, 
1226, 1183, 1130, 1038, 947, 816, 736.  Purity: 97.9% (Method A). 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((R)-sec-butyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (52).  ITZ analogue 52 was prepared using the general method described 
above for analogue 46 utilizing the requisite linker/side chain and dioxolane 
intermediates (77%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.89 (s, 1H), 7.64 – 
7.54 (m, 2H), 7.50 – 7.40 (m, 3H), 7.03 (d, J = 8.6 Hz, 2H), 6.95 (s, 1H), 6.81 (d, J = 8.4 
Hz, 2H), 4.84 (d, J = 14.7 Hz, 1H), 4.76 (d, J = 14.7 Hz, 1H), 4.39 – 4.25 (m, 2H), 3.92 
(m, 1H), 3.86 – 3.77 (m, 2H), 3.50 (m, 1H), 3.38 (s, 2H), 3.25 (s, 3H), 1.87 (m, 1H), 1.72 
(m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
152.5, 152.0, 151.3, 150.5, 146.0, 136.0, 134.0, 133.8, 133.1, 131.4, 129.5, 127.2, 
125.9, 123.5, 118.4, 116.6, 115.2, 107.6, 77.2, 74.7, 67.6, 67.4, 53.6, 52.6, 50.5, 49.2, 
28.4, 19.2, 10.7. DART-HRMS: m/z calcd. for C35H39Cl2N8O4 [MH]+, 705.2471; Found: 
705.2468. II R (solid) vmax: 3067, 2966, 2934, 2878, 2832, 1695, 1585, 1551, 1509, 
1450, 1379, 1225, 1180, 1136, 1039, 944, 820, 794. Purity: 95.0% (Method A). 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-propyl-1H-1,2,4-triazol-5(4H)-one (53). 
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ITZ analogue 53 was prepared using the general method described above for analogue 
47 utilizing the requisite linker/side chain and dioxolane intermediates (50 mg, 68%). 1H 
NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.89 (s, 1H), 7.59 (d, J = 21.6 Hz, 2H), 7.48 (s, 
1H), 7.41 (s, 2H), 7.04 (s, 2H), 6.93 (s, 2H), 6.81 (s, 2H), 4.80 (d, J = 23.3 Hz, 2H), 4.36 
(s, 1H), 3.92 (s, 1H), 3.82 (s, 4H), 3.52 (s, 1H), 3.37 (s, 4H), 3.24 (s, 5H), 1.84 (s, 2H), 
0.98 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 152.60, 136.48, 134.30, 133.55, 131.85, 
130.02, 127.65, 123.98, 117.08, 115.73, 108.05, 75.13, 68.11, 54.05, 51.01, 49.60, 
47.62, 22.43, 11.50. DART-HRMS: m/z calcd. for C34H36Cl2N8O4 [MH]+, 691.2315; 
Found: 691.2329.  IR (solid) vmax: 3068, 2960, 2925, 2873, 2835, 1696, 1585, 1553, 
1510, 1452, 1379, 1225, 1160, 1136, 1045, 944, 823, 794. Purity: 95.2% (Method A). 
1-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)-4-(4-nitrophenyl)piperazine (54). To a solution of 44 (100 mg, 
0.336 mmol) in DMSO (4 mL) was added Cs2CO3 (1.1 g, 3.36 mmol) and 43 (0.29 g, 
0.604 mmol). The solution was warmed to 90° C and stirred for 12 h. The mixture was 
cooled to room temperature and water was added slowly with vigorous stirring (~6 mL). 
A yellow precipitate formed, which was filtered and recrystallized in EtOH to yield 54 
(150 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 8.22 – 8.12 (m, 3H), 7.90 (s, 1H), 7.58 (d, 
J = 8.5 Hz, 1H), 7.48 (d, J = 2.1 Hz, 1H), 6.95 – 6.86 (m, 4H), 6.86 – 6.78 (m, 2H), 4.84 
(d, J = 14.8 Hz, 1H), 4.76 (d, J = 14.7 Hz, 1H), 4.36 (m, 1H), 3.92 (m, 1H), 3.85 – 3.75 
(m, 3H), 3.61 – 3.55 (m, 4H), 3.48 (m, 1H), 3.26 – 3.20 (m, 4H). 13C NMR (126 MHz, 
CDCl3) δ 154.79, 152.90, 151.42, 145.67, 144.94, 138.79, 136.14, 134.08, 133.17, 
131.49, 129.63, 127.28, 125.99, 118.58, 115.39, 112.90, 107.69, 74.72, 67.71, 67.45, 
53.63, 50.33, 47.29. DART-HRMS: m/z calcd. for C29H28Cl2N6O5 [MH]+, 611.1577; 
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Found: 611.1601.  IR (solid) vmax: 3116, 2923, 2852, 1589, 1557, 1506, 1456, 1377, 
1318, 1226, 1136, 1029, 975, 942, 896, 823, 737, 691. Purity: 95.0% (Method A). 
4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)aniline (55). 10% palladium on carbon (1.04 mg, 
5% mole ratio) was added to a dry round bottom flask. Ethanol (25 mL) was added 
followed by slow addition of 54 (120 mg, 0.196 mmol). Hydrazine monohydrate (0.06 
mL, 1.96 mmol) was added dropwise and the mixture was stirred at reflux for 2 h.  Upon 
cooling to RT, the mixture was filtered through celite. The celite was washed with 
ethanol (100 mL) and chloroform (250 mL) to ensure complete elution of the aniline. 
The filtrate was concentrated to afford a yellow solid, which was recrystallized in EtOH 
to afford 55 (70 mg, 61%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 8.15 (d, J = 9.4Hz, 
2H), 7.89 (s, 1H), 7.57 (d, J = 8.4Hz, 1H), 7.47 (m, 1H), 7.25 (m, 1H), 6.92 (m, 2H), 6.88 
(d, J = 9.5Hz, 2H), 6.80 (d, J = 9.0Hz, 2H), 4.80 (m, 2H), 4.36 (m, 1H), 3.91 (m, 1H), 
3.80 (m, 2H), 3.58 (m, 4H), 3.47 (m, 1H), 3.22 (m, 4H).  13C NMR (126 MHz) δ 154.7, 
152.8, 151.3, 145.6, 144.9, 138.7, 136.1, 134.0, 133.1, 131.4, 129.6, 127.2, 125.9, 
118.5, 115.3, 112.8, 107.6, 74.6, 67.6, 67.4, 53.6, 50.3, 47.2.  DART-HRMS: m/z calcd. 
for C29H31Cl2N6O3 [MH]+, 581.1835; Found: 581.1818.  IR (solid) vmax: 3084, 2886, 
2827, 1558, 1504, 1313, 1224, 113, 1030, 942, 821, 749. Purity: 96.1% (Method A). 
General protocol for tosylate/phenol coupling and final analogue purification. To 
a solution of alkyl-substituted phenol (28-31) (40 mg, 0.102 mmol) in DMSO (2.0 mL) 
was added des-triazole-tosylate (57b-57c, 59-62) (46 mg, 0.110 mmol) followed by 
Cs2CO3 (0.82 mmol). The mixture was warmed to 80° C and stirred for 16 h. The 
mixture was then cooled to RT and water was added slowly (6 mL) with vigorous 
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stirring, which resulted in formation of a precipitate. The mixture was transferred to a 
separatory funnel, diluted with EtOAc (60 mL) and washed with water (50 mL). The 
aqueous layer was washed with EtOAc (1 X 60 mL). The organic layers were combined, 
dried (MgSO4), filtered, and concentrated. The crude residue was purified by column 
chromatography (SiO2, 0 to 24% acetone in hexanes) to afford 47, 63-76 as white to 
slightly off-white solids in good yields (45-88%). Final analogues were subsequently 
sonicated in pentanes (10-30 min) to remove a “grease-like” impurity (observed in 1H 
NMRs at 0.88, 1.31 ppm) and collected for purity analysis and biological evaluation 
following filtration on a fine-fritted glass Buchner style filter funnel. 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (63). 1H NMR (500 MHz, CDCl3) δ 7.62 (m, 2H), 7.42 (m, 3H), 7.23 (m, 
1H), 7.03 (m, 2H), 6.92 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.01 (m, 1H), 3.97 (m, 1H), 
3.84 (m, 1H), 3.36 (m, 4H), 3.24 (m, 4H), 1.87 (m, 1H), 1.81 (s, 3H), 1.72 (m, 1H), 1.39 
(d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.7, 152.0, 
150.5, 145.8, 139.2, 134.2, 133.8, 132.7, 130.9, 128.5, 126.6, 125.9, 123.5, 118.3, 
116.6, 115.2, 109.1, 73.9, 69.3, 66.9, 52.6, 50.6, 49.2, 28.4, 25.6, 19.2, 10.7.  DART-
HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2328.  IR (solid) 
vmax 2961, 2918, 2849, 1694, 1584, 1556, 1509, 1449, 1374, 1329, 1294, 1224, 1186, 
1149, 1094, 1035, 1017, 942, 873, 821, 802, 734. Purity: 97.0% (Method B). 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (64).  1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 
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7.42 (m, 2H), 7.38 (d, J = 2.1 Hz, 1H), 7.19 (m, 1H), 7.01 (m, 2H), 6.89 (m, 2H), 6.73 
(m, 2H), 4.60 (m, 1H), 4.29 (m, 2H), 3.94 (m, 1H), 3.73 (m, 1H), 3.35 (m, 4H), 3.21 (m, 
4H), 1.85 (m, 1H), 1.77 (s, 3H), 1.71 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4 
Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.7, 152.0, 150.5, 145.8, 139.2, 134.2, 133.8, 
132.7, 130.9, 128.5, 126.6, 125.9, 123.5, 118.3, 116.6, 115.2, 109.1, 75.0, 68.3, 67.3, 
52.6, 50.5, 49.2, 28.4, 25.8, 19.2, 10.7.  HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 
638.2301; Found: 638.2325.  IR (solid) vmax 3102, 3008, 2961, 2918, 2899, 2849, 
1699, 1597, 1538, 1515, 1411, 1355, 1337, 1254, 1236, 1189 1159, 1106, 1064, 1036, 
1024, 999, 936, 896, 831, 807, 741. Purity: 95.1% (Method B). 
2-((S)-sec-butyl)-4-(4-(4-(4-(((2S,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (65). 
1H NMR (500 MHz, CDCl3) δ 7.61 (m, 3H), 7.42 (m, 2H), 7.40 (m, 1H), 7.23 (m, 1H), 
7.02 (m, 2H), 6.94 (m, 2H), 6.88 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.00 (m, 1H), 3.96 
(m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.85 (m, 1H), 1.81 (s, 3H), 1.72 (m, 1H), 1.39 (d, J 
= 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.9, 152.0, 
150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9, 123.5, 118.4, 
116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2, 10.7.  DART-
HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2282.  IR (solid) 
vmax 2962, 2875, 2826, 1694, 1555, 1509, 1448, 1374, 1224, 1186, 1149, 1035, 942, 
824, 735. Purity: 97.4% (Method A). 
2-((S)-sec-butyl)-4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (66). 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.4 Hz, 2H), 7.61 (s, 1H), 7.42 (d, J = 8.5 Hz, 
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2H), 7.38 (d, J = 2.2 Hz, 2H), 7.19 (m, 1H), 7.02 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 
2H), 6.73 (d, J = 8.5 Hz, 2H), 4.60 (m, 1H), 4.30 (m, 2H), 3.94 (m, 1H), 3.73 (m, 2H), 
3.35 (m, 4H), 3.21 (m, 4H), 1.86 (m, 1H), 1.78 (s, 3H), 1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 
3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.8, 152.0, 150.5, 145.8, 
139.3, 134.3, 133.8, 132.7, 130.9, 128.5, 126.6, 125.9, 123.5, 118.4, 116.6, 115.2, 
109.1, 75.0, 68.4, 67.3, 52.6, 50.6, 49.2, 28.4, 25.8, 19.2, 10.7.   DART-HRMS: m/z 
calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2288.  IR (solid) vmax 2923, 
2851, 1714, 1703, 1683, 1613, 1548, 1509, 1452, 1374, 1271, 1226, 1188, 1150, 1094, 
1035, 965, 942, 817, 735.  Purity: 95.5% (Method A). 
2-((S)-sec-butyl)-4-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (67). 
1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.41 (m, 3H), 7.23 (m, 1H), 7.02 (m, 2H), 
6.94 (m, 2H), 6.89 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.00 (m, 1H),  3.96 (m, 1H), 3.84 
(m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.81 (s, 3H), 1.72 (m, 1H), 1.39 (d, J 
= 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.9, 152.0, 
150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9, 123.5, 118.4, 
116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2, 10.7.  DART-
HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2284.  IR (solid) 
vmax 2966, 2935, 2874, 2824, 1693, 1584, 1555, 1508, 1464, 1447, 1373, 1293, 1223, 
1186, 1149, 1095, 1035, 942, 875, 824, 734. Purity: 97.3% (Method A). 
2-((S)-sec-butyl)-4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (68). 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 7.42 (m, 2H), 7.38 
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(d, J = 2.1 Hz, 1H), 7.19 (m, 1H), 7.02 (m, 2H), 6.89 (m, 2H), 6.73 (m, 2H), 4.60 (m, 1H), 
4.30 (m, 2H), 3.94 (m, 1H), 3.73 (m, 2H), 3.35 (m, 4H), 3.21 (m, 4H), 1.85 (m, 1H), 1.78 
(s, 3H), 1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 
MHz, CDCl3) δ 152.8, 152.0, 150.5, 145.8, 139.3, 134.3, 133.8, 132.7, 130.9, 128.5, 
126.6, 125.9, 123.5, 118.4, 118.4, 116.6, 115.2, 109.1, 75.0, 68.4, 67.3, 52.6, 50.6, 
49.2, 28.4, 25.8, 19.2, 10.7.  DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 
638.2301; Found: 638.2281. IR (solid) vmax 2919, 2876, 2849, 1693, 1585, 1555, 1509, 
1450, 1375, 1329, 1295, 1225, 1188, 1149, 1095, 1034, 934, 872, 819, 734. Purity: 
98.4% (Method A). 
2-((R)-sec-butyl)-4-(4-(4-(4-(((2S,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (69).   
1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.42 (m, 2H), 7.41 (m, 1H), 7.23 (m, 1H), 
7.03 (m, 2H), 6.94 (m, 2H), 6.89 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.01 (m, 1H), 3.96 
(m, 1H), 3.84 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.87 (m, 1H), 1.81 (s, 3H), 1.72 (m, 
1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 
152.9, 152.0, 150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9, 
123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2, 
10.7.  DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2282.  
IR (solid) vmax 2967, 2932, 2878, 2827, 1695, 1612, 1586, 1552, 1510, 1460, 1377, 
1292, 1253, 1225, 1187, 1147, 1096, 1036, 940, 827, 735. Purity: 95.0% (Method B). 
2-((R)-sec-butyl)-4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (70). 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 7.42 (m, 2H), 7.38 
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(m, 1H), 7.20 (m, 1H), 7.02 (m, 2H), 6.90 (m, 2H), 6.73 (m, 2H), 4.60 (m, 1H), 4.30 (m, 
1H), 3.94 (m, 1H), 3.73 (m, 1H), 3.35 (m, 4H), 3.21 (m, 4H), 1.86 (m, 1H), 1.78 (s, 3H), 
1.71 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, 
CDCl3) δ 152.9, 152.0, 150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.7, 126.7, 
125.9, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 
19.2, 10.7.  DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 
638.2287.  IR (solid) vmax 3060, 2967, 2932, 2830, 1698, 1611, 1586, 1550, 1512, 
1461, 1384, 1296, 1252, 1225, 1189, 1149, 1098, 1036, 940, 896, 824, 735. Purity: 
95.0% (Method B). 
2-((R)-sec-butyl)-4-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (71).   
1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.43 (m, 2H), 7.41 (m, 1H), 7.23 (m, 1H), 
7.03 (m, 2H), 6.94 (m, 2H), 6.89 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.01 (m, 1H), 3.96 
(m, 1H), 3.84 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.81 (s, 3H), 1.72 (m, 
1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 
153.0, 152.0, 150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9, 
123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 67.0, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2, 
10.7.  DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2285.  
IR (solid) vmax 2971, 2937, 2879, 2827, 1697, 1509, 1451, 1376, 1296, 1225, 1194, 
1147, 1073, 1035, 942, 819, 734.  Purity: 97.5% (Method B). 
2-((R)-sec-butyl)-4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-
4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (72). 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 2H), 7.61 (s, 1H), 7.42 (m, 2H), 7.37 
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(m, 1H), 7.19 (m,1H), 7.02 (m, 2H), 6.90 (m, 2H), 6.73 (m, 2H), 4.60 (m, 1H), 4.30 (m, 
2H), 3.95 (m, 1H), 3.73 (m, 2H), 3.35 (m, 4H), 3.22 (m, 4H), 1.86 (m, 1H), 1.78 (s, 3H), 
1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, 
CDCl3) δ 152.8, 152.0, 150.5, 145.9, 139.3, 134.3, 133.8, 132.7, 130.9, 128.5, 126.6, 
125.9, 123.5, 118.4, 118.4, 116.6, 115.2, 109.1, 75.0, 68.4, 67.3, 52.6, 50.6, 49.2, 28.4, 
25.8, 19.2, 10.7.   DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 
638.2284.  IR (solid) vmax 2966, 2932, 2904, 2829, 1695, 1553, 1512, 1460, 1444, 
1399, 1382, 1254, 1224, 1187, 1148, 1063, 1036, 939, 827, 735.  Purity: 96.4% 
(Method A). 
4-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3-
one (73). 1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.41 (m, 3H), 7.23 (m, 1H), 7.02 
(m, 2H), 6.94 (m, 2H), 6.89(m, 2H), 4.32 (m, 1H), 4.11 (m, 1H), 4.01 (m, 1H), 3.96 (m, 
1H), 3.82 (m, 3H), 3.36 (m, 4H), 3.23 (m, 4H), 1.84 (m, 2H), 1.81 (s, 3H), 0.98 (t, J = 7.4 
Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 153.0, 152.1, 150.6, 145.9, 138.1, 134.5, 133.8, 
132.8, 131.1, 128.8, 126.7, 125.8, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 
50.6, 49.2, 47.2, 25.7, 22.0, 11.1.  DART-HRMS: m/z calcd. for C32H36Cl2N5O4 [MH]+, 
624.2144; Found: 624.2143.  IR (solid) vmax 3125, 3059, 2935, 2876, 2829, 1703, 
1686, 1614, 1585, 1551, 1510, 1454, 1405, 1375, 1336, 1297, 1225, 1194, 1143, 1094, 
1035, 944, 869, 814, 733. Purity: 96.6% (Method B). 
4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3-
one (74). 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.41 (m, 
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2H), 7.38 (d, J = 2.1 Hz, 1H), 7.20 (m, 1H), 7.02 (d, J = 8.9 Hz, 2H), 6.90 (d, J = 8.9 Hz, 
2H), 6.73 (d, J = 8.9 Hz, 2H), 4.64 (m, 1H), 4.30 (m, 1H), 3.94 (m, 1H), 3.82 (t, J = 7.2 
Hz, 2H), 3.73 (m, 2H), 3.35 (m, 4H), 3.21 (m, 4H), 1.83 (m, 2H), 1.78 (s, 3H), 0.98 (t, J = 
7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 152.8, 152.1, 150.5, 145.8, 139.3, 134.3, 
133.8, 132.7, 130.9, 128.5, 126.6, 125.8, 123.5, 118.4, 116.6, 115.2, 109.1, 99.9, 75.0, 
68.3, 67.3, 50.6, 49.2, 47.2, 25.8, 22.0, 11.1.  HRMS: m/z calcd. for C32H36Cl2N5O4 
[MH]+, 624.2144; Found: 624.2142.  IR (solid) vmax 2966, 2932, 2904, 2830, 1698, 
1609, 1585, 1550, 1511, 1461, 1402, 1385, 1336, 1296, 1224, 1189, 1148, 1097, 1036, 
940, 875, 824, 735. Purity: 96.5% (Method B). 
4-(4-(4-(4-(((2S,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3-
one (75). 1H NMR (500 MHz, CDCl3) δ 7.64(d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.41 (d, J = 
8.8 Hz, 2H), 7.38 (d, J = 2.1 Hz, 1H), 7.02 (m, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.73(m, 
2H), 4.60 (m, 1H), 4.30 (m, 1H), 3.94 (m, 1H), 3.81 (t, J = 7.2 Hz, 2H), 3.73 (m, 2H), 
3.35 (m, 4H), 3.22 (m, 4H), 1.83 (m, 2H), 1.78 (s, 3H), 0.98 (t, J = 7.4 Hz, 3H).  13C 
NMR (126 MHz, CDCl3) δ 153.0, 152.1, 150.6, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 
128.8, 126.7, 125.8, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 50.6, 49.2, 
47.2, 25.7, 22.0, 11.1.  DART-HRMS: m/z calcd. for C32H36Cl2N5O4 [MH]+, 624.2144; 
Found: 624.2140.  IR (solid) vmax 2919, 2876, 2849, 1693, 1601, 1585, 1555, 1509, 
1450, 1403, 1375, 1331, 1295, 1225, 1188, 1149, 1095, 1032, 1017, 943, 871, 814, 
734. Purity: 95.4% (Method B). 
4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3-
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one (76). 1H NMR (500 MHz, CDCl3) δ 7.61(m, 2H), 7.41 (m, 3H), 7.23 (m, 1H), 7.03 
(m, 2H), 6.95 (m, 2H), 6.89 (m, 2H), 4.32 (m, 1H), 4.11 (m, 1H), 4.00 (m, 1H), 3.94 (m, 
1H), 3.82 (m, 3H), 3.37 (m, 4H), 3.24 (m, 4H), 1.83 (m, 2H), 1.81 (s, 3H), 0.98 (t, J = 7.4 
Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 153.0, 152.1, 150.5, 145.9, 138.0, 134.5, 133.8, 
132.7, 131.1, 128.8, 126.7, 125.9, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 
50.6, 49.1, 47.2, 25.7, 22.0, 11.0.  DART-HRMS: m/z calcd. for C32H36Cl2N5O4 [MH]+, 
624.2144; Found: 624.2105.  IR (solid) vmax 2918, 2876, 2849, 1693, 1585, 1555, 
1509, 1464, 1449, 1374, 1330, 1294, 1224, 1187, 1149, 1095, 1035, 964, 942, 872, 
817, 734.  Purity: 97.8% (Method B). 
 
4.2 Biological Assay Protocols 
Gene expression assay protocol (C3H10T1/2): Cells were seeded (50,000 cells per 
well; 500 µL total volume per well) in a 24-well tissue culture plate.  After 24h of 
incubation (37°C, 5% CO2), growth media was removed and replaced with low FBS 
media.  DMSO (vehicle control) and analogues (1% DMSO concentration) were added 
to the wells.  Cells were incubated (37°C, 5% CO2) for 24h and RNA was isolated and 
evaluated by qRT-PCR.  
Gene expression assay protocol (ASZ-001): Cells were seeded (10,000 cells per well; 
100 µL total volume per well) in a 96-well tissue culture plate.  After 24h of incubation 
(37°C, 5% CO2), growth media was removed and replaced with low FBS media.  Cells 
were incubated for an additional 24h.  After this time, DMSO (vehicle control) and 
analogues (1% DMSO concentration) were added to the wells.  Cells were incubated 
(37°C, 5% CO2) for 48h and RNA was isolated and evaluated by qRT-PCR.   
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RT-PCR protocol: Following treatment and incubation periods, both RNA extraction and 
cDNA synthesis were performed using a TaqMan Cells-to-CT (fast) kit.  cDNA synthesis 
utilized a BioRad MyCycler and was programmed according to the manufacturer’s 
instructions.  Quantitative RT-PCR was performed on an ABI 7500 system and made 
use of the following TaqMan Gene Expression Probes: mouse ActB (Mm00607939_s1) 
and mouse Gli1 (Mm00494654_m1).  Relative gene expression levels were computed 
via ΔΔCT method using GraphPad Prism.  Corresponding IC50 values were calculated 
as mean ± SEM for at least three separate experiments performed in triplicate. 
CYP3A4 inhibition protocol: ITZ and des-triazole ITZ were evaluated for their ability to 
inhibit CYP3A4 by Cyprotex. This was accomplished by measuring their ability to inhibit 
the metabolism of the known CYP3A4 substrate testosterone via LC/MS/MS.  Briefly, 
varying concentrations of either ITZ or des-triazole ITZ was mixed with microsomes (0.5 
mg/mL) and testosterone (50 µM) in 50 mM potassium phosphate buffer containing 
2mM NADPH and 3mM MgCl2 at pH 7.4.  Following a10 min incubation at 37°C, the 
assay was quenched with the addition of MeCN containing an internal standard.  The 
samples were centrifuged and the quantity of testosterone metabolite in the supernatant 
was determined by LC/MS/MS. 
Anti-proliferation protocol: HUVECs were seeded (3,000 cells per well; 100 µL) in a 96-
well tissue cultured plate and incubated (37°C, 5% CO2) overnight.  After 24h, cells 
were drugged with DMSO (control), and drugs at varying concentrations (1% DMSO 
final concentration).  Following 72h incubation, cells were treated with MTS: PMS and 
incubated (37°C, 5% CO2) for 3h.  Plates were read at 490 nm utilizing a BioTek 
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Synergy H1 Hybrid plate reader.  Protocol follows Promega CellTiter 96 ® Aqueous Non-
Radioactive Cell Proliferation Assay. 
Tube formation protocol: Matrigel (BD Biosciences) was diluted 1:1 with DMEM 
(Matrigel protein concentration no less than 3 mg/mL) and used to coat the wells of a 
24-well tissue culture dish (280 µL per well).  Plates were incubated (37°C, 5% CO2) for 
no more than 1h until the Matrigel solidified.  HUVECs were suspended in M199 media 
with 1% FBS and penicillin/streptomycin, and 50,000 cells were added to each well.  
Plates were incubated at (37°C, 5% CO2) for 20-30 min to allow HUVECs to attach to 
the Matrigel.  Cells were treated with control (DMSO), known angiogenic inhibitor 
suramin (10 µM), or varying doses (10, 1, and 0.1 µM) of drug and incubated for 16h.  
Phase contrast images were taken from multiple locations in each well (8/well) on an 
inverted microscope and tube formation parameters were quantified using ImageJ 
software (NIH). 
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CHAPTER III: Structure-Activity Relationship Studies of Itraconazole Analogue 
Generations III and IV 
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1. Introduction 
 Based on our SAR results from analogue generations I and II, it was determined 
that the triazole moiety of ITZ is not necessary for potent Hh pathway inhibition.  These 
SAR studies have resulted in a novel class of Hh pathway antagonists: des-triazole ITZ 
analogues.  It was also previously determined that the stereochemistry of the dioxolane 
is important in terms of Hh pathway inhibition; the most potent stereochemical 
orientation is the 2R,4R-trans-dioxolane region.  Thorough SAR studies have been 
performed in terms of this dioxolane region and there is a solid understanding of what 
structural functionalities of the dioxolane region of ITZ are necessary and unnecessary 
for potent Hh pathway inhibition.  It has been established that while the chlorine-
substituents are less important, the phenyl moiety is necessary for anti-Hh activity.  The 
dioxolane region as a whole cannot be truncated to a smaller functionality without 
abolishing activity.115 Further SAR could be performed on this region in terms of 
exploring different N-containing substituents in replacement of the triazole group.  In 
addition, exploration could also be made in terms of different heteroatom ring systems 
to compare to the dioxolane region.  Eventually, this may be necessary to improve the 
overall drug properties, such as solubility and stability, of this modified ITZ scaffold. 
 SAR data from generations I and II also yielded ample information in terms of the 
triazolone and side-chain regions of the ITZ scaffold.  While the stereochemistry is less 
important, the methyl group of the sec-butyl region is crucial for Hh inhibitory activity.  
Substitution of a propyl side chain region completely abolishes activity.  Interestingly, 
truncation of the side-chain region to the free triazolone maintains anti-Hh activity.  In 
addition, truncation of the entire triazolone region to smaller moieties such as an aniline 
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or nitro substituent maintains this activity.115 With that being said, this triazolone/side-
chain functionality of the ITZ scaffold remains an interesting region in terms of Hh 
inhibitory activity.  These regions of ITZ are amendable for further modification and the 
resulting SAR studies could potentially improve both drug-like properties and biological 
activity. 
2. Design, Synthesis, and Evaluation of Generation III Analogues 
2.1 Analogue Design 
 
Figure 1. Design of Generation III Analogues 
 The third generation of ITZ analogues focuses on probing the triazolone/side-
chain region of the original ITZ scaffold.  In particular, this generation contains the 
optimal dioxolane stereochemical orientation and substitutes the triazolone/side-chain 
regions of the molecule with amide functionality (Figure 1).  Utilizing amide functionality 
would aid in exploring the electronics, hydrogen bonding, and sterics of the 
triazolone/side-chain region of the ITZ scaffold.  Amide functionality was chosen due to 
its chemical stability, solubility, and ease of synthesis.  An amide group consists of a 
carbonyl bond (C=O) and a C—N bond, which both contain dipoles.  The dipole of the 
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carbonyl is stronger than the C—N due to increased π-bonding arrangement and the 
electronegativity of the oxygen atom; this classifies an amide bond as being a 
hydrogen-bond acceptor (HBA).117  The oxygen and nitrogen atoms can both bond with 
water or protic solvents serving as hydrogen bond acceptors and the N—H bond can 
serve as a hydrogen-bond donor (Figure 2).  Amide bonds are generally stable due to 
resonance and the synthetic approach towards this functionality is low-cost and time 
efficient. 
 
Figure 2. Physiochemical Properties of Amides 
 Initially, this series of analogues was only going to include the most optimal 
2R,4R-trans-dioxolane orientation; however, these initial compounds had very limited 
activity during our preliminary in vitro evaluation.  Because of this, amide analogues 
were also synthesized containing the 2S,4R-cis-dioxolane region to determine if there 
was a difference in activity between stereoisomers. 
2.2 Synthetic Routes 
2.2.1 Synthesis towards Key Aniline Intermediate 
 The synthetic approach towards the third generation of analogues begins with 
the coupling of desired dioxolane with the unprotected nitro-linker region (44) as 
described previously.  The dioxolane containing nitro (77 or 87) can be reduced to the 
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aniline (78 or 88) in the presence of 10% Pd/C and hydrazine monohydrate.103 This key 
dioxolane-containing aniline intermediate (78 or 88) can then be utilized in amidation 
reactions with standard amide coupling conditions and various carboxylic acids.  This 
synthetic route was deemed the most optimal due to the ability to produce key 
intermediate (78 or 88) in bulk for rapid amidation with a variety of carboxylic acids 
(Scheme 1).  While there are a few different ways to approach the synthesis of ITZ, and 
thus ITZ analogues, this synthetic route provides the most efficient production of a 
diverse set of analogues.  
Scheme 1. Synthesis of Aniline Intermediates 
 
Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 90ºC, 12 h, 34-85%; (b) EDCI, DMAP, 
DCM, RT, 12h, < 50%. 
 
2.2.2 Synthesis of Final Amide Analogues 
 All amide analogues were synthesized utilizing standard amidation reaction 
conditions: activating agent 1-ethyl-3-(3-dimethylamiopropyl)carboniimide (EDCI), 4-
dimethylaminopyridine (DMAP), and various carboxylic acids dissolved in anhydrous 
DCM and stirred at room temperature for 12h (Scheme 2).118 This reaction must be 
anhydrous, as any trace of water will not allow the amidation to proceed.  These final 
amide reactions did not provide an optimal yield < 50%; however, enough analogue was 
obtained for characterization and preliminary biological evaluation. 
N N NO2O
O
O
Cl Cl
OTs
O
O
Cl Cl
HO N N NO2+
N N NH2O
O
O
Cl Cl
a
b
59: trans
60: cis
77: trans
87: cis
78: trans
88: cis
44
		 	 		
 95		
Scheme 2. Synthesis towards Amide Analogues 
 
Reagents and conditions: (a) EDCI, DMAP, DCM, RT, 12h, < 50%. 
 
2.2.3 Synthesis towards Phenol-Substituted Amide Analogues 
 The above amidation method worked well for all amide substitutions except for 
the phenol-substituted analogues.  In the presence of EDCI, DMAP, and free acid, the 
amidation reaction would not proceed.  It was anticipated that the free acid was 
potentially reacting with itself rather than the aniline. Due to this hypothesis, the free 
phenol was protected before coupling.  Various esters were protected with a methoxy-
methyl ether (MOM-) and then saponified to yield MOM-protected carboxylic acids.119 
These acids were then reacted with aniline under the previously described amide 
conditions to obtain the MOM-protected amide analogue.  Ideally, the MOM group could 
then be cleaved to yield the final desired phenol amide product.  However, this reaction 
did not yield desired product regardless of the reaction conditions (Scheme 3).119,120  
We believe that the MOM- group was removed but that the dioxolane ring was not 
stable under the acidic and harsh conditions associated with MOM-deprotection 
reactions. 
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Scheme 3. MOM- Protected Amidation Route 
 
 
Reagents and conditions: (a) DIPEA, MOM-Cl, 0°C à RT, 12h, 33-84%; (b) 10% NaOH, MeOH, 
RT, 4h, 48-85%;(c) EDCI, DMAP, DCM, RT, 12h, < 50%;(d) TFA, DCM 40min-1h, RT; (e) 3M 
HCl (~10 drops), MeOH, RT, 12h; (f) TMSCl (10 eq), NaI (10 eq), ACN: DCM, RT, 20 min 
 
There are a variety of synthetic approaches to form amide bonds.118,121  It is 
known that acyl chlorides are generally more reactive than carboxylic acids.  We 
attempted to form MOM- protected and free phenol acyl chlorides and then react them 
with aniline intermediate (78 or 88).  Another attempt was made to couple MOM-
protected and free phenol esters to the aniline intermediate (78 or 88) in the presence of 
trimethyl aluminum (Scheme 4).122 Neither of these synthetic routes proved successful 
despite the use of the more reactive acyl chloride functionality. 
Scheme 4. Alternate Amidation Approaches 
 
Reagents and conditions: (a) thionyl chloride, DCM, 1 drop of DMF, reflux 4.5 h; (b) Pyr, DMAP, 
DCM, 4°C, 12h; (c) AlMe3, K2CO3, DCM 0°C à RT 
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 As the most successful amidation attempt involved protecting the starting 
carboxylic acid and only did not yield product due to the deprotection reaction, it was 
anticipated that a different protecting group could be utilized instead of MOM.  Benzyl 
(Bn) protecting groups were a feasible option as they are easily synthesized and stable.  
In addition, benzyl groups can be removed under less harsh conditions including Pd/C 
and H2.  This approach was successful for the phenol-substituted analogues; however, 
the analogues were obtained in low yields after the final hydrogenation reaction 
(Scheme 5).123 
Scheme 5. Benzyl- Protected Amides 
 
Reagents and conditions: (a) BnBr, K2CO3, acetone, RT, 12h, 64-quant.%; (b) LiOH (3 eq), 
H2O:THF, 52-66%; (c) EDCI, DMAP, DCM, RT, 12h, < 50%; (d) 10% Pd/C, THF:EtOH, H2 
  
In an attempt to obtain a higher yield for all of the amidation reactions, a new set 
of conditions was utilized: N-methylmorpholine (NMM) and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5,6]pyridinium3-
oxidhexafluorophosphate) HATU in DMF for 12h at room temperature (Scheme 6).124,125   
These conditions were chosen as they are not as sensitive to water as are the 
previously used reagents (EDCI and DMAP).     In addition to improving the yield of 
amide product, these reaction conditions also allowed for direct coupling of free phenol 
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carboxylic acids to the dioxolane containing aniline intermediate.  This is a more 
efficient approach, as it would eliminate the benzyl-protected intermediate and 
subsequent additional reactions. 
Scheme 6. Synthesis towards Free-Phenol Analogues 
 
Reagents and conditions: (a) HATU, NMM, DMF, RT, 12h 
2.3 Biological Evaluation 
Table 1. Generation III Analogues 
	
Compound R1 R2 
Final 
Stereochemistry 
77 
 
 Trans-2R,4R 
78 
 
 Trans-2R,4R 
79 
  
Trans-2R,4R 
80 
  
Trans-2R,4R 
81 
  
Trans-2R,4R 
82 
  
Trans-2R,4R 
83 
  
Trans-2R,4R 
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84 
  
Trans-2R,4R 
85 
  
Trans-2R,4R 
86 
  
Trans-2R,4R 
87 
 
 Cis-2S,4R 
88 
 
 Cis-2S,4R 
89 
  
Cis-2S,4R 
90 
  
Cis-2S,4R 
91 
  
Cis-2S,4R 
92 
  
Cis-2S,4R 
93 
  
Cis-2S,4R 
94 
  
Cis-2S,4R 
95 
  
Cis-2S,4R 
96 
  
Cis-2S,4R 
97 
  
Cis-2S,4R 
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98 
  
Cis-2S,4R 
99 
  
Cis-2S,4R 
100 
  
Cis-2S,4R 
101 
  
Cis-2S,4R 
102 
  
Cis-2S,4R 
103 
  
Cis-2S,4R 
104 
  
Cis-2S,4R 
105 
  
Cis-2S,4R 
 
 The third generation of ITZ analogues was evaluated for Hh pathway inhibitory 
activity by monitoring endogenous Gli1 mRNA levels in ASZ-001 cells (Table 1).  
Analogues were tested in a dose-dependent manner in 96-well tissue culture plates; this 
was done for efficiency and in an attempt to test these analogues in a higher-throughput 
fashion. Des-triazole ITZ analogues were not evaluated in the initial mouse embryonic 
fibroblast (C3H10T1/2) cells due to conflicting results from generation II analogue 
biological evaluation.115  It was established from this generation II data that the ASZ cell 
line represents a more appropriate model for Hh pathway activity in MB.126 Overall, the 
evaluation of generation III analogues and their ability to inhibit Hh signaling in the ASZ 
cell line provided interesting results (Tables 2, 3, and 4).   
N
H
O
OH
N
H
O
OH
N
H
O
Cl
N
H
O
OMe
N
H
O
O
N
H
O
S
N
H
O
N
H
O O
		 	 		
 101		
Table 2. In Vitro Activity of Trans-Amide Analogues 
Compound  IC50 (µM) a, b Compound  IC50 (µM) a, b 
77 0.31 ± 0.04 82 4.3 ± 0.2 
78 0.92 ± 0.04 83 >10 
79 >10 84 >>10 
80 >10 85 0.19 ± 0.008 
81 >10 86 >>10 
aIC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. bAll 
analogues evaluated following 48 hr incubation.  
 
Generation III analogue synthesis began with the 2R,4R-trans-dioxolane 
stereochemistry because this was the most potent orientation determined in previous 
SAR studies.  This initial amide series with 2R,4R-trans-dioxolane stereochemistry 
yielded minimally active compounds with most IC50 values >10 µM (Table 2).  However, 
the truncated nitro (77) and aniline (78) intermediates exhibited moderate potency (IC50 
= 0.31 ± 0.04 and 0.92 ± 0.04 µM, respectively) indicating that the truncation of both the 
triazolone region and the triazole group is acceptable.  Despite limited Hh inhibitory 
activity within this first class of amides, the SAR data indicated that the meta-position 
functionality off of the phenyl ring was favorable as 82 was moderately active (IC50 = 4.3 
± 0.2 µM) and 85 was potent (IC50 = 0.19 ± 0.008 µM) when compared to the ortho- and 
para- position analogues (Table 2).  The nitrogen atom in the pyridine ring of 82 serves 
as an H-bond acceptor while the oxygen in the phenol of 85 may serve as both an H-
bond donor and an H-bond acceptor supporting the increased potency.  These results 
from this initial amide series indicate that functionality capable of hydrogen bonding at 
the meta-position of the phenyl ring may be advantageous to binding with Smo, the 
hypothesized target of these des-triazole ITZ analogues.  
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Table 3. In Vitro Activity of Cis-Amide Analogues 
Compound IC50 (µM) a, b Compound  IC50 (µM) a, b 
87 0.26 ± 0.04 94 1.8 ± 0.4 
88 0.39 ± 0.09 95 2.3 ± 0.05 
89 >10 96 >10 
90 >10 97 2.2 ± 0.3 
91 3.9 ± 0.3 98 0.16 ± 0.03 
92 0.19 ± 0.09 99 3.0 ± 0.1 
93 >10   
aIC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. bAll 
analogues evaluated following 48 hr incubation.  
 
 Despite the majority of analogues being inactive, this initial series of trans-
amides provided interesting SAR information in terms of the triazolone/side-chain region 
of the ITZ scaffold (Table 2).  Thus, a second series of amide analogues was 
synthesized containing the 2S,4R-cis-dioxolane orientation.  These cis-amide 
analogues contained the same functionality and substituents as the trans-amide 
analogues in order to better compare the stereoisomers.  Evaluation of the cis-amide 
analogues provided confounding data (Table 3).  First, all of the cis-amide analogues 
were more potent than the trans-amide analogues, specifically amongst the phenol and 
pyridine containing compounds.  Second, following the same trend as the trans-amide 
analogues, substituents at the meta-position better inhibited the Hh pathway in 
comparison to the ortho- and para- positions.  The meta-pyridine analogues had a 
modest difference in potency  (82 = 4.3 ± 0.2 and 96 = 0.19 ± 0.09 µM) while the meta-
phenol analogues resulted in similar IC50 values (85 = 0.19 ± 0.008 and 98 = 0.16 ± 
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0.03 µM).  It is possible that the cis-amide analogues are more permeable than the 
trans-amide analogues, accounting for their increased potency within these preliminary 
cellular assays (Table 2 and Table 3).  The SAR results from the stereochemically-
defined amide analogues reiterated the importance of the triazolone/side-chain region 
and Hh pathway inhibitory activity.  This highlights the need to further explore this region 
of the ITZ scaffold.   
Table 4. In Vitro Activity of Cis-Amide Analogues: Meta-Functionality 
Compound  IC50 (µM) a, b Compound  IC50 (µM) a, b 
100 >10 103 >10 
101 5.7 ± 1.9 104 >10 
102 >10 105 0.089 ± 0.01 
aIC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. bAll 
analogues evaluated following 48 hr incubation.  
 
Taken together, a third series of amide analogues was designed and synthesized 
to contain optimal cis-dioxolane stereochemistry and optimal amide meta-substitution.  
This series of amides was necessary to further probe the sterics, electronics, and 
hydrogen bonding of the triazolone/side-chain region of the original ITZ scaffold.  
Analogues were designed according to the availability of carboxylic acids resulting in six 
diverse derivatives, which included both 6-membered rings and 5-membered rings.  
SAR studies concluded that the 5-membered ring analogues (102 and 103) are not 
optimal for Hh pathway inhibition (Table 4).  Not surprisingly due to the results from the 
benzene and naphthalene analogues, the cyclohexane derivative (104) did not inhibit 
the Hh pathway.  Results further indicated that the most potent analogue, 105, 
contained an acetyl- functionality (Table 4).  The trend in Hh inhibitory activity can 
partially be attributed to polarity at the meta-position of the phenyl ring.  Although, 
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alcohol or amine functionality is typically more polar than a ketone, other characteristics 
of this moiety may be contributing to its potent activity (Figure 3).   
      
Ketone >> Alcohol >> Amine >> Methoxy >> Halogen 
Figure 3. Relative Potency of Meta-Functionality in Amide Analogues 
One difference between a ketone and an alcohol is that ketones are considered 
to be electron-withdrawing groups (EWG) while alcohols are considered to be electron-
donating groups (EDG).  In addition, a ketone serves as a hydrogen bond acceptor 
(HBA) while an alcohol can act as a hydrogen bond donor (HBD) or an HBA.  The bond 
length of the carbonyl and position of the oxygen atom may allow for tighter binding to a 
particular residue in the Smo binding pocket.  It is also interesting to note that the Hh 
pathway inhibitor posaconazole (PSZ), an azole antifungal similar in structure to ITZ, 
contains a hydroxylated side-chain region.  These structural-similarities further support 
adding polar moieties to the triazolone/side-chain region to improve drug-like properties 
yet maintain Hh-pathway inhibitory activity (Figure 4). 
 
Figure 4. Triazolone/side-chain regions of PSZ vs. 105 
Due to promising in vitro activity, a few select compounds were evaluated in 
preliminary in vitro pharmacokinetic (PK) assays.  These PK data helped determine if 
any of the changes made to the ITZ scaffold improved their overall drug-like properties 
(Table 5).  Surprisingly, the amide substituents did not aid in increased solubility.  The 
half-life (T1/2) did not significantly change between ITZ and analogue 98.  Interestingly, 
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stereoisomers 82 and 92 had significantly different half-lives suggesting that the 
stereochemistry plays a role in compound metabolism and clearance (T1/2 = 59.9 ± 2.0 
and 8.9 ± 0.03 min, respectively). It was previously determined that removal of the 
triazole group abolishes inhibition of CYP3A4.  This also translates over to the 
generation III des-triazole amide analogues. Lastly, as these compounds are being 
targeted to treat MB, they were screened in a parallel artificial membrane permeability 
assay (PAMPA) for their ability to passively permeate cell membranes.  Unfortunately, 
while ITZ had moderate PAMPA permeability, none of the des-triazole ITZ analogues 
were able to passively cross this artificial membrane barrier (Table 5). 
Table 5. Pharmacokinetic Evaluation of Amide Analogues 
Compound T1/2 (HLM, min) Solubility (µM) PAMPA CYP3A4 IC50 (µM) 
ITZ 27.0 ± 6.2 0.8 Moderate 0.04 
82 59.9 ± 2.0 0.0042 Poor >20 
92 8.9 ± 0.03 0.0069 Poor >30 
98 19.9 ± 0.6 0.0016 Poor 11.4 
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3. Design, Synthesis, and Evaluation of Generation IV Analogues 
3.1 Analogue Design 
 
Figure 5. Design of Generation IV Analogues 
  The fourth generation of ITZ analogues focuses on further probing the 
triazolone/side-chain region of the original ITZ scaffold.  In particular, this generation 
contains the optimal 4R-cis/trans-dioxolane stereochemistry determined through 
previous SAR studies.  In addition, this series of compounds will substitute the right-
most portion of the molecule with various functional moieties: carbamates, hydrazine 
carboxamides, and triazolones (Figure 5).  These functional groups were chosen, as 
they are the intermediates leading up to the formation of the triazolone ring during the 
linker region synthesis.    Utilizing this diverse set of functionality will further aid in 
probing the electronics, hydrogen bonding, and sterics of the triazolone/side-chain 
region of ITZ.  This series of “triazolone mimic analogues” will provide a broader subset 
of SAR data as it explores a variety of functionality that have differing physiochemical 
properties.  The overall goal of this series is to determine a potent ITZ analogue with 
improved drug-like properties.  These moieties may contribute to improved solubility 
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while decreasing molecule size.  This, along with truncation of the triazole region, will 
greatly improve both drug-like properties and target selectivity of the ITZ scaffold in 
terms of its Hh-inhibitory activity.  
3.2 Synthetic Routes 
 Originally, the synthetic plan for the triazolone mimic analogues followed the 
same route as the previously mentioned amide analogues (Figure 6).  
Stereochemically-defined dioxolane would be coupled to the unprotected-nitro-linker 
(44); this dioxolane containing nitro-linker (77 or 87) would then be reduced to the 
aniline in the presence of Pd/C to yield key intermediate 78 or 88.103 However, as 
previously noted, the dioxolane region is not stable under acidic conditions.  A multitude 
of these triazolone mimic analogue reactions require use of acid in order to form the 
designated product.  As a result, the synthetic approach was adjusted to avoid exposing 
the dioxolane region to acid; this synthetic plan contains a few extra steps and 
unfortunately is not as efficient as amide analogue production. 
 
Figure 6. Original Synthetic Approach 
  As ITZ is FDA-approved, there are several synthetic approaches that have been 
reported previously.  One of which, involves the coupling of dioxolane to the linker 
region at the beginning.  After this initial coupling, the subsequent transformations can 
be made towards the triazolone region.103 In order to effectively perform this synthesis, 
the initial coupling must be done at a large enough scale to undergo all of these 
transformations and result in ample product.  While this is a possible synthetic route for 
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des-triazole ITZ analogues, it is not necessarily feasible to produce a large amount of 
stereochemically-defined dioxolane.  For this reason, methoxy-protected linker regions 
(carbamate, hydrazine carboxamide, and triazolone) were deprotected using HBr at 
reflux (Scheme 7).   
Scheme 7. Deprotection of Linker Intermediates 
 
Reagents and conditions: (a) HBr, AcOH, reflux 12h. 
The resulting phenols were then utilized in the coupling reaction with 
stereochemically-defined dioxolane and Cs2CO3 in DMSO.  This reaction was 
performed at 90°C for the carbamate analogue and 40°C for the hydrazine carboxamide 
and triazolone analogues.  The temperature was adjusted in an attempt to discourage 
dual dioxolane addition to both the phenol and hydrazine carboxamide/triazolone 
moieties.  Despite the temperature of the reaction, only the hydrazine carboxamide 
substituent was successful.  The carbamate coupling reaction did not proceed and the 
triazolone coupling reaction underwent duel-addition of dioxolane to both the phenol 
and the free triazolone.  In an attempt to avoid going through all of the linker region 
transformations starting from 44, previously synthesized analogues served as building 
blocks for the carbamate and triazolone analogues (Scheme 8).  The carbamate 
analogues (106 or 108) were synthesized from the aniline intermediate (78 or 88) with 
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the previously utilized conditions of phenyl chloroformate and pyridine.  The triazolone 
analogue (110) was ultimately synthesized from the hydrazine carboxamide analogue 
(109) with the previously utilized conditions of formamidine acetate.115 It is important to 
note that this reaction also calls for the use of acetic acid (AcOH).  AcOH is utilized to 
aid in the crystallization of the triazolone product during linker synthesis.  As this 
reaction was performed on a < 10 mg scale, precipitation of the desired product was not 
expected to be the means of purification.  As a result, this reagent could successfully be 
removed without affecting the formation of the triazolone ring. 
Scheme 8. Synthesis towards Triazolone Intermediates 
 
Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 40ºC, 12 h, 56-94%; (b) Pyr (17 eq), 
ClCOOPh (1.1 eq), 3 h, 24-40%; (c) formamidine acetate (4.5 eq), reflux, 3 h, 20% 
 
It was also attempted to protect the triazolone region with a Boc-protecting 
group.127 However, this proved unsuccessful, as the Boc group could not be added 
before methoxy- deprotection; Boc-protection in the presence of both phenol and aniline 
functionality resulted in dual-Boc addition.  Selective Boc-deprotection was also 
attempted and did not yield desired product (Scheme 9).128 
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Scheme 9. Protection of Free Triazolone Intermediate 
 
Reagents and conditions: (a) Boc anhydride, DMAP (10% mol), ACN, RT, 12 h; (b) 20% 
KOH, MeOH, RT, 12h 
 
3.3 Biological Evaluation 
Table 6. Generation IV Analogues 
 
Compound R1 R2 
Final 
Stereochemistry 
106 
  
Trans-2R,4R 
107 
  
Trans-2R,4R 
108 
  
Cis-2S,4R 
109 
  
Cis-2S,4R 
110 
  
Cis-2S,4R 
 
 The fourth generation of des-triazole ITZ analogues was evaluated for Hh 
inhibitory activity by monitoring endogenous Gli1 mRNA levels in ASZ-001 cells (Table 
6).  It was previously established that this cell line represents an appropriate model for 
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Hh pathway activity in MB.115 This fourth generation of analogues was designed to 
further probe the triazolone/side-chain region of the ITZ scaffold.  These analogues offer 
a wide range of functionality including carbamates, hydrazine carboxamides, and 
triazolones.  While these moieties were mainly chosen as they serve as intermediates 
leading up to the formation of the triazolone ring, they also may aid in improving the 
drug-like properties of this scaffold.  For instance, carbamate functionality has been 
widely studied within the field of medicinal chemistry and is a key structural moiety in 
many FDA-approved compounds and prodrugs.  Carbamates offer chemical stability 
and hydrogen bonding; in addition, they are capable of penetrating cell membranes.129 
Table 7. In Vitro Evaluation of Generation IV 
Compound  IC50 (µM) a, b Compound   IC50 (µM) a, b 
106 3.2 ± 0.6 109 0.28 ± 0.01 
107 0.29 ± 0.08 110 0.95 ± 0.08 
108 1.0 ± 0.4   
aIC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. bAll 
analogues evaluated following 48 hr incubation. 
  
SAR results for generation IV analogues indicate that the most potent carbonyl 
derivatives are the hydrazine carboxamides (107 and 109) (Table 7).  This is likely due 
to the increased polarity and ability to donate and accept hydrogen atoms. Interestingly, 
the hydrazine carboxamide is an acyclic motif providing evidence that anti-Hh activity 
can still be achieved without the cyclic functionality seen in the original triazolone region 
and generation III analogues.  The carbamate analogues (106 and 108) are the least 
potent in this series and this may be attributed to the presence of the bulky 
nonsubstituted hydrophobic ring.  Surprisingly, the des-triazole ITZ analogue containing 
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the free triazolone was not as potent as the structurally similar triazole-containing 
analogue 53  (IC50 = 0.12 ± 0.03 µM).115 This may be due to decreased solubility or 
ability to penetrate the cell membrane.  A similar trend is seen in terms of the 
stereochemistry of the dioxolane ring: the cis-analogues are more potent than the trans-
analogues.  Both dioxolane orientations were synthesized as the trans-isomer is formed 
more readily in the ketalization reaction.  The trans-dioxolane was utilized during 
reaction optimization and then the corresponding cis-analogue was subjected to these 
reaction conditions.  These SAR data support the design and synthesis of a further 
subset of analogues containing truncated triazolone regions with acyclic polar moieties.  
This will ultimately decrease overall size of the des-triazole ITZ scaffold as well as 
increase Hh inhibitory activity.  
4. Conclusion 
 Two subsequent des-triazole ITZ analogue generations were designed, 
synthesized, and evaluated for their ability to inhibit the Hh pathway.  The goal of these 
analogues was to further probe the sterics, electronics, and hydrogen bonding in terms 
of the triazolone/side-chain region of the ITZ scaffold.  Des-triazole ITZ analogues 
contained the optimal 2S,4R-dioxolane region determined from previous SAR studies.  
The triazolone/side-chain region was replaced with various functionalities: amide, 
carbamate, hydrazine carboxamide, or triazolone.  SAR generation III analogues 
determined the 2S,4R-cis-dioxolane amide analogues to be more potent than the 
2R,4R-trans-dioxolane amide analogues.  In addition, different substituents and 
positions around the phenyl ring were explored to determine if either of these 
components contributed to potent Hh pathway inhibition.  The most potent des-triazole 
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ITZ analogues contained the 4R-cis-dioxolane region and meta-substitution around the 
phenyl ring.  Generally, anti-Hh activity becomes more potent with increasing meta-
substituent polarity.  
 SAR results from generation IV analogues also determined that the 2S,4R-cis-
dioxolane containing analogues were the most potent.  Within this small subset of 
compounds, the most potent analogues contained the hydrazine carboxamide moiety in 
replacement of the triazolone/side-chain region.  These results indicate that a small, 
polar, acyclic motif may be favorable within this region of the ITZ scaffold; this would be 
an ideal way to further scale down the overall size of these novel Hh pathway inhibitors.  
Additional SAR studies should be performed to probe the triazolone/side-chain region 
for potent Hh pathway inhibitory activity while also improving the overall properties of 
the scaffold.  
 
4.1 Experimental 
Previously Characterized Intermediates: Benzyl-protected intermediates were prepared 
as described previously and are described in the Appendix A. 
 
1-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)-
4-(4-nitrophenyl)piperazine (77) To a solution of 44 (0.77 g, 2.61 mmol) in DMSO (30 
mL) was added Cs2CO3 (8.5 g, 26.14 mmol) and 59 (1.2 g, 2.87 mmol). The solution 
was warmed to 90° C and stirred for 12 h. The mixture was cooled to room temperature 
and water was added slowly with vigorous stirring (~20 mL). A yellow precipitate 
formed, which was filtered and recrystallized in EtOH to yield 77 (1.2g, 85%). 1H NMR 
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(500 MHz, Chloroform-d) δ 8.28 – 8.14 (m, 2H), 7.66 (d, 1H), 7.46 (d, 1H), 7.28 (m, 1H), 
7.03 – 6.87 (m, 6H), 4.37 (m, 1H), 4.16 (m, 1H), 4.11 – 3.95 (m, 2H), 3.89 (m, 1H), 3.69 
– 3.53 (m, 4H), 3.35 – 3.18 (m, 4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 153.29, 
134.59, 131.21, 128.89, 126.79, 125.98, 118.58, 115.56, 112.90, 109.99, 109.12, 77.28, 
77.02, 76.77, 73.94, 69.27, 66.99, 50.39, 47.31, 25.73. DART-HRMS: m/z calcd. for 
C27H27Cl2N3O5 [MH]+, 544.1406; Found: 544.1388. IR (solid) vmax: 3060, 2926, 2880, 
2828, 1556, 1507, 1485, 1446, 1376, 1222, 1190, 1142, 1047, 995, 942, 821, 737. 
4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)aniline (78) 10% palladium on carbon (24.4 mg, 5% 
mole ratio) was added to a dry round bottom flask. Ethanol (100 mL) was added 
followed by slow addition of 77 (250 mg, 0.459 mmol). Hydrazine monohydrate (0.14 
mL, 4.59 mmol) was added dropwise and the mixture was stirred at reflux for 2 h.  Upon 
cooling to RT, the mixture was filtered through celite. The celite was washed with 
ethanol (500 mL) to ensure complete elution of the aniline. The filtrate was concentrated 
to afford a yellow solid, which was recrystallized in EtOH to afford 78 (100 mg, 42%).  
1H NMR (500 MHz, Chloroform-d) δ 8.20 (d, 1H), 7.66 (d, 1H), 7.46 (t, 1H), 7.06 – 6.85 
(m, 6H), 6.72 (d, 1H), 4.37 (s, 1H), 4.16 (m, 1H), 4.13 – 3.94 (m, 2H), 3.94 – 3.82 (m, 
1H), 3.63 (t, 2H), 3.50 (s, 1H), 3.35 – 3.16 (m, 6H), 1.86 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 131.20, 128.91, 126.79, 125.99, 118.85, 118.59, 118.25, 116.23, 115.56, 
115.46, 112.90, 77.28, 77.03, 76.78, 73.97, 69.29, 67.04, 51.25, 50.86, 50.39, 47.31, 
25.74, 0.02. DART-HRMS: m/z calcd. for C27H29Cl2N3O3 [MH]+, 514.1664; Found: 
514.1648. IR (solid) vmax: 2919, 2850, 1595, 1560, 1510, 1464, 1450, 1375, 1228, 
1196, 1150, 1037, 877, 825, 754.  
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N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (79) Aniline 78 (20 mg, 0.039 
mmol), benzoic acid (14.3 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP 
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under 
argon for 12h at room temperature.  The crude reaction was immediately purified via 
column chromatography (SiO2, 0-60% acetone in hexanes) to afford 79 (13.0 mg, 54%). 
1H NMR (500 MHz, Chloroform-d) δ 7.92 (d, 2H), 7.73 (s, 1H), 7.66 (d, 1H), 7.59 (m, 
2H), 7.54 (t, 2H), 7.46 (d, 1H), 7.28 (m, 1H), 7.05 (d, 2H), 7.02 – 6.97 (m, 2H), 6.94 (d, 
2H), 4.37 (m, 1H), 4.17 (m, 1H), 4.09 – 3.98 (m, 2H), 3.89 (t, 1H), 3.38 (m, 4H), 3.29 (m, 
4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.48, 152.92, 148.50, 146.09, 
138.15, 135.17, 134.56, 132.83, 131.69, 131.19, 130.61, 128.91, 128.78, 126.95, 
126.79, 121.64, 118.40, 116.95, 115.48, 110.66, 109.09, 77.27, 77.23, 77.02, 76.76, 
73.96, 69.29, 67.03, 50.74, 49.88, 29.72, 25.74. DART-HRMS: m/z calcd. for 
C34H33Cl2N3O4 [MH]+, 618.1926; Found: 618.1919. IR (solid) vmax: 3367, 3333, 2958, 
2924, 2853, 1693, 1638, 1547, 1511, 1450, 1375, 1248, 1230, 1194, 1157, 1037, 941, 
822, 703.  
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-naphthamide (80) Aniline 78 (20 mg, 
0.039 mmol), naphtholic acid (20.1 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and 
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred 
under argon for 12h at room temperature.  The crude reaction was immediately purified 
via column chromatography (SiO2, 0-60% acetone in hexanes) to afford 80 (6.0 mg, 
23%).  1H NMR (500 MHz, Chloroform-d) δ 8.39 (d, 1H), 7.97 (d, 1H), 7.93 – 7.85 (m, 
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1H), 7.75 (d, 1H), 7.66 – 7.48 (m, 7H), 7.41 (d, 1H), 7.24 (m, 1H), 7.03 (d, 2H), 6.96 (d, 
2H), 6.90 (d, 2H), 4.33 (m, 1H), 4.12 (m, 1H), 4.05 – 3.93 (m, 2H), 3.85 (m, 1H), 3.38 – 
3.30 (m, 5H), 3.26 (m, 5H), 1.82 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 167.31, 152.94, 
148.59, 146.09, 138.15, 134.75, 134.56, 133.81, 132.84, 131.20, 130.94, 130.75, 
130.17, 128.91, 128.43, 127.33, 126.79, 126.59, 125.38, 125.02, 124.79, 121.41, 
118.41, 117.01, 115.92, 115.49, 111.61, 109.09, 106.00, 101.89, 97.74, 77.28, 77.22, 
77.02, 76.77, 73.96, 69.29, 67.03, 50.74, 49.92, 29.72, 25.74, 0.02. DART-HRMS: m/z 
calcd. for C38H35Cl2N3O4 [MH]+, 668.2083; Found: 668.2075. IR (solid) vmax: 3294, 
3247, 3042, 2985, 2873, 1639, 1586, 1509, 1450, 1373, 1226, 1192, 1146, 1035, 942, 
821, 733.  
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)picolinamide (81) Aniline 78 (20 mg, 0.039 
mmol), picolinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP 
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under 
argon for 12h at room temperature.  The crude reaction was immediately purified via 
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 81 (9.0 mg, 37%).   
1H NMR (500 MHz, Chloroform-d) δ 9.96 (s, 1H), 8.69 – 8.62 (m, 1H), 8.35 (d, 1H), 7.95 
(m, 1H), 7.76 (d, 2H), 7.66 (d, 1H), 7.55 – 7.48 (m, 1H), 7.46 (d, 1H), 7.28 (m, 1H), 7.06 
(d, 2H), 7.00 (d, 2H), 6.94 (d, 2H), 4.37 (s, 1H), 4.17 (m, 1H), 4.09 – 3.97 (m, 2H), 3.89 
(m, 1H), 3.38 (m, 4H), 3.33 – 3.25 (m, 4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
161.67, 152.90, 150.10, 148.20, 147.94, 146.11, 138.16, 137.64, 134.56, 132.84, 
131.20, 130.66, 128.91, 126.79, 126.26, 122.32, 120.91, 118.38, 116.97, 115.48, 
111.61, 109.09, 106.05, 102.12, 77.28, 77.23, 77.03, 76.77, 73.97, 69.30, 67.04, 50.75, 
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49.91, 25.74. DART-HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 
619.1872. IR (solid) vmax: 3367, 2923, 2851, 1672, 1585, 1552, 1509, 1454, 1385, 
1268, 1227, 1192, 1148, 1020, 940, 912, 814, 747, 620.  
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)nicotinamide (82) Aniline 78 (20 mg, 0.039 
mmol), nicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP 
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under 
argon for 12h at room temperature.  The crude reaction was immediately purified via 
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 82 (6.2 mg, 25%).    
1H NMR (500 MHz, Chloroform-d) δ 9.14 (s, 1H), 8.83 (s, 1H), 8.26 (d, 1H), 7.72 (s, 1H), 
7.66 (d, 1H), 7.59 (d, 2H), 7.49 (d, 1H), 7.46 (d, 1H), 7.28 (m, 1H), 7.05 (d, 2H), 7.00 (d, 
2H), 6.96 – 6.90 (m, 2H), 4.37 (m, 1H), 4.17 (m, 1H), 4.10 – 3.94 (m, 2H), 3.89 (m, 1H), 
3.44 – 3.33 (m, 4H), 3.33 – 3.20 (m, 4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
131.20, 128.91, 126.80, 121.87, 118.43, 116.86, 115.49, 111.26, 109.10, 105.77, 
101.72, 77.28, 77.23, 77.03, 76.77, 73.96, 69.29, 67.03, 50.73, 49.72, 25.74. DART-
HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1876. IR (solid) 
vmax: 3639, 3570, 2920, 2824, 1644, 1509, 1447, 1374, 1227, 1194, 1150, 1037, 941, 
828, 733, 534.  
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)isonicotinamide (83) Aniline 78 (20 mg, 
0.039 mmol), isonicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and 
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred 
under argon for 12h at room temperature.  The crude reaction was immediately purified 
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via column chromatography (SiO2, 0-80% acetone in hexanes) to afford 83 (12.0 mg, 
49%).    1H NMR (500 MHz, Chloroform-d) δ 8.85 (d, 2H), 7.75 (d, 3H), 7.66 (d, 1H), 
7.60 (d, 2H), 7.05 (d, 2H), 7.00 (d, 2H), 6.94 (d, 2H), 4.17 (m, 1H), 4.09 – 3.95 (m, 2H), 
3.44 – 3.33 (m, 4H), 3.33 – 3.24 (m, 4H). 13C NMR (126 MHz, Chloroform-d) δ 150.79 , 
131.19 , 126.79 , 121.81 , 120.79 , 118.43 , 116.79 , 115.50 , 115.25 , 110.09 , 104.91 , 
77.22 , 73.96 , 69.30 , 67.02 , 50.72 , 49.66 , 25.73 . DART-HRMS: m/z calcd. for 
C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1871. IR (solid) vmax: 3302, 3290, 2950, 
2936, 1662, 1587, 1512, 1458, 1377, 1249, 1225, 1194, 1151, 1035 943, 823, 690.  
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-hydroxybenzamide (84) Salicylic acid 
(13.4 mg, 0.097 mmol) and HATU (81.3 mg, 0.21 mmol) were added to a round bottom 
flask.  Anhydrous DMF was added (5 mL) followed by NMM (0.1 mL, 0.38 mmol) and 
this reaction was stirred at room temperature for 30 mins.  Aniline 88 (50 mg, 0.097) 
was added to the reaction mixture and stirred for 12h at room temperature.  The 
reaction was then added to ice cold water and extracted with EtOAc (3 x 20 mL).  
Organic layers were combined and washed with H2O (2 x 20 mL) and brine (1 x 20 mL).  
The organic layers were dried over Na2SO4 and evaporated to dryness.  Crude material 
was purified via column chromatography (SiO2, 0-50% acetone in hexanes) to afford 84 
(10.0 mg, 16%).  1H NMR (500 MHz, Chloroform-d) δ 7.87 (s, 1H), 7.58 – 7.42 (m, 5H), 
7.28 (m, 1H), 7.07 (m, 3H), 7.02 – 6.91 (m, 5H), 4.37 (m, 1H), 4.17 (m, 1H), 4.09 – 3.98 
(m, 2H), 3.93 – 3.85 (m, 1H), 3.44 – 3.35 (m, 4H), 3.29 (t, 4H), 1.86 (s, 2H). 13C NMR 
(126 MHz, Chloroform-d) δ 134.52 , 131.20 , 128.91 , 126.79 , 125.25 , 122.85 , 118.97 
, 118.43 , 116.79 , 115.49 , 73.96 , 69.29 , 67.03 , 50.72 , 49.65 . DART-HRMS IR 
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(solid) vmax: 3310, 2956, 2916, 2848, 1646, 1596, 1511, 1453, 1373, 1250, 1228, 
1196, 1152, 1036, 942, 821, 755. 
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-hydroxybenzamide (85) 3-
Hydroxybenzoic acid (5.4 mg, 0.038 mmol) and HATU (31.7 mg, 0.083 mmol) were 
added to a round bottom flask.  Anhydrous DMF was added (5 mL) followed by NMM 
(0.1 mL, 0.15 mmol) and this reaction was stirred at room temperature for 30 mins.  
Aniline 88 (20 mg, 0.038 mmol) was added to the reaction mixture and stirred for 12h at 
room temperature.  The reaction was then added to ice cold water and extracted with 
EtOAc (3 x 20 mL).  Organic layers were combined and washed with H2O (2 x 20 mL) 
and brine (1 x 20 mL).  The organic layers were dried over Na2SO4 and evaporated to 
dryness.  Crude material was purified via preparative thin layer chromatography 
(Analtech Uniplate 20x20 cm 2000 micron, 3% acetone in hexanes) to afford 85 (6.0 
mg, 24.8%). 1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, 4H), 7.63 – 7.48 (m, 6H), 7.48 
– 7.37 (m, 6H), 7.17 – 6.84 (m, 8H), 5.21 (s, 1H), 4.37 (s, 1H), 4.16 (m, 1H), 4.12 – 3.95 
(m, 2H), 3.37 (d, 4H), 3.29 (t, 4H), 1.88 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 
131.20 , 130.08 , 126.79 , 125.30 , 121.68 , 118.41 , 116.94 , 115.49 , 114.42 , 69.29 , 
67.03 , 50.73 , 49.84 , 25.73 . DART-HRMS: m/z calcd. for C34H33Cl2N3O5 [MH]+, 
634.1876; Found: 634.1847. IR (solid) vmax: 3311, 2967, 2926, 2877, 1736, 1644, 
1586, 1513, 1449, 1375, 1230, 1198, 1038, 945, 825, 746. 
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide (86) (13.4 mg, 
0.097 mmol) and HATU (81.3 mg, 0.21 mmol) were added to a round bottom flask.  
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Anhydrous DMF was added (5 mL) followed by NMM (0.1 mL, 0.38 mmol) and this 
reaction was stirred at room temperature for 30 mins.  Aniline 88 (50 mg, 0.097) was 
added to the reaction mixture and stirred for 12h at room temperature.  The reaction 
was then added to ice cold water and extracted with EtOAc (3 x 20 mL).  Organic layers 
were combined and washed with H2O (2 x 20 mL) and brine (1 x 20 mL).  The organic 
layers were dried over Na2SO4 and evaporated to dryness.  Crude material was purified 
via column chromatography (SiO2, 0-50% acetone in hexanes) to afford 84 (5.0 mg, 
8%).  
1-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)-
4-(4-nitrophenyl)piperazine (87) To a solution of 44 (260 mg, 0.87 mmol) in DMSO (20 
mL) was added Cs2CO3 (3.1 g, 9.58 mmol) and 60 (400 mg, 0.0958 mmol). The solution 
was warmed to 90° C and stirred for 12 h. The mixture was cooled to room temperature 
and water was added slowly with vigorous stirring (~10 mL). A yellow precipitate 
formed, which was filtered and recrystallized in EtOH to yield 87 (175 mg, 34%) 1H NMR 
(500 MHz, Chloroform-d) δ 8.22 – 8.17 (m, 2H), 7.68 (d, 1H), 7.42 (d, 1H), 7.24 (m, 1H), 
6.96 – 6.89 (m, 4H), 6.81 – 6.76 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 3.99 (m, 1H), 3.81 
– 3.76 (m, 2H), 3.64 – 3.59 (m, 4H), 3.26 (m, 4H), 1.83 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 154.78, 153.09, 145.50, 139.34, 138.76, 134.35, 132.82, 130.97, 128.55, 
126.70, 125.98, 118.53, 115.31, 112.89, 109.18, 77.29, 77.03, 76.78, 75.05, 68.41, 
67.33, 50.38, 47.30, 25.90. DART-HRMS: m/z calcd. for C27H27Cl2N3O5 [MH]+, 
544.1406; Found: 544.1409. IR (solid) vmax: 2922, 2850, 1596, 1555, 1509, 1450, 
1375, 1321, 1228, 1195, 1151, 1036, 944, 827, 753. 
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4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)aniline (88) 10% palladium on carbon (10 mg, 5% 
mole ratio) was added to a dry round bottom flask. Ethanol (50 mL) was added followed 
by slow addition of 87 (100 mg, 0.184 mmol). Hydrazine monohydrate (0.06 mL, 1.84 
mmol) was added dropwise and the mixture was stirred at reflux for 2 h.  Upon cooling 
to RT, the mixture was filtered through celite. The celite was washed with ethanol (300 
mL) to ensure complete elution of the aniline. The filtrate was concentrated to afford a 
yellow solid, which was recrystallized in EtOH to afford 88 (89 mg, 94%).   1H NMR (500 
MHz, Chloroform-d) δ 8.20 (d, 1H), 7.68 (d, 1H), 7.43 (s, 1H), 7.24 (d, 1H), 6.92 (m, 
3H), 6.81 – 6.68 (m, 3H), 4.70 – 4.59 (m, 1H), 4.35 (m, 1H), 4.00 (d, 1H), 3.78 (m, 2H), 
3.61 (m, 1H), 3.49 (s, 1H), 3.25 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 130.97, 128.59, 
126.70, 125.99, 118.85, 118.54, 118.21, 116.24, 115.21, 112.90, 77.28, 77.03, 76.78, 
75.07, 68.43, 67.40, 51.24, 50.85, 50.38, 47.30, 25.90. DART-HRMS: m/z calcd. for 
C27H29Cl2N3O3 [MH]+, 514.1664; Found: 514.1666. IR (solid) vmax: 2921, 2823, 1590, 
1510, 1450, 1375, 1321, 1227, 1193, 1149, 1037, 944, 824, 753. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (89) Aniline 88 (20 mg, 0.039 
mmol), benzoic acid (14.3 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP 
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under 
argon for 12h at room temperature.  The crude reaction was immediately purified via 
column chromatography (SiO2, 0-60% acetone in hexanes) to afford 89 (5.0 mg, 
20.6%).  1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, 2H), 7.73 (s, 1H), 7.69 (d, 1H), 
7.59 (m, 2H), 7.54 (t, 2H), 7.04 (d, 2H), 6.95 (d, 2H), 6.78 (d, 2H), 4.65 (m, 1H), 4.35 (m, 
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1H), 4.00 (m, 1H), 3.82 – 3.74 (m, 2H), 3.36 (d, 3H), 3.28 (d, 4H), 1.83 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 131.68, 130.97, 128.78, 128.58, 126.95, 126.70, 121.64, 118.35, 
116.95, 115.24, 112.04, 109.16, 106.31, 77.27, 77.22, 77.02, 76.77, 75.07, 68.44, 
67.39, 50.73, 49.88, 25.90. DART-HRMS: m/z calcd. for C34H33Cl2N3O4 [MH]+, 
618.1926; Found: 618.1916. IR (solid) vmax: 3305, 2964, 2824, 1637, 1592, 1511, 
1448, 1374, 1226, 1192, 1152, 1034, 943, 818, 728, 703. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-naphthamide (90) Aniline 88 (20 mg, 
0.039 mmol), naphtholic acid (20.1 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and 
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred 
under argon for 12h at room temperature.  The crude reaction was immediately purified 
via column chromatography (SiO2, 0-60% acetone in hexanes) to afford 90 (3.0 mg, 
11.5%).   1H NMR (500 MHz, Chloroform-d) δ 8.43 (s, 1H), 8.08 – 7.92 (m, 4H), 7.89 (s, 
1H), 7.73 – 7.58 (m, 5H), 7.06 (d, 2H), 6.96 (d, 2H), 6.78 (d, 2H), 4.65 (m, 1H), 4.35 (m, 
1H), 4.00 (m, 2H), 3.86 – 3.71 (m, 2H), 3.45 – 3.33 (m, 4H), 3.33 – 3.21 (m, 4H), 1.83 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.53, 152.75, 148.50, 146.03, 139.34, 134.83, 
134.36, 132.80, 132.69, 132.36, 130.97, 130.68, 128.96, 128.73, 128.59, 127.83, 
127.41, 126.94, 126.71, 123.57, 121.69, 118.36, 116.96, 115.63, 115.24, 111.68, 
109.16, 105.89, 77.27, 77.22, 77.02, 76.77, 75.07, 68.44, 67.40, 50.74, 49.87, 25.91, 
1.04. DART-HRMS: m/z calcd. for C38H35Cl2N3O4 [MH]+, 668.2083; Found: 668.2116. IR 
(solid) vmax: 3326, 2920, 2851, 1663, 1596, 1558, 1513, 1450, 1373, 1229, 1195, 
1151, 1037, 948, 822, 760. 
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N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)picolinamide (91) Aniline 88 (20 mg, 0.039 
mmol), picolinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP 
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under 
argon for 12h at room temperature.  The crude reaction was immediately purified via 
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 91 (5.0 mg, 
20.6%).   Aniline 78 (20 mg, 0.039 mmol), picolinic acid (14.4 mg, 0.117 mmol), EDCI 
(22.4 mg, 0.117 mmol), and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous 
DCM (10mL) and stirred under argon for 12h at room temperature.  The crude reaction 
was immediately purified via column chromatography (SiO2, 0-80% acetone in hexanes) 
to afford 81 (9.0 mg, 37%).    1H NMR (500 MHz, Chloroform-d) δ 9.96 (s, 1H), 8.71 – 
8.60 (m, 1H), 8.34 (m, 1H), 7.95 (m, 1H), 7.76 (m, 2H), 7.69 (d, 1H), 7.57 – 7.48 (m, 
1H), 7.25 (m, 1H), 7.06 (d, 2H), 6.96 (d, 2H), 6.78 (d, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 
4.00 (m, 1H), 3.83 – 3.74 (m, 2H), 3.37 (s, 5H), 3.28 (s, 4H), 1.83 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 147.93, 137.64, 130.97, 128.58, 126.71, 122.31, 120.91, 118.33, 
116.96, 115.25, 111.75, 77.28, 77.02, 76.77, 75.06, 68.44, 67.39, 50.74, 49.90, 25.91. 
DART-HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1862. IR 
(solid) vmax: 3365, 2955, 2849, 1675, 1586, 1568, 1510, 1453, 1373, 1268, 1229, 
1193, 1151, 1097, 1037, 942, 823, 747. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)nicotinamide (92) Aniline 88 (20 mg, 0.039 
mmol), nicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP 
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under 
		 	 		
 124		
argon for 12h at room temperature.  The crude reaction was immediately purified via 
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 92 (6.0 mg, 
24.7%).     1H NMR (500 MHz, Chloroform-d) δ 9.15 (s, 1H), 8.83 (s, 1H), 8.26 (d, 1H), 
7.86 (s, 1H), 7.68 (d, 1H), 7.60 (d, 2H), 7.49 (s, 1H), 7.43 (d, 1H), 7.28 – 7.20 (m, 1H), 
7.01 (m, 4H), 6.83 – 6.73 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.83 – 3.74 
(m, 2H), 3.44 – 3.34 (m, 4H), 3.29 (t, 4H), 1.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
139.33, 134.36, 132.80, 130.97, 128.58, 126.71, 121.92, 118.54, 116.92, 115.27, 
109.17, 77.29, 77.24, 77.03, 76.78, 75.05, 68.43, 67.36, 50.88, 49.67, 25.90. DART-
HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1866. IR (solid) 
vmax: 3364, 3315, 2960, 2924, 2853, 1673, 1511, 1456, 1372, 1259, 1227, 1193, 1097, 
1035, 826, 807. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)isonicotinamide (93) Aniline 88 (20 mg, 
0.039 mmol), isonicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and 
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred 
under argon for 12h at room temperature.  The crude reaction was immediately purified 
via column chromatography (SiO2, 0-80% acetone in hexanes) to afford 93 (8.0 mg, 
33%). 1H NMR (500 MHz, Chloroform-d) δ 8.85 (s, 2H), 7.82 – 7.70 (m, 3H), 7.68 (d, 
1H), 7.59 (d, 2H), 7.43 (d, 1H), 7.24 (m, 1H), 7.04 (d, 2H), 7.01 – 6.88 (m, 2H), 6.82 – 
6.72 (m, 2H), 4.66 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.85 – 3.71 (m, 2H), 3.38 (m, 
4H), 3.27 (m, 4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.80, 150.80, 145.98, 
139.36, 134.36, 132.81, 130.97, 128.58, 126.70, 121.81, 120.80, 118.38, 116.79, 
115.27, 111.58, 109.16, 77.27, 77.22, 77.02, 76.77, 75.07, 68.46, 67.39, 50.71, 49.65, 
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29.72, 25.90, 1.03. DART-HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; 
Found: 619.1866. IR (solid) vmax: 3256, 2963, 2854, 1660, 1587, 1510, 1449, 1376, 
1261, 1226, 1193, 1150, 1034, 940, 826, 740. 
2-(benzyloxy)-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (94) Aniline 88 (100 mg, 0.194 
mmol), 2-(benzyloxy)benzoic acid (133 mg, 0.583 mmol), EDCI (111.8 mg, 0.583 
mmol), and DMAP (14.3 mg, 0.583 mmol) was dissolved in anhydrous DCM (10mL) and 
stirred under argon for 12h at room temperature.  The crude reaction was immediately 
purified via column chromatography (SiO2, 0-30% acetone in hexanes) to afford 94 (20 
mg, 14.2%).  1H NMR (500 MHz, Chloroform-d) δ 9.91 (s, 1H), 8.39 (m, 1H), 7.69 (d, 
1H), 7.62 – 7.49 (m, 6H), 7.43 (d, 1H), 7.29 – 7.15 (m, 5H), 6.97 – 6.91 (m, 2H), 6.91 – 
6.85 (m, 2H), 6.82 – 6.73 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.82 – 3.74 
(m, 2H), 3.31 (m, 4H), 3.25 (m, 4H), 1.83 (s, 3H).13C NMR (126 MHz, CDCl3) δ 156.61, 
135.35, 132.99, 132.63, 131.57, 130.97, 129.15, 129.08, 128.59, 126.71, 122.13, 
121.96, 120.88, 118.31, 116.81, 115.23, 112.58, 109.15, 77.28, 77.03, 76.77, 75.07, 
71.81, 68.44, 67.40, 50.73, 49.99, 25.90. 
3-(benzyloxy)-N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (95) Aniline 88 (100 mg, 0.194 
mmol), 3-(benzyloxy)benzoic acid (133 mg, 0.583 mmol), EDCI (111.8 mg, 0.583 
mmol), and DMAP (14.3 mg, 0.583 mmol) was dissolved in anhydrous DCM (10mL) and 
stirred under argon for 12h at room temperature.  The crude reaction was immediately 
purified via column chromatography (SiO2, 0-30% acetone in hexanes) to afford 95 (60 
mg, 43%). 1H NMR (500 MHz, Chloroform-d) δ 7.80 (s, 1H), 7.69 (d, 1H), 7.62 – 7.54 
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(m, 3H), 7.52 – 7.35 (m, 10H), 7.27 – 7.22 (m, 1H), 7.18 (m, 1H), 7.03 (d, 2H), 6.96 (d, 
2H), 6.78 (d, 2H), 5.16 (d, 3H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.78 (m, 2H), 
3.42 – 3.32 (m, 4H), 3.28 (m, 4H), 1.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.13, 
139.34, 136.64, 136.53, 134.36, 132.80, 130.98, 129.82, 128.69, 128.59, 128.17, 
127.59, 126.72, 121.62, 119.02, 118.61, 118.41, 116.97, 115.24, 113.50, 109.16, 77.31, 
77.05, 76.80, 75.07, 70.25, 68.42, 67.38, 50.74, 49.85, 25.91. DART-HRMS: m/z calcd. 
for C41H39Cl2N3O5 [MH]+, 724.2345; Found: 724.2377. IR (solid) vmax: 3289, 2928, 
2878, 2824, 1693, 1639, 1583, 1556, 1509, 1484, 1451, 1225, 1188, 1027, 941, 820, 
732, 622, 600 
4-(benzyloxy)-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (96) Aniline 88 (100 mg, 0.194 
mmol), 3-(benzyloxy)benzoic acid (133 mg, 0.583 mmol), EDCI (111.8 mg, 0.583 
mmol), and DMAP (14.3 mg, 0.583 mmol) was dissolved in anhydrous DCM (10mL) and 
stirred under argon for 12h at room temperature.  The crude reaction was immediately 
purified via column chromatography (SiO2, 0-30% acetone in hexanes) to afford 95 (50 
mg, 35%).  1H NMR δ 9.04 (s, 2H), 7.91 – 7.84 (m, 7H), 7.71 – 7.63 (m, 2H), 7.57 (d, J 
= 8.5 Hz, 2H), 7.52 – 7.36 (m, 22H), 7.09 (d, J = 8.6 Hz, 6H), 7.05 – 6.96 (m, 5H), 6.95 
(d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 5.13 (s, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 
3.85 – 3.73 (m, 2H), 3.35 (d, J = 5.5 Hz, 5H), 3.28 (d, J = 5.3 Hz, 5H), 1.83 (s, 3H). 
DART-HRMS: m/z calcd. for C41H39Cl2N3O5 [MH]+, 724.2345; Found: 724.2329. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-hydroxybenzamide (97) DART-HRMS: 
m/z calcd. for C34H33Cl2N3O5 [MH]+, 634.1876; Found: 634.1843.  
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N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-hydroxybenzamide (98) Protected ester 
95 (20 mg, 0.0276 mmol) was dissolved in EtOH: THF (2:1). 10% palladium on carbon 
(10 mg) was then added.  The reaction vessel was sealed with a rubber septum and 
charged with an atmosphere of hydrogen gas.  The reaction was stirred overnight at 
room temperature.  The reaction mixture was filtered over a pad of celite and rinsed with 
EtOAc and concentrated under reduced pressure.  The crude residue was purified via 
column chromatography (SiO2, 0-80% acetone in hexanes) to yield 98 (8 mg, 45.5%). 
1H NMR (500 MHz, Chloroform-d) δ 7.70 (s, 1H), 7.64 (d, 1H), 7.52 (d, 2H), 7.46 (s, 
1H), 7.38 (s, 1H), 7.34 (s, 2H), 7.24 – 7.17 (m, 1H), 7.04 – 6.96 (m, 3H), 6.90 (d, 2H), 
6.73 (d, 2H), 5.72 (s, 1H), 4.65 – 4.56 (m, 1H), 4.31 (t, 1H), 3.95 (m, 1H), 3.74 (t, 2H), 
3.31 (d, 4H), 3.23 (d, 4H), 1.80 (d, 3H). 13C NMR  (126 MHz, Chloroform-d) δ 130.05 , 
128.58 , 126.71 , 121.75 , 118.47 , 118.36 , 116.92 , 115.25 , 114.62 , 111.69 , 106.06 , 
102.05 , 77.22 , 75.07 , 67.39 , 50.71 , 49.81 , 25.90 . DART-HRMS: m/z calcd. for 
C34H33Cl2N3O5 [MH]+, 634.1876; Found: 634.1884. IR (solid) vmax: 3279, 2925, 2852, 
2824, 1639, 1590, 1446, 1409, 1373, 1228, 1190, 115, 1036, 944, 826, 747. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide (99) DART-HRMS: 
m/z calcd. for C34H33Cl2N3O5 [MH]+, 634.1876; Found: 634.1843.  
3-chloro-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (100) Aniline 88 (20 mg, 0.039 
mmol), 3-chlorobenzoic acid (18.3 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and 
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred 
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under argon for 12h at room temperature.  The crude reaction was immediately purified 
via column chromatography (SiO2, 0-80% acetone in hexanes) to afford 100 (6.0 mg, 
23.5%).     1H NMR (500 MHz, Chloroform-d) δ 7.90 (t, 1H), 7.78 (d, 1H), 7.68 (d, 2H), 
7.60 – 7.54 (m, 3H), 7.47 (t, 1H), 7.43 (d, 1H), 7.24 (m, 1H), 7.04 (d, 2H), 6.98 – 6.92 
(m, 2H), 6.81 – 6.75 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.82 – 3.73 (m, 
2H), 3.41 – 3.32 (m, 4H), 3.27 (m, 4H), 1.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
130.97, 130.10, 128.58, 127.34, 126.71, 121.74, 118.36, 116.88, 115.24, 111.47, 
109.16, 105.92, 101.77, 77.27, 77.02, 76.76, 75.06, 68.44, 67.39, 50.72, 49.77, 25.90. 
DART-HRMS: m/z calcd. for C34H32Cl3N3O4 [MH]+, 648.2032; Found: 648.1998. IR 
(solid) vmax: 3311, 3283, 3254, 2961, 2854, 1640, 1588, 1512, 1451, 1375, 1228, 
1192, 1152, 1037, 943, 820, 755. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-methoxybenzamide (101) Aniline 88 
(20 mg, 0.039 mmol), m-anisic acid (17.8 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 
mmol), and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and 
stirred under argon for 12h at room temperature.  The crude reaction was immediately 
purified via column chromatography (SiO2, 0-60% acetone in hexanes) to afford 101 
(4.0 mg, 15.7%).  1H NMR (500 MHz, Chloroform-d) δ 7.74 (s, 1H), 7.68 (d, 1H), 7.59 
(d, 2H), 7.51 – 7.46 (m, 1H), 7.45 – 7.41 (m, 3H), 7.24 (m, 1H), 7.14 – 7.08 (m, 1H), 
7.04 (d, 2H), 6.95 (d, 2H), 6.81 – 6.75 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 
3.92 (s, 3H), 3.81 – 3.74 (m, 2H), 3.42 – 3.31 (m, 5H), 3.27 (t, 4H), 1.83 (s, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 129.75 , 121.58 , 118.35 , 118.35 , 116.93 , 116.93 , 115.24 
, 110.72 , 109.81 , 104.93 , 100.60 , 96.72 , 77.21 , 55.52 , 50.72 , 49.86 . 
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 DART-HRMS: m/z calcd. for C35H35Cl2N3O5 [MH]+, 652.1537; Found: 652.1532. IR 
(solid) vmax: 3289, 2922, 2823, 138, 1580, 1510, 1450, 1374, 1288, 1190, 1150, 1033, 
943, 817, 746, 686, 524 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)furan-3-carboxamide (102) Aniline 88 (20 
mg, 0.039 mmol), 3-thiophene carboxylic acid (14.9 mg, 0.117 mmol), EDCI (22.4 mg, 
0.117 mmol), and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM 
(10mL) and stirred under argon for 12h at room temperature.  The crude reaction was 
immediately purified via column chromatography (SiO2, 0-50% acetone in hexanes) to 
afford 102 (2.0 mg, 8.1%).    1H NMR (500 MHz, Chloroform-d) δ 7.53 (s, 3H), 7.02 (d, 
2H), 6.98 – 6.90 (m, 2H), 6.83 – 6.71 (m, 3H), 4.35 (m, 1H), 3.78 (m, 2H), 3.43 – 3.30 
(m, 4H), 3.30 – 3.17 (m, 4H), 1.83 (s, 3H). DART-HRMS m/z calcd. for C32H31Cl2N3O5 
[MH]+, 608.1719; Found: 608.1701  
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)thiophene-3-carboxamide (103) Aniline 88 
(20 mg, 0.039 mmol), 3-furic acid (13.1 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), 
and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred 
under argon for 12h at room temperature.  The crude reaction was immediately purified 
via column chromatography (SiO2, 0-50% acetone in hexanes) to afford 90 (3.0 mg, 
12.6%).    1H NMR (500 MHz, Chloroform-d) δ 7.99 (d, 1H), 7.68 (d, 1H), 7.59 – 7.49 
(m, 4H), 7.44 (m, 2H), 7.24 (m, 1H), 7.03 (d, 2H), 6.95 (d, 2H), 6.78 (d, 2H), 4.65 (m, 
1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.78 (m, 2H), 3.41 – 3.32 (m, 4H), 3.27 (m, 4H). 13C 
NMR (126 MHz, CDCl3) δ 152.75, 146.02, 139.34, 134.36, 130.97, 128.58, 128.36, 
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126.83, 126.70, 126.03, 121.67, 119.77, 118.35, 116.93, 115.88, 115.24, 111.51, 
109.16, 105.96, 101.84, 97.85, 93.77, 77.27, 77.22, 77.01, 76.76, 75.07, 68.44, 67.39, 
50.72, 49.84, 31.95, 30.18, 29.72, 29.38, 25.90, 22.71, 14.13, 1.04. DART-HRMS: m/z 
calcd. for C32H31Cl2N3O4S [MH]+, 624.1491; Found: 624.1473.  
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)cyclohexanecarboxamide (104) 1H NMR 
(500 MHz, Chloroform-d) δ 8.19 (s, 1H), 7.56 (d, J = 7.5 Hz, 2H), 7.46 – 7.33 (m, 3H), 
6.92 (dd, J = 18.1, 8.7 Hz, 4H), 6.79 (dd, J = 12.5, 8.7 Hz, 2H), 6.72 (d, J = 8.5 Hz, 2H), 
4.42 – 4.28 (m, 1H), 4.00 (dd, J = 9.6, 5.8 Hz, 1H), 3.83 – 3.66 (m, 2H), 3.40 (s, 4H), 
3.24 (d, J = 6.3 Hz, 8H), 2.28 – 2.18 (m, 2H), 1.93 (d, J = 12.9 Hz, 3H), 1.89 – 1.79 (m, 
5H), 1.72 (s, 4H), 1.68 (s, 1H), 1.52 (t, J = 12.7 Hz, 5H). 
3-acetyl-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (105) 1H NMR (500 MHz, 
Chloroform-d) δ 8.47 (s, 1H), 8.15 (t, J = 8.6 Hz, 2H), 7.92 (s, 1H), 7.71 – 7.52 (m, 5H), 
7.45 – 7.32 (m, 2H), 7.29 – 7.22 (m, 1H), 7.04 (d, J = 8.7 Hz, 2H), 6.95 (t, J = 6.5 Hz, 
2H), 6.84 – 6.74 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.82 – 3.66 (m, 2H), 
3.36 (m, 4H), 3.27 (m, 4H), 2.71 (d, J = 6.6 Hz, 3H).  
phenyl (4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)carbamate (106) 1H NMR (500 MHz, 
Chloroform-d) δ 7.66 (m, 1H), 7.52 – 7.36 (m, 6H), 7.30 – 7.21 (m, 4H), 7.21 – 7.17 (m, 
1H), 7.04 – 6.96 (m, 4H), 6.96 – 6.90 (m, 2H), 6.86 (s, 1H), 4.38 (m, 1H), 4.16 (m, 1H), 
4.09 – 4.04 (m, 1H), 4.04 – 3.97 (m, 1H), 3.90 (m, 1H), 3.44 (m, 1H), 3.35 (m, 3H), 3.28 
(m, 4H), 1.87 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 152.92 , 138.15 , 134.56 , 
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132.83 , 131.20 , 129.39 , 128.91 , 126.80 , 125.59 , 121.66 , 121.30 , 120.32 , 118.38 , 
117.16 , 116.17 , 115.49 , 109.09 , 77.24 , 73.96 , 69.30 , 67.03 , 50.74 , 49.98 , 48.91 , 
25.75. IR (solid) vmax: 3332, 3292, 2926, 2825, 1733, 1706, 1510, 1490, 1450, 1414, 
1227, 1179, 1161, 1034, 943, 823, 747, 687. 
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)hydrazinecarboxamide (107) 1H NMR 
(500 MHz, Chloroform-d) δ 7.66 (d, 1H), 7.45 (d, 1H), 7.28 (m,  1H), 7.02 – 6.95 (m, 
2H), 6.92 (m, 4H), 6.76 – 6.68 (m, 2H), 4.37 (m, 1H), 4.16 (m, 1H), 4.06 (m, 1H), 4.01 
(m, 1H), 3.89 (m, 1H), 3.41 (d, 1H), 3.32 – 3.26 (m, 4H), 3.26 – 3.17 (m, 3H), 1.86 (s, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 131.19 , 128.91 , 126.79 , 118.85 , 118.25 , 
116.23 , 115.46 , 110.18 , 77.23 , 73.97 , 69.30 , 67.04 , 51.25 , 50.86 , 25.74. IR (solid) 
vmax: 2916, 2848, 1546, 1510, 1462, 1450, 1375, 1225, 1197, 1037, 945, 824. 
phenyl (4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)carbamate (108) 1H NMR (500 MHz, 
Chloroform-d) δ 7.59 – 7.53 (m, 2H), 7.47 – 7.37 (m, 11H), 7.27 – 7.22 (m, 6H), 7.01 (d, 
J = 8.9 Hz, 3H), 6.95 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 7.9 Hz, 2H), 6.84 – 6.73 (m, 3H), 
4.65 (p, J = 6.1 Hz, 1H), 4.39 – 4.30 (m, 1H), 4.00 (s, 2H), 3.82 – 3.69 (m, 3H), 3.40 (s, 
3H), 3.33 (d, J = 5.4 Hz, 4H), 3.27 (dd, J = 6.3, 3.7 Hz, 4H). IR (solid) vmax: 3332, 
2958, 2926, 2853, 1757, 1736, 1553, 1510, 1491, 1417, 1229, 1195, 1181, 1162, 1024, 
911, 828, 751, 688. 
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)hydrazinecarboxamide (109) 1H NMR 
(500 MHz, Chloroform-d) δ 7.68 (d, 1H), 7.43 (d, 1H), 7.24 (m, 1H), 6.99 – 6.87 (m, 5H), 
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6.81 – 6.68 (m, 4H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.85 – 3.74 (m, 3H), 3.40 
(s, 2H), 3.30 – 3.20 (m, 8H), 1.82 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 128.59 , 
126.71 , 119.01 , 118.35 , 116.21 , 115.22 , 110.03 , 105.12 , 76.87 , 75.06 , 68.43 , 
67.39, 50.80 , 29.72 , 25.89. IR (solid) vmax: 2920, 2876, 2851, 1554, 1511, 1464, 
1450, 1377, 1225, 1184, 1151, 1035, 944, 826. 
4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (110). 1H NMR 
(500 MHz, Chloroform-d) δ 8.55 (d, J = 11.6 Hz, 0H), 8.38 (s, 0H), 7.68 (d, J = 8.4 Hz, 
1H), 7.50 (d, J = 16.7 Hz, 1H), 7.43 (s, 1H), 7.23 (d, J = 2.1 Hz, 1H), 7.08 (d, J = 18.3 
Hz, 1H), 7.00 (d, J = 15.3 Hz, 2H), 6.93 (s, 2H), 6.78 (s, 2H), 4.65 (s, 1H), 4.36 (s, 1H), 
3.98 (s, 1H), 3.81 – 3.75 (m, 2H), 3.40 (s, 1H), 3.26 (q, J = 4.6, 3.6 Hz, 5H), 1.83 (s, 
3H). 
 
4.2 Biological Assay Protocols 
Gene expression assay protocol (ASZ-001): Cells were seeded (10,000 cells per well; 
100 µL total volume per well) in a 96-well tissue culture plate.  After 24h of incubation 
(37°C, 5% CO2), growth media was removed and replaced with low FBS media.  Cells 
were incubated for an additional 24h.  After this time, DMSO (vehicle control) and 
analogues (1% DMSO concentration) were added to the wells.  Cells were incubated 
(37°C, 5% CO2) for 48h and RNA was isolated and evaluated by qRT-PCR.   
RT-PCR protocol: Following treatment and incubation periods, both RNA extraction and 
cDNA synthesis were performed using a TaqMan Cells-to-CT (fast) kit.  cDNA synthesis 
utilized a BioRad MyCycler and was programmed according to the manufacturer’s 
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instructions.  Quantitative RT-PCR was performed on an ABI 7500 system and made 
use of the following TaqMan Gene Expression Probes: mouse ActB (Mm00607939_s1) 
and mouse Gli1 (Mm00494654_m1).  Relative gene expression levels were computed 
via ΔΔCT method using GraphPad Prism.  Corresponding IC50 values were calculated 
as mean ± SEM for at least three separate experiments performed in triplicate. 
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CHAPTER IV: Using Nanotechnology for Targeted ITZ Delivery 
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1. Introduction 
 Nanoscience refers to research at a scale of 100 nm or less and it represents a 
broad range of scientific disciplines.  Nanomedicine consists of utilizing nanoscience for 
medical diagnosis, prevention, and treatment of a disease.  Applying nanoscience to 
drug delivery is seen to be extremely promising and represents the bulk usage of 
nanoscience.130,131 Often times, clinically approved drugs are not necessarily the most 
potent but rather have the most optimal physicochemical properties.  Nanoparticles 
mask a drug’s limiting properties as the drug of interest is dissolved, entrapped, 
absorbed, attached and/or encapsulated into or onto the nano-matrix.132 As a result, 
utilizing nanotechnology will aid in the approval of compounds with the most potent 
activity rather than the most optimal drug properties.  Nanotechnology offers a wide 
range of advantages including improved delivery of water insoluble drugs, targeted 
delivery of drugs in a cell or tissue specific manner, crossing of drugs across tight 
epithelial/endothelial barriers, delivery of large macromolecule drugs to intracellular 
sites of action, co-delivery of two or more drugs, visualization of drug delivery with 
imagining, and real-time read out of in vivo efficacy experiments.133 To date, there are 
over two-dozen nanotechnology therapeutic products that are clinically approved and 
this number is expected to increase as research in the nanomedicine field is rapidly 
growing.133  
 The most studied nanoparticles, liposomes, were first discovered in the 1960s.134 
Liposomes can be described as molecules that self-assemble into hollow spherical 
structures into which a wide variety of cargo molecules can be packaged.135,134  
Liposomes bring tremendous promise towards achieving targeted drug-delivery.  
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Various lipids can be utilized to form liposomes and these lipids affect the overall size 
and charge of the liposome.134,136  In addition, there are a variety of different ways to 
manufacture liposomes, and this process ultimately affects these same properties of the 
liposomes.  The flexibility in making liposomes presents an ideal way to selectively 
target certain types of diseases such as cancer.134,136 
2. Liposomes 
Liposomes are composed of naturally occurring or synthetically produced 
phospholipids such as phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), 
phosphatidyl serine (PS), phosphatidyl inositol (PI), and phosphatidyl glycerol (PG).135 
Phospholipids themselves have rotational freedom, which can lead to leaky liposomes, 
and the addition of cholesterol helps stabilize this bilayer.  The hydroxyl group of 
cholesterol is positioned towards the aqueous surface and the aliphatic chain is aligned 
in parallel to the hydrocarbon chains of the bilayer.134,135 The high solubility of 
cholesterol within the phospholipid bilayer is attributed to its aliphatic chemical structure.  
Cholesterol is usually added to the liposome formulation in high concentrations; 
however, large amounts of cholesterol have been attributed to larger liposome 
vesicles.134,135  This is important to consider if a certain size liposome is necessary for 
targeted drug delivery.  Polyethylene glycol (PEG) is the standard polymer that is 
attached to the drug molecule or added to the liposome formulation to aid with safety 
and efficacy.134,135  By covalently linking PEG to liposomes, the active drug is protected 
from the immune system and therefore increases its blood circulatory time.  PEG has 
also been shown to aid in binding efficiency and general targeted transport in vitro and 
in vivo.137 
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2.1 Liposome Formation 
There are four conventional ways to prepare liposomes: thin-film hydration method, 
reverse-phase evaporation technique, ethanol-injection method, and detergent 
dialysis.132,134 The thin-film hydration method involves dissolving lipids in organic solvent 
and then evaporating off the solvent resulting in a thin-film.  To ensure that solvents are 
removed completely, the film is put on high vacuum overnight.132,134 Rehydration with 
aqueous solvent forms the liposomes: vigorous shaking yields multilamellar vesicles 
(MLVs) and gentle shaking yields giant unilamellar vesicles.  Small unilamellar vesicles 
can be formed with various size reduction techniques.  The reverse-phase evaporation 
technique involves dissolving lipid in organic solvent and then evaporating off the 
solvent to create a thin film.132,134 The film is redissolved in solvent and aqueous buffer 
is added to create a two-phase system.  Slow evaporation of the organic solvent leads 
to liposome formation.  The ethanol-injection method involves dissolving phospholipids 
in organic solvent (ethanol) and adding to aqueous solvent.  Upon addition of the 
ethanol solution, liposomes are formed.132,134 The detergent dialysis method uses 
phospholipids dissolved in detergents to create micelles, which are added to an 
aqueous phase.  Removal of the detergent via dialysis or size-exclusion gel 
chromatography results in large unilamellar vesicles.132,134   
All four of these liposome formation methods typically result in larger-sized 
liposomes.134 However, small unilamellar vesicles can be formed with various size 
reduction techniques. As liposome size and size distribution are the most important 
liposome characteristics, it is often necessary to utilize additional size reduction 
techniques after the initial liposome formation.134,132 Size reduction can be achieved via 
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sonication or extrusion.  Probe sonication uses a titanium probe inserted into the 
liposome preparation.  This generates smaller liposomes efficiently and can be used to 
prepare a desired liposome size.134 Water sonication can also be used if there is 
concern of metal contamination or high temperature affecting liposomes/lipid 
components.  Alternatively, the size extrusion method uses a pressurized instrument to 
force liposomes through a polycarbonate membrane.  The number of extrusion cycles 
depends on the size of the polycarbonate membrane pores.134  
 
Figure 1. Structure of Liposome 
Liposomes are useful drug delivery vehicles as they can carry hydrophilic, lipophilic, 
and amphiphilic drugs.134  Hydrophilic drugs reside in the core of the nanoparticle while 
hydrophobic drugs are incorporated into the lipid bilayer (Figure 1).  It is important to 
understand the physicochemical properties of both the drug and the lipids being used in 
the formulation.  For instance during the thin film hydration method, lipophilic drugs are 
often highly embedded in the lipid bilayer during the step when liposomes self-
assemble.134  However, hydrophilic drugs often do not get encapsulated as well due to 
water content being higher outside of the liposome than inside of the liposome.  Drug 
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loading is dependent not only on the physicochemical properties of drug/lipids but it is 
also dependent on the method of liposome formulation.  There are two types of drug 
loading: passive and active.134 Passive loading consists of drug loading during the 
method of preparation without any additional steps.  Active loading involves forming the 
liposome without the drug and adding it into the liposome after.  This is done with a 
series of buffers to actively load a drug into the liposome and keep it within the 
liposome.134 
2.2 Liposome Characterization 
As previously described, the characteristics of the liposomes depend heavily on the 
lipid composition and liposome formation method. Liposome characteristics such as 
size, membrane lamellarity, and charge are crucial for ultimately determining a route of 
administration (Table 1).134 Liposome size varies from very small (0.025 µM) to large 
vesicles (2.5 µM).  The liposome size is important for in vivo distribution, biological fate, 
toxicity, and target specificity.132 In addition, particle size affects drug release and 
storage.  Smaller particles have a larger surface area-to-volume ratio and result in faster 
drug release while larger particles encapsulate more drug particles and allow for slower 
release.  In terms of storage, smaller particles have a greater risk of aggregation.132 It is 
also important to consider the liposome size dispersion throughout a sample.  This is 
referred to as the polydispersity index (PDI) and samples with uniform size distribution 
are optimal (PDI = 0.1).132 Liposomes can be classified by different bilayers, also known 
as membrane lamellarity, (Table 1) and this affects a wide-range of properties such as 
drug entrapment capacity, the addition of surface bound ligands, drug release from the 
system, storage characteristics, and liposome cell interaction and internalization.134 
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Unilamellar liposomes consist of one lipid bilayer while multilamellar liposomes consist 
of multiple concentric lipid bilayers, similar to an onion.138 Liposomes can be either 
negatively or positively charged depending on their composition.  The addition of oleic 
acid generates negatively charged liposomes while the addition of N-[1(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) results in the 
generation of positively charged liposomes.134 When liposomes are charged, they 
exhibit electrostatic repulsion, which is favorable for storage conditions as the liposomes 
are unable to aggregate.  In addition, cell membranes are negatively charged and there 
is an electrostatic interaction with positively charged (cationic) liposomes.  This 
ultimately increases cell permeability and internalization.134   
Table 1. Classification of Liposomes134 
Vesicle Size (nm) Composition 
Small unilamellar (SUV) 20-100 Conventional liposomes 
Large unilamellar (LUV) > 100 Long-circulating liposomes 
Giant unilamellar (GUV) > 1000 Cationic liposomes 
Oligolamellar (OLV) 100-1000 Stimuli-sensitive liposomes 
Multilamellar (MLV) > 500 Immunoliposomes 
  
 Liposome size can be determined by a variety of different methods, which 
include dynamic light scattering (DLS), size exclusion chromatography (SEC), nuclear 
magnetic resonance (NMR), and microscope technologies including transmission 
electron microscopy (TEM), cryogenic-TEM, and atomic force microscopy.134 Dynamic 
light scattering is the easiest and most popular technique.  DLS analyzes Brownian 
motion of colliding particles resulting from scattering of the incident light; light scattering 
depends on the refractive index between suspended particles and solvent.134 Size 
exclusion chromatography with the use of HPLC provides high-resolution results while 
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only using a small amount of sample.134 This can be used alone or in combination with 
DLS.  While this method is efficient in determining and separating size, it also may lead 
to issues as a result of the liposome chemistry and columns.  Microscopy is used to 
visualize and measure the size of liposomes.  The downside to this method is that 
liposomes must be removed from their native environment and the lipid chemistry may 
be disturbed.134 
 In addition to affecting cell permeability, liposome charge is also important for 
stability.  The charge of a liposome sample can be calculated via the zeta-potential.134 
The zeta-potential is measured by adding liposomes to a sample cell, which is then 
illuminated with light.  The scattered light measures the zeta potential as the liposomes 
move due to their electric fields.134 The number of bilayers in a liposome will influence in 
vivo fate and applications.  There are various chemical based techniques that use 
labeled reagents or radiolabeled ions that aid in estimating the number of layers or the 
amounts of lipids on the surface.  Other techniques used include cryo-TEM analysis, 
NMR and small-angle x-ray scattering (SAXS).134 
2.3 Liposome-Cell Interactions 
There are four different in vitro mechanisms of liposome-cell interaction: exchange of 
lipids or proteins with cell membranes, adsorption or binding of liposomes to cells, 
internalization of liposomes by endocytosis or phagocytosis, and fusion of bound bilayer 
with the cell membrane (Figure 2).139 All four of these interactions are dependent on 
lipid composition, type of cell, and presence of specific receptors/targeting vectors.   
Stable absorption consists of the association of intact liposomes with the cell surface, 
without internalization.139 This adsorption may be mediated by nonspecific forces 
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(hydrophobic, electrostatic) or by specific components (surface receptors, antibodies).  
Endocytosis is the uptake of intact liposomes into endocytotic vesicles.139 Endocytosis 
leads to delivery to the lysosome; however, in some cases content may be released into 
the cytoplasm.  Fusion is the merging of the lipid bilayer with the plasma membrane and 
simultaneous release of liposome contents into the cytoplasm.139 It is possible that 
liposome contents release into the medium during this process.  Lipid transfer includes 
the transfer of lipid molecules between liposomes and cells without cell association of 
aqueous liposome contents.139 
 
Figure 2. Schematic Liposome-Cell Interactions139 
3. Coaxial Continuous Liposome Formation 
 As previously described, there are a variety of methods to form liposomes.  After 
this initial formation, liposomes must often undergo size reduction to attain the optimal 
size liposome and to improve the uniformity of the particle size distribution.  This 
complete process may take hours or days to obtain the desired size liposome.132,134 
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These methods of formation are not optimal or convenient for large-scale liposome 
processing.  It is necessary to have direct control over the size and distribution of 
liposomes as the size ultimately affects cellular uptake and biodistribution.140 As a 
result, recent advances in technology have been utilized to create novel methods to 
mass-produce liposomes of a particular size in an efficient and sterile manner.   
 The most well-known liposomal formulation is the ethanol-injection method.  This 
method offers a plethora of advantages including using less toxic solvents, control over 
particle size/distribution, avoiding size reduction measures, and most importantly, that it 
is a naturally continuous process.140 Continuous processing offers benefits in 
comparison to batch processing and is thus important to consider in the pharmaceutical 
industry.  Continuous processing is faster, more efficient, and may also be safer than 
batch processing.  In addition, continuous processing has the potential to be automated 
and this reduces human involvement and error.140 Both of these factors are important to 
consider when scaling up a pharmaceutical process. 
 With this in mind, Dr. Diane Burgess and her lab at the University of Connecticut 
set out to determine a continuous processing method for the production of 
monodispersed liposomes.140 This production method depends heavily on fluid 
mechanics and physics.  There have been a few reports of utilizing the ethanol-injection 
method for the production of unilamellar liposomes and these processes involve the use 
of two different fluid mixing techniques: laminar and turbulent.140 In terms of the ethanol-
injection method, laminar flow consists of smooth, steady fluid motion and relies heavily 
on fluid viscosity and turbulent flow consists of chaotic fluid motion and relies less on 
the viscosity of the fluid.141 Reynolds number (Re) is an important factor in fluid flow and 
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is described as the ratio of inertial to viscous forces.  Reynolds number takes into 
account the fluid’s resistance to change of motion and the amount of friction due to 
viscosity of fluid.142   Laminar conditions consist of water slowly mixing with the alcohol 
phase (low Reynolds number).  Turbulent conditions consist of rapid mixing of the 
alcohol stream with the aqueous stream (high Reynolds number).142 Taking this into 
consideration, the liposome formation process was explored by relating these fluid 
dynamic properties with liposomal physical properties. 
 The Burgess lab successfully identified a novel continuous processing method 
for the formation of liposomes that utilizes a coaxial turbulent jet in co-flow.  The 
turbulent jet co-flow apparatus begins with preparation containers that house lipid and 
aqueous solutions separately (Figure 3).140 A solution containing lipids and a water-
miscible organic solvent is prepared by heating the solution to 50-60°C and sonication.  
Once the components are dissolved, the lipid solution can be taken up by stainless steel 
tanks, which are pressurized and can be heated to help maintain lipid solubility.140 
These three tanks converge at a single point and static mixers are used to make sure 
the lipid solutions from three different tanks are mixed appropriately before introducing 
the aqueous phase.  The aqueous phase enters the apparatus straight from its 
preparation container.  The lipid solution is injected into the aqueous phase at different 
flow rates (5-40 mL/min or 60-400 mL/min, respectively).140  It is important to note that a 
hydrophilic drug would be incorporated into the aqueous solution and a hydrophobic 
drug would be incorporated into the lipid solution.  This apparatus is controlled by a 
computer program, which was custom designed by the Burgess lab.  The entire system 
is automated and exceptionally user friendly.140  The user only needs to define the final 
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lipid concentration and the molar ratios of the lipid formulation.  This apparatus is also 
attached to a Zetasizer® which records the size and polydispersity index (PDI) of a 
liposome population.  This allows the lipid and aqueous phase flow rates to be adjusted 
in real-time to obtain the optimal size liposomes.140 
 
Figure 3. Coaxial Turbulent Jet in Co-Flow Schematic140 
4. FDA-Approved and Clinical Stage Liposome Formulations 
To date, liposomal drug formulations are becoming increasingly popular within 
the clinic.  Liposomes are the first nanoparticles that have been successfully translated 
into clinically utilized applications.  Liposomes have been FDA-approved for a wide 
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variety of indications including cancer, fungal infections, viral infections, and pain 
management (Table 2).143   
Table 2. Clinically Approved Liposomes143 
Clinical Products 
(Approval Year) Administration Active Agent Indication 
Doxil® (1995) i.v. Doxorubicin Cancer 
DaunoXome® 
(1996) i.v. Daunorubicin Cancer 
Depocyt® (1999) Spinal Cytarabine/Ara-C Cancer 
Myocet® (2000) i.v. Doxorubicin Cancer 
Mepact® (2004) i.v. Mifamurtide Cancer 
Marqibo® (2012) i.v. Vincristine Cancer 
Onivyde® (2015 i.v. Irinotecan Fungal 
Abelcet® (1995) i.v. Amphotericin B Fungal 
Ambisome® 
(1997) i.v. Amphotericin B Fungal 
Amphotec® 
(1996) i.v. Amphotericin B Fungal 
Visudyne® (2000) i.v. Verteporphin Fungal 
DepoDur® (2004) Epidural Morphine sulfate Pain 
Exparel® (2011) i.v. Bupivacaine Pain 
Epaxal® (1993) i.m. Inactivated hepatitis A virus (strain RGSB) Hepatitis A 
Inflexal®V (1997) i.m. Inactivated hemaglutinine of Influenza virus strains A/B Influenza 
i.v. (Intravenous); i.m. (Intramuscular) 
The first liposome formulation approved in the U.S. in 1995 was Doxil®, which 
delivered doxorubicin and was approved for the treatment of patients with ovarian 
cancer and AIDS-related Kaposi’s sarcoma.143  A year later DaunoXome® was 
approved for the delivery of daunorubicin for the management of advanced HIV-
associated Kaposi’s sarcoma.  Depocyt® was approved in 1999 for the delivery of 
Cytarabine/Ara-C for the treatment of neoplastic meningitis.  In 2000, Myocet® was 
another approved doxorubicin formulation for combinatory chemotherapeutic treatment 
alongside cyclophosphamide in metastatic breast cancer.143  Liposome formulation 
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containing mifamurtide, Mepact®, was approved in 2004 for the treatment of high-grade 
resectable non-metastatic osteosarcoma.  In 2012, Marqibo® (vincristine) was approved 
for acute lymphoblastic leukemia.143  In 2015, OnivydeTM, which contains Irinotecan, 
was approved for the treatment of metastatic pancreas adenocarcinoma in combination 
with fluorouracil and leocovorin.  While the majority of research in terms of liposomes 
and drug discovery is aimed at cancer, a few liposome formulations are approved for 
other indications (Figure 4).143 
 
Figure 4. Structures of Liposome-Encapsulated Chemotherapeutic Drugs 
 During 1995-1997, the FDA approved three different formulations (Abelcet®, 
Ambisome®, and Amphotec®) containing amphotericin B for various fungal 
infections.143 These three liposome formulations treat invasive and life-threating fungal 
infections, especially if patients have renal impairment or experience unexpected 
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toxicity to typical amphotericin B treatment.  Visudyne® was the first light-activated drug 
available for eradicating abnormal blood vessels that result from age-related macular 
degeneration.143  This liposome contains verteporfin, which absorbs light at 692nm.  
DepoDur®, a liposome formulation of morphine, is intended for administration before 
surgery or following clamping of the umbilical cord during caesarean section.  Exparel® 
is an approved formulation containing bupivacaine, designed for extended release of 
drug up to 72h.143  In 1993, the first approved liposome vaccine (virosome) was FDA-
approved for hepatitis A and this formulation causes fewer adverse local side effects.  
Inflexal® V is a virosomal influenza vaccine that shows superior immunogenicity above 
other influenza vaccines and this was FDA-approved in 1997 (Figure 5).143 
 
Figure 5. Structures of Liposome-Encapsulated Therapeutic Agents 
 Due to their success in the clinic to date, there has been extensive research in 
regards to liposomes and drug discovery.  This has led to a multitude of formulations 
that are currently being studied in clinical trials for the treatment of various diseases 
(Figure 6).143  Current liposomes in Phase III clinical trials include Stimuvax®, a vaccine 
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that has shown positive results in cancer patients.  Thermodox is a temperature 
sensitive liposome formulation that does not release drug until 42°C.  Most of the 
liposome formulations in Phase III clinical trials are tumor or site specific for more 
targeted therapy.  Current treatments in Phase II clinical trials include liposomes that 
contain both novel and established chemotherapeutic agents.143  This includes two 
Paclitaxel liposome formulations that decrease side effects; Endotag-1 contains 
Paclitaxel and also consists of a cationic lipid formulation that can interact with the 
negatively charged endothelial cells required for tumor angiogenesis.  OSO-211 
contains a novel topoisomerase I inhibitor, lurtotecan, which will be a competitor to 
topotecan.  Phase I clinical trials include both liposomal formulations composed of 
siRNA and sphingosomal encapsulations (INX-0125 and INX-0076).143  Phospholipids 
are compounds of fatty acids, a nitrogenous base, phosphoric acid, and either glycerol, 
inositol, or sphingosine.  Sphingosomal liposome formulations consist of sphingosine, 
which is an amino alcohol that contains a long unsaturated hydrocarbon chain.144 While 
sphingosomal encapsulation is a novel form of targeted drug delivery, utilizing 
sphingoloids has demonstrated increased cell permeability and increased tumor 
targeting specificity.143 
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Figure 6. Liposomes in Clinical-Development143 
5. Liposome-Based Strategies for Effective Drug Delivery  
5.1 Brain Cancer 
 Currently, there are an estimated 700,000 Americans living with a brain tumor.  
There are more than 140 types of malignant brain tumors and most of these tumors also 
have their own subtypes.145 Despite the amount of brain tumors and their devastating 
prognosis, there are only 4 FDA-approved drugs and one device being used to treat 
brain tumors.  In children, brain tumors are the leading cause of cancer-related death 
(Figure 7).146 It is important to highlight that there has never been a drug developed and 
approved specifically for malignant pediatric brain tumors despite the relatively high 
diagnosis rate. Brain tumors are still a difficult health challenge due to their fast 
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development and poor prognosis despite the application of aggressive surgery, 
radiation, and chemotherapy treatments.145 
 
Figure 7. Pediatric Cancer Diagnosis146 
 Malignant brain tumors are difficult to treat with chemical and pharmaceutical 
compounds due to the presence of the blood brain barrier.  The blood-brain barrier 
(BBB) is an intricate network of vascular endothelial cells, cerebral endothelial cells, 
glial cells, pericytes, and neurons.147 The BBB endothelium is uniquely characterized by 
the presence of tight junctions, which consist of transmembrane proteins including 
claudin (3,5, and 12), occludin (1,2, and 3), and junctional-adhesion molecules (JAM-A, 
-B, and –C).148 The BBB has dual functions as it restricts the transport of potentially 
toxic and harmful substances from the blood to the brain and it also allows for the 
selective transport of nutrients to the brain and removal of metabolites from the cerebral 
spinal fluid that surrounds CNS tissue.147 The BBB contains efflux transporters that 
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significantly limit delivery of numerous therapeutics that could otherwise diffuse across 
the plasma membrane.  Two such efflux transporters are P-glycoprotein (P-gp) and 
breast cancer resistance protein (BCRP) which are classified as ATP-binding cassette 
(ABC) transporters.149,150  ABC transporters are ATP-dependent pumps that are 
ubiquitous membrane bound proteins that  can move substances into (influx) and out 
(efflux) of the cell.  These transporters are predominantly found in the liver, BBB, 
kidney, and placenta.151 Thus, the BBB remains a constant challenge in the world of 
drug discovery and development. 
 Liposomes offer an alternative mode of delivery of drugs to the brain.  Often 
times, drugs that could be advantageous chemotherapeutic agents are not considered 
due to their physicochemical properties.  A nanoparticle vehicle such as a liposome 
holds promise as a large percentage of small molecules and antibodies are not able to 
penetrate the BBB.  In addition to modifying liposome properties via different lipids and 
different formation methods, liposomes can also be tagged with proteins that can aid in 
BBB penetration.152 For instance, liposomes can be formulated to contain a target 
ligand that can aid in penetrating the BBB and reaching the brain; these proteins include 
but are not limited to transferrin receptor (TfR), lipoprotein receptor-related protein 
(LRP), and nicotinic acetylcholine receptor (nAChRs).  Transferrin receptors are widely 
expressed in endothelial cells of the BBB.  While nanotechnology has proved successful 
with transferrin ligand, it is not optimal to have this drug delivery system competing with 
natural ligand.152  A mouse monoclonal antibody (MAb) against rat TfR, OX26, has 
successfully been used to target liposomes across the BBB and coined 
“immunoliposome-based drug delivery.”  LRP has been reported to mediate transport of 
		 	 		
 153		
various lipid-conjugated nanoparticles across the BBB.  The LRP ligand Aprotinin and 
more specifically, Angioprep, have effectively increased liposome treatment to the brain 
and have increased survival time of brain tumor-bearing mice.152  Nicotinic acetylcholine 
receptors (nAChRs) are ligand-ion channels that are expressed in the brain and brain 
capillary endothelial cells.  Various peptides derived from viruses and toxins have been 
tagged to nanoparticles and enabled successful brain-targeted drug delivery.152 In 
addition to being advantageous for brain cancers, liposomes serve as a promising route 
of drug delivery for pediatric cancers.   
5.2 Pediatric Cancer 
 In the mid-1970s, the 5-year survival rate for pediatric cancer was 58%.  While 
this number has improved to 80%, this survival rate has remained steady for the past 
few decades.153,154 In addition, chemotherapy has become more aggressive and long-
term toxicities are becoming more frequent in children that survive through adulthood.  
Current chemotherapy involves administration of drug with the hope that enough of the 
active agent permeates tumor cells and does not prove cytotoxic to the rest of the body.  
Nanotechnology presents an alternative drug delivery system for the treatment of 
pediatric malignancies.154 Specifically, liposomes serve as flexible drug delivery vehicles 
that have the potential to improve targeted delivery while minimizing effective drug 
dose.154 In addition to improving drug specificity and minimizing short and long-term 
side effects, more efficacious drugs could be utilized despite their undesired 
physicochemical properties.  Macromolecules, such as siRNA, hold promise as specific 
chemotherapeutic agents in pediatric bone and soft tissue sarcomas such as Ewing 
sarcoma, rhabdomyosarcoma, and synovial sarcoma.154 These promising 
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macromolecules could be formulated into liposomes and provide a more promising form 
of treatment for these children.  There are a few liposomal drug formulations in clinical 
trials to date reiterating the promise of this drug delivery system for the treatment of 
pediatric malignancies (Table 3).11 
Table 3. Liposomal Drug Formulations in Clinical Trials for Pediatric Indications 
Formulation Active Agent Pediatric Indication Phase 
ThermoDox Doxorubicin 
Solid tumors, Ewing sarcoma, soft tissue 
sarcoma, osteosarcoma, neuroblastoma, 
Wilms’ tumors, hepatic tumors, and germ cell 
tumors 
I 
LipoDox Doxorubicin Liver cancer and soft tissue sarcoma I 
VSLI Vincristine Soft tissue sarcoma, lymphoma, leukemia, Wilms’ tumors, and osteosarcoma II 
MM-398 Irinotecan 
Recurrent or refractory solid tumors, Ewing 
sarcoma, rhabdomyosarcoma, neuroblastoma, 
and osteosarcoma 
I 
       
 6. Itraconazole Liposome Formulations: Fungal Infections 
 There have been numerous efforts to aid in improving the physicochemical 
properties of itraconazole (ITZ).  These efforts include utilizing nanotechnology such as 
nano-amorphous powders and nanocrystalline suspensions.155,156 Both of these drug 
formulations have improved the bioavailability of this poorly soluble drug.  Due to the 
success of amphotericin B liposomes for the treatment of fungal infections, there have 
been attempts at formulating azole antifungals into liposomes.  ITZ, specifically, offers 
treatment to a wide range of fungal infections.  However, orally available compounds 
are not necessarily ideal for immunocomprised patients.157 There have been significant 
efforts to formulate ITZ into liposomes to improve solubility and aid in producing an 
intravenous ITZ formulation (Table 4).157,158,159 These liposome formulations improved 
bioavailability, maintained fungal activity, and in one instance resulted in BBB 
		 	 		
 155		
penetration.  Formulating ITZ into liposomes proves promising for the ultimate treatment 
of MB.  However, there are currently no FDA-approved or clinical stage ITZ liposome 
formulations.11 
Table 4. Experimental ITZ Liposome Formulations 
 Lipids Solvent Aqueous Phase Ref 
1 Soy phosphatidyl choline, 
cholesterol, stearylamine 
CHCl3 Phosphate buffer (pH = 7.4) 160 
2 Lecithin, cholesterol, CHCl3 Phosphate buffer (pH = 5.8) 157 
3 Lecithin, cholesterol, cyclodextrin CHCl3: 
MeOH 
N/A 161 
4 Soy lecithin, cholesterol, 
carboxymethyl chitosan 
CHCl3 Phosphate buffer (pH = 7.4) 158 
5 DPPC, cortisone acetate, 
polyethylene glycol (PEG200) 
CHCl3 Phosphate buffer (pH = 7.4) 159 
6 DPPC CHCl3 10 mM PBS (pH = 7.4) 162 
7 Egg PC, MPEG-2000 DSPE, 
cholesterol 
CHCl3 6.67 mM KH2PO4 (pH = 6) 163 
Dipalmitoylphosphotidylcholine (DPPC), potassium dihydrogen phosphate (KH2PO4), 
1,2-distearoyl-phosphitdylehtanolamine-methyl-polyethylene glycol-2000 (DSPE) 
 
7. Itraconazole Liposome Formulation: Medulloblastoma 
 There is tremendous promise in utilizing liposomes to attain more targeted 
treatment regimens for both pediatric and brain cancers. If ITZ or des-triazole ITZ 
analogues are going to be used for the treatment of MB, they must be able to penetrate 
the BBB and reach the brain.  Due to their large size, it is anticipated that ITZ and our 
des-triazole ITZ analogues will have trouble crossing the BBB and liposomes serve as a 
viable option for achieving this targeted drug delivery.  Modifying the characteristics of 
liposomes, such as size and composition, can aid in the nanoparticles’ ability to cross 
the BBB.  Liposomes containing ITZ or des-triazole ITZ analogues would be 
advantageous for the targeted treatment of pediatric SHH subtype MB.     
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7.1 ITZ Liposome Formulation 
 
Figure 8. Structures of Lipid Components 
 Our liposome formulation was based on previous ITZ formulations with a few 
modifications.  The lipids used were hydrogenated soy phosphatidyl choline (HSPC), 
1,2-distearoyl-phosphitdylethanolamine-methyl-polyethylene glycol-2000 (mPEG-2000 
DSPE), and cholesterol (Figure 5).163 This liposome formulation consists of PEG, 
cholesterol, and synthetic lipid (HSPC) while other ITZ liposome formulations contain 
natural ligand and either PEG or cholesterol.  Synthetic lipid is present in all FDA-
approved parenteral liposome formulations while natural lipid is utilized in FDA-
approved liposome formulations with a variety of administration routes.164,165 In addition, 
these liposomes are being formed with the novel coaxial jet in co-flow apparatus 
established by the Burgess Lab.  As the liposomes were being manufactured with the 
turbulent coaxial jet in co-flow, lipids and ITZ could not be dissolved in a water-
immiscible solvent such as chloroform (CHCl3).  Because of this, the solubility of ITZ 
was determined in a variety of water-miscible solvents such as ethanol (EtOH), 
methanol (MeOH), and isopropanol (IPA).  ITZ was most soluble in EtOH (0.6 mg/mL) 
after heating and sonication.  The aqueous solvent utilized was 6.67 mM potassium 
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dihydrogen phosphate (KH2PO4) at pH = 6.  The flow rates of both the organic phase 
and the aqueous phase were adjusted until the optimal size liposomes (ITZ liposomes = 
67.72 nm – 75.23 nm; empty liposomes = 65.42 – 72.39 nm) and reasonable poly-
dispersion index (PDI) values were attained.  It was determined that faster flow rates for 
both the lipid solution (30 mL/min) and aqueous solution (300 mL/min) resulted in 
smaller particle size and optimal PDI values (Table 5).  Sample #6 had a particle size of 
66.82 nm and a PDI of 0.086.  It is important to note that the optimal size liposome to 
achieve BBB penetration is less than 100 nm and an optimal PDI for a sample of 
liposomes is around 0.1.166,167  To date, ITZ liposomes have not been formed with the 
coaxial jet in co-flow apparatus, and as a result, this preliminary batch of liposomes was 
utilized solely for optimization of the formulation within this instrument (Table 5).  After 
this initial optimization, a second batch of liposomes was formulated and analyzed for 
encapsulation efficiency and in vitro Hh pathway inhibitory activity. 
Table 5. ITZ Liposome Batch 1: Flow Rate Optimization  
 Lipid Solution (mL/min) 
Aqueous Solution 
(mL/min) Particle Size (nm) PDI 
#1 10 90 174.8 0.446 
#2 10 100 204.3 0.676 
#3 10 300 170.1 0.362 
#4 30 300 112.4 0.235 
#5 30 300 100.6 0.173 
#6 30 300 66.82 0.086 
 
7.2 Separation of Free Drug 
Inevitably, free drug will remain in the aqueous environment after liposome 
formulation because not all of the drug will be encapsulated into the liposomes.  Free 
drug must be removed before determining the encapsulation efficiency.  With 
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hydrophilic drugs, this is often done with filtration.  Liposomes can be rinsed on a filter 
with water; however, this will not work for hydrophobic drugs.  Liposomes containing 
hydrophobic drug could be rinsed with organic solvent, but ITZ is soluble only in harsh 
solvents (dichloromethane and chloroform) that may disrupt the liposome.  Therefore, a 
centrifugation method was utilized to separate free hydrophobic drug from liposomes.168  
This method relies on the size and density of free drug.  As ITZ is large, hydrophobic, 
dense (d = 1.41 g/cm3), and poorly water-soluble it was anticipated that free ITZ would 
form a pellet upon centrifugation.  Liposomes remain suspended in the aqueous 
solution and upon decanting, are separated from free drug.  Removal of free drug is 
necessary for further liposome evaluation including calculating the encapsulation 
efficiency.   
7.3 Encapsulation Efficiency 
 It is necessary to determine the amount of drug encapsulated into the liposomes.  
Encapsulation efficiency is described as the concentration of the incorporated material, 
in this instance ITZ, detected in the formulation over the initial concentration used to 
make the formulation.169 Lysing the liposomes and measuring drug content via UV or 
fluorescence detection can determine the drug concentration.  When comparing to a 
standard curve of drug, the concentration can be determined. The absorbance of 
various concentrations of ITZ was measured using a UV-vis-spectrophotometer at 254 
nm.  Plotting absorbance versus concentration created a standard curve of ITZ 
(Appendix A).  After removal of free drug via centrifugation, the liposomes were lysed to 
release ITZ.  ITZ liposomes were lysed with 5% Triton solution and heated for 2 h at 
60°C.  Upon heating for shorter time periods (20 min), less ITZ was released from the 
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liposomes.  This may be due to the way ITZ is being encapsulated into the lipid bilayer 
of the liposome or the way it is interacting with the other lipids.  Absorbance of these 
liposome samples was measured and concentrations of drug released were determined 
by using the slope equation of the standard curve.  Drug concentrations ranged from 
115.3 µg/mL – 162.2 µg/mL throughout the liposome samples collected (Table 6).  If 
100% of ITZ (60 mg) were encapsulated into the collected volume (~350 mL) of 
liposomes, the concentration would be 171 µg/mL. The encapsulation efficiency of ITZ 
into this liposome formulation was averaged to be 80.2% across the different 
samples.170 
 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 − 𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 × 100% 
 
Table 6. ITZ Liposome Batch #2: Encapsulation Efficiency 
 ITZ 
Concentration 
(µg/mL) 
Encapsulation 
Efficiency (%) 
 ITZ 
Concentration 
(µg/mL) 
Encapsulation 
Efficiency (%) 
#1 162.2 94.8 #5 124.7 72.9 
#2 146.9 85.9 #6 147.9 86.5 
#3 115.3 67.4 #7 124.6 72.8 
#4 138.6 81.1    
 
7.4 In Vitro Biological Evaluation 
 After determining the encapsulation efficiency and concentration of ITZ in 
liposomes, they were used in our cellular assays to determine if ITZ liposomes exhibit 
biological activity comparable to free drug.  Empty liposomes were also utilized during in 
vitro evaluation as a secondary control.  Ideally, ITZ liposomes will exhibit potent Hh 
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pathway inhibitory activity similar to free ITZ.  Both ITZ and empty liposomes utilized 
within in vitro assays were formulated in a second liposome batch with a previously 
optimized flow rate of 30 mL/min (lipid solution) and 300 mL/min (aqueous solution); 
these ITZ liposome encapsulation efficiencies are described in Table 6. 
 ITZ liposomes, empty liposomes, and free ITZ were evaluated in our gene 
expression assay utilizing ASZ cells.  Before testing liposomes in vitro, a drug 
concentration of encapsulated ITZ needed to be determined and this was calculated 
from the same ITZ concentration used to determine the encapsulation efficiency 
(Appendix A).  It is important to note that the same ITZ liposome sample was used 
throughout all in vitro assays.  Liposomes were also frequently checked via UV (254 
nm) to confirm that they were not leaking drug contents over time.  Initial gene 
expression assays were run in a time dependent manner.  Instead of immediately lysing 
cells after 48h incubation with treatment, cells were lysed at various time points (24h, 
48h, 72h, and 96h) to determine if liposomes exhibited anti-Hh activity in a similar 
manner to free drug.  Evaluation of Hh pathway inhibition at various time points was 
performed as it is unknown how long it would take ITZ liposomes to enter the cell and 
release drug.  Two subsequent time course experiments were performed, each 
exploring different concentrations of liposomes and free drug.  An initial experiment was 
performed utilizing 0.195 mM, 0.01 mM, and 0.001 mM concentrations of treatment 
(Figure 9A).  This experiment resulted in ~50% Gli1 mRNA expression when cells were 
treated with 0.195 mM of liposomes at all time points explored.  However, lower 
concentrations of ITZ liposomes (0.01 and 0.001 mM) as well as empty liposomes 
exhibited 100% Gli1 mRNA expression indicating that the Hh pathway remained active.  
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While there was a dose-dependent trend with free ITZ, there was no clear dose-
dependent trend in terms of the ITZ liposomes.  In fact, this early data suggested that 
low concentrations of ITZ liposomes and empty liposomes might be upregulating the Hh 
pathway as some Gli1 mRNA expression values exceeded 100%.  Because of this, a 
second gene expression assay was performed utilizing 0.195 mM, 0.075 mM, and 0.01 
mM concentrations of treatment (Figure 9B).  This assay resulted in more of a dose-
dependent trend within the ITZ liposomes at all the observed time points.  Interestingly, 
empty liposomes at 48h and 72h time points resulted in high Gli1 mRNA values further 
suggesting that empty liposomes may actually upregulating the Hh pathway.  It is 
important to note that in both assays, treatment with empty liposomes resulted in cell 
death at 96h. 
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Figure 9. Time Dependent Gli1 mRNA Expression in ASZ Cells 
Cells were treated with ITZ liposomes/empty liposomes and incubated for various time periods 
(24h, 48h, 72h, and 96h).  At each time period, cells were lysed and the Gli1 mRNA expression 
was determined via q-PCR.  (a) Treatment with 0.195 mM, 0.01 mM, and 0.001 mM of 
drug/liposome; (b) Treatment with 0.195 mM, 0.075 mM, and 0.01 mM of drug/liposome. 
 
 Due to these preliminary ASZ results, it was hypothesized that the cholesterol 
component of the liposome formulation may be upregulating the Hh pathway.  
Oxysterols, oxidated forms of cholesterol, are known to upregulate the Hh pathway and 
are a well-characterized method to activate Hh signaling in MEFs.  Due to cholesterol 
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having a similar steroidal structure to oxysterols, we needed to determine if the 
liposomes themselves were having an effect on the Hh pathway.   Empty liposomes, 
centrifuged and not centrifuged, were treated in our gene expression assay with MEF 
cells.  This cell line does not have aberrant Hh signaling and therefore these cells need 
to typically be treated with Hh pathway activators (Hh ligand or oxysterols).  Cells were 
only treated with empty liposomes at various volumes and it was determined that they 
did not activate Hh signaling.  Water was set to “100% Gli1 activation” despite the 
pathway not being activated with Hh ligand or oxysterols.  Empty liposomes that were 
centrifuged and not centrifuged exhibited similar Gli1 expression levels to water, 
indicating that the liposomes themselves were not activating or deactivating Gli1 mRNA 
expression in C3H10T1/2 cells (Figure 7).    
 
Figure 10. Relative Gli1 mRNA Expression in C3H10T1/2 Cells 
Cells were treated with empty liposomes for 24h at different volumes, as a “drug” concentration 
could not be experimentally determined.  Water (no liposomes) was set to 100% and mRNA 
expressions for empty liposomes were calculated accordingly. 
 
 After determining that the liposomes themselves were not upregulating the Hh 
pathway, ITZ liposomes were tested in a dose dependent manner alongside free ITZ 
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was not centrifuged.  Both liposome samples were tested to confirm removal of free ITZ; 
however, there should be a difference in activity between liposomes alone and 
liposomes with free drug.  At two different time points (48h and 96h) results indicated 
that the most potent compound was free ITZ, followed by non-centrifuged liposomes, 
and then centrifuged liposomes.  ITZ potently inhibited the Hh pathway (IC50 = 0.11 ± 
0.025 µM at 48h) followed by liposome + free drug treatment (IC50 = 0.49 ± 0.04 µM at 
48h) and liposome treatment alone (IC50 = 2.5 ± 0.37 µM at 48h).  There is a trend in 
this data indicating that the liposomes containing free ITZ were more potent than the 
ITZ liposomes that were subjected to centrifugation (Table 6).  This further confirms that 
free drug was removed with the centrifugation method.  It is important to note that at 
96h, liposome potency slightly increased (IC50 = 1.04 ± 0.17 µM) in comparison to 48h 
(IC50 = 2.5 ± 0.37 µM) indicating that more drug may have been released during this 
longer incubation period resulting in increased Hh inhibitory activity (Table 6).  
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Figure 11. Relative Gli1 mRNA Expression in ASZ Cells 
Cells were treated with ITZ liposomes/empty liposomes for 48h and 96h in a dose dependent 
manner.  At each time point, cells were lysed and Gli1 mRNA expression was determined via q-
PCR.  (a) Dose dependent treatment for 48h (b) Dose dependent treatment for 96h 
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Table 7. In Vitro Analysis of Liposomes 
Treatment IC50 (µM) 48h a, b IC50 (µM) 96h a, c 
ITZ 0.11 ± 0.025 0.14 ± 0.012 
Liposomes 2.5 ± 0.37 1.04 ± 0.17 
Liposomes + ITZ 0.49 ± 0.04 0.45 ± 0.26 
aIC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. bAll 
analogues evaluated following 48 hr incubation. cAll analogues evaluated following 96 hr incubation.  
 
8. Conclusion 
 Liposome formulations would be advantageous to brain cancer patients.  
Specifically, incorporation of ITZ into liposomes may prove beneficial for the treatment 
of pediatric SHH subtype MB.  Itraconazole was successfully formulated into a novel 
liposome formulation utilizing a coaxial turbulent jet in co-flow.  This ITZ liposome 
formulation was prepared specifically for BBB penetration and optimal liposomal size 
was obtained (< 100 nm).  ITZ liposomes demonstrated moderate Hh pathway inhibitory 
activity in comparison to free ITZ.  While ITZ liposomes would ideally exhibit similar anti-
Hh activity as free drug, this proves to be a good starting point for achieving targeted 
drug delivery of ITZ utilizing nanotechnology.  To date, it is unknown how ITZ liposomes 
are releasing their drug in vitro.  Both drug release and cell permeability issues may 
explain the difference in anti-Hh activity between ITZ liposomes and free ITZ.  Further 
exploration towards ITZ liposome behavior in vitro will determine how this formulation 
can be optimized to improve overall biological activity.  
 
Thank you to Dr. Diane Burgess and Rajan Jog for their help and guidance with the 
formulation and preparation of ITZ liposomes. 
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8.1 Experimental Protocols 
Preparation of liposomes: Liposomes were formulated utilizing the coaxial turbulent jet 
in co-flow instrument developed by Dr. Diane Burgess and her lab. HSPC (900 mg), 
DSPC mPEG-2000 (300 mg), cholesterol (300 mg), and ITZ (60 mg) were dissolved in 
EtOH (100 mL) with the help of slight heating (50°C) and sonication.  In parallel, four 
liters of a 6.6 mM KH2PO4 solution were prepared and adjusted to pH 6.  Lipid solution 
was added to stainless steel tank within the coaxial turbulent jet apparatus and this 
solution were incubated at 50°C to ensure lipids and drug remains in solution.  The 
aqueous solution was attached to the apparatus within its preparation container.  The 
lipid concentration and lipid formulation were added into the computer program and the 
flow rates were set.  Liposome size and PDI were measured with Malvern Zetasizer 
Nano S and liposomes were collected in 50 mL Eppendorf centrifuge tubes.  Liposome 
samples were stored at 4°C. 
Free drug separation: Free ITZ was separated from liposomes by centrifugation.  
Liposomes were centrifuged in a Beckman J2-HC centrifuge at 13,000 rpm for 90 
minutes in a 4°C environment.  Liposomes were decanted leaving behind a pellet 
containing free drug. 
Determination of encapsulation efficiency: After removal of free drug, the percentage of 
drug encapsulated into liposomes was determined by monitoring UV absorbance with a 
plate reader (BioTek Synergy H1 Hybrid Reader).  Liposomes were lysed with 5% triton 
and heat (60°C) for 2 hours.  The concentration of ITZ was determined by measuring 
UV at 254 nm in triplicate and comparing to a standard curve of ITZ.   
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Gene expression assay protocol (ASZ-001): Cells are seeded (10,000 cells per well; 
100 µL total volume per well) in a 96-well tissue culture plate.  After 24h of incubation 
(37°C, 5% CO2), growth media was removed and replaced with low FBS media.  Cells 
were incubated for an additional 24 h.  After this time, DMSO (vehicle control) and 
liposomes (Aqueous Solution) were added to the wells.  Cells were incubated (37°C, 
5% CO2) for 48h and RNA was isolated and evaluated by qRT-PCR.   
RT-PCR protocol: Following treatment and incubation periods, both RNA extraction and 
cDNA synthesis were performed using a TaqMan Cells-to-CT (fast) kit.  cDNA synthesis 
utilized a BioRad MyCycler and was programmed according to the manufacturer’s 
instructions.  Quantitative RT-PCR was performed on an ABI 7500 system and made 
use of the following TaqMan Gene Expression Probes: mouse ActB (Mm00607939_s1) 
and mouse Gli1 (Mm00494654_m1).  Relative gene expression levels were computed 
via ΔΔCT method using GraphPad Prism.  Corresponding IC50 values were calculated 
as mean ± SEM for at least three separate experiments performed in triplicate. 
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CHAPTER V: Future Directions in the Development of ITZ and des-ITZ Analogues 
for the Treatment of SHH Subtype Medulloblastoma 
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1. Contributions of ITZ Project 
High-throughput screening efforts have recently been utilized to repurpose FDA-
approved and clinical stage compounds for novel biological indications.  This idea of 
“repurposing” or “repositioning” drugs has become a way to bypass the long and 
expensive process of drug development.1 Itraconazole  (ITZ), a clinically efficacious 
antifungal agent, has recently been determined to inhibit both the hedgehog (Hh) 
pathway and angiogenesis.9,10  Dysregulation of both the Hh pathway and angiogenesis 
contribute to various types of tumors and cancers.  In particular, Hh pathway 
antagonists that are clinically approved often lose activity due to conferred resistance as 
a result of a point mutation in Smo.49–51 ITZ is able to potently inhibit the Hh pathway in 
the presence of wild type Smo and mutant Smo, making it a very desirable candidate 
especially for those patients who have acquired resistance from other Hh pathway 
antagonists.9,78 As a result, ITZ is currently in clinical trials for various cancers resulting 
from these aberrant activities.11 While ITZ is FDA-approved, it still contains a few 
properties that are not considered to be “drug-like.”  For instance, ITZ has a large 
molecular weight and is poorly soluble.  In addition, ITZ contains a triazole moiety, while 
important for its antifungal activity, is able to coordinate with CYP3A4 leading to drug-
drug interactions and adverse side effects.171 As cancer patients are often on a multi-
drug treatment regimen to treat the cancer and resulting symptoms, it is necessary to try 
to minimize these drug-drug interactions and adverse side effects. 
 The structure of ITZ has been minimally explored in terms of its novel anticancer 
activities.  Thus, a series of thorough structure-activity relationship (SAR) studies were 
undertaken to determine the ITZ functional groups required for potent Hh pathway and 
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angiogenesis inhibition.115 Four generations of analogues were designed, synthesized, 
and evaluated in preliminary cellular assays.  Analogue generations I and II focused on 
exploring all three regions of the ITZ scaffold and its stereochemistry.  SAR data 
concluded that the triazole moiety of ITZ can be removed and potent Hh pathway 
inhibition is maintained.  Removal of the triazole group also abolishes unwanted 
inhibition of CYP3A4 and its subsequent adverse side effects.115  It was also determined 
that the most potent stereoisomer of des-triazole ITZ contains the 2R,4R-dioxolane 
orientation and the 2’(R)-sec-butyl side-chain region (Figure 1).  In terms of 
angiogenesis, there was not a clear SAR pattern; however, none of the generation I and 
II analogues were more potent than ITZ in two separate in vitro assays indicating that all 
of the functionality of ITZ, including the triazole region, must be crucial for potent 
angiogenesis inhibition.115  
 
Figure 1. Summary of Generations I and II 
SAR results from generations I and II were crucial in the design of subsequent 
analogues.  Generations III and IV contained the optimal des-triazole-dioxolane 
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stereochemistry and focused on probing the triazolone/side-chain region of the original 
ITZ scaffold.  Modulation to this region included a range of functionality such as amides, 
carbamates, hydrazine carboxamides, and triazolones.  SAR data indicated that polar 
substitution at the meta-position of amide functionality was favorable for Hh pathway 
inhibitory activity (Figure 2).  This potency increased in the presence of the 2S,4R-
dioxolane orientation.  In terms of other functionalities in this region, the hydrazine 
carboxamide analogues were moderately potent suggesting that an acyclic moiety can 
be utilized in replacement of the bulky triazolone ring.  SAR results from generations III 
and IV proved interesting in exploring the triazolone/side-chain region of ITZ and further 
modifications should be explored in this area to improve the potency and 
physicochemical properties of these des-triazole ITZ analogues. 
 
Figure 2. Summary of Generations III and IV 
These SAR results from generations I-IV offer interesting information surrounding 
the ITZ scaffold and its novel anticancer properties.  However, preliminary PK studies 
indicate that the modifications being made to the scaffold are not improving the overall 
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drug like properties. There are still a few regions and structural features of ITZ that 
could be further explored in terms of Hh pathway inhibition (Figure 3).  For instance, the 
triazolone/side chain region could be modified to contain different acyclic and cyclic 
ureas such as modified 5- and 6-membered rings (113).  The sec-butyl side-chain 
region could also be replaced with modified alkyl chains that contain polar functionality 
(alcohols, thiols, and amines), similarly to the hydroxylated side-chain region of PSZ 
(114).  It is also important to note that previous SAR studies determined that the 
triazolone region could be truncated to the nitro, aniline, and hydrazine carboxamide 
functionalities indicating that a cyclic moiety may not be necessary at this position.  
Acyclic moieties should be synthesized and explored as this is a position to incorporate 
hydrogen-bonding functionality and this would also reduce the overall size of the 
molecule (115).    These additional modifications to the triazolone/side-chain region will 
offer more information in terms of the electronics, sterics, and hydrogen bonding of this 
region of the scaffold. 
The linker region has generally remained untouched throughout these analogue 
generations and this may be a way to incorporate polar groups to help aid in the 
solubility of the scaffold.  Such modifications include adding nitrogen atoms to the 
aromatic rings of the linker region (116).  In terms of the dioxolane region, it would be 
worth exploring different polar moieties in replacement of the triazole group.  Removal 
of this triazole substituent abolishes CYP3A4 coordination but also decreases the 
solubility of the des-triazole ITZ analogues.  Various polar moieties could be utilized at 
this position such as amines, alcohols, thiols, amides, and other 5-membered rings such 
as thiophenes, imidazoles, or pyrroles (111).  While CF3 functionality typically adds 
		 	 		
 174		
lipophilicity, it may be interesting to utilize this moiety to further explore the triazole 
region in terms of electronegativity.  The phenyl ring of the dioxolane region was also 
determined to be necessary for Hh pathway inhibition.  However, the chlorine 
substitution was not necessary.  This functionality of the dioxolane region offers another 
location for adding polar groups in an attempt to increase solubility.  Various 
heterocycles could substitute the phenyl ring, including pyridine (112). As the ITZ 
scaffold contains a lot of functionality that is amendable for modification, it is important 
to further explore this structure to both improve the physicochemical properties as well 
as improve Hh pathway inhibitory activity.  
 
Figure 3. Proposed Future ITZ Analogues 
In addition to further SAR studies, it will be necessary to determine the binding 
mode of ITZ/des-triazole ITZ analogues within the Hh pathway.  While ITZ has been 
hypothesized to bind to Smo in a different manner than other Hh pathway antagonists, it 
has not been experimentally determined.  A photo-affinity probe of ITZ has been 
previously developed and could be utilized to isolate and identify the binding mode of 
ITZ within the ASZ cell line.172 Cells could be treated with probe and co-treated with ITZ 
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to confirm the binding proteins are the same.  Treated cells could then be subjected to 
UV to activate the photolabile diazirine and covalently link the probe to the binding 
protein.  Cells could then be lysed, proteins could be denatured, and denatured lysates 
could then be subjected to fluorophores via click chemistry and proteins can be resolved 
on SDS-PAGE.  To isolate and identify a protein of interest, biotin can be used, as the 
fluorophore and biotinylated proteins can be isolated on streptavidin-agarose beads 
before SDS-PAGE.  From this pull down experiment, the band can be cut out and 
analyzed via mass spectrometry.172 It is important to note that a des-triazole ITZ probe 
could also be synthesized and subjected to pull down assays.  This would confirm if 
these analogues inhibit the Hh pathway in a similar manner. 
 
Figure 4. Structure of ITZ Probe 
One of the main reasons why ITZ is being explored as an anticancer 
chemotherapeutic is because of its ability to inhibit the Hh pathway in the presence of 
both wild type Smo and mutant Smo.  It is crucial to determine if des-triazole ITZ and 
our analogues are also able to inhibit the Hh pathway in the presence of these Smo 
mutants.  Two in vitro assays could be utilized to determine the ability of these 
analogues to remain active in the presence of Smo mutants.  Both cell assays would 
utilize an Hh-dependent mouse embryonic fibroblast (C3H10T1/2).  These cells could 
be transfected with various Smo constructs (Smo mutant constructs were generously 
gifted to the Hadden lab).  For screening a few select ITZ analogues, transfected cells 
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can be incubated for 24 hours with recombinant sonic hedgehog ligand (rShh) and drug.  
A gene expression assay measuring endogenous Gli1 mRNA could determine whether 
the Hh pathway is active or inactive.  For a higher-throughput screen of compounds, a 
Gli-luciferase assay could be utilized.  C3H10T1/2 cells could be plated in a 96-well 
plate (20,000 cells/well).  After 24 hours, cells could be transfected with Smo construct, 
Renilla luciferase control reporter, and Gli-Luc reporter using Gene Juice transfection 
agent.  After 12 hours of incubation, recombinant hedgehog ligand (rShh) or sonic 
hedgehog (Shh) supplemented media would be added to each well along with drug.  
Luciferase activities would be determined 48 hours after transfection using DualGlo 
luciferase reporter assay system.51,60 
In collaboration with Dr. Robert Wechsler-Reya and the Sanford Burnham Prebys 
Medical Discovery Institute, the most potent des-triazole ITZ analogues can be 
evaluated for their anti-proliferative and anti-Hh activity in primary Hh dependent murine 
cells.  These cells are isolated from Patched (Ptch) knockout (Math1-Cre-ER; Ptc11/11, 
MERP) mice.  Mice with Ptch mutations have been used to mimic human Hh-associated 
MB.112–114 These primary cells will more closely represent the disease state of cells in 
vivo and have been used for the preclinical testing of other Hh pathway inhibitors.  
Evaluation of these compounds in this primary MB cell line will provide more relevant 
data in comparison to the preliminary evaluation within our established cell lines (murine 
embryonic fibroblast C310T1/2 and ASZ).  The Sanford Burnham Prebys Medical 
Discovery Institute will also aid in testing the most potent ITZ analogues in vivo with 
these same Ptch knockout (MERP) mice. 
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2. Contributions of ITZ Liposome Project 
Thorough SAR studies were undertaken to improve the drug-like properties of ITZ.  
However, despite our efforts, it is anticipated that ITZ and des-triazole ITZ analogues 
will have issues crossing the BBB and reaching the brain.  In addition to medicinal 
chemistry efforts, nanotechnology can be utilized to encapsulate drugs and improve 
targeted tissue delivery.134 Liposomes are the most studied form of nanoparticles and 
have the potential of improving treatment for patients suffering from pediatric and/or 
brain cancer.152,154 ITZ-liposomes have been studied for the treatment of various fungal 
infections, however, there are currently no ITZ-liposome formulations that are FDA-
approved or in clinical trials.11,157,158–163 In collaboration with Dr. Diane Burgess, a 
preliminary ITZ liposome formulation for the treatment of MB was developed and 
studied in vitro.  These liposomes were an optimal size for penetrating the BBB (<100 
nm) and had good encapsulation efficiency (~80%).  While ITZ liposomes were not as 
potent as free ITZ within our in vitro assays, this formulation still offers promise for the 
targeted treatment of MB. 
More research is still necessary to understand how ITZ liposomes behave in vitro.  
Further exploration is needed in terms of how ITZ liposomes interact with cells and how 
they release their drug contents. This information is critical for determining what 
modifications could be made to the liposome formulation to aid in their cell penetration 
or to manipulate the speed at which they release their contents.  Drug release could be 
explored with a dialysis assay or by evaluating the media environment of our gene 
expression assay with the use of mass spectrometry.173 In addition, liposomes could 
undergo a BBB model PAMPA assay to determine if this liposome formulation is 
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actually capable of penetrating the BBB.174  The Burgess Lab utilizes a PAMPA assay 
with primary rat brain endothelial cells that would represent a good model of the BBB.175  
Based on these results, it may be necessary to further modify this current ITZ-liposome 
formulation to improve BBB and/or cellular permeability.  Such modifications include 
adding BBB-targeting proteins to the liposomes or utilizing cationic liposomes as they 
have been determined to increase BBB permeability and cell permeability, 
respectively.134,137   
3. Future Outlook on the Development of ITZ and Des-triazole-ITZ Analogues 
as Anticancer Chemotherapeutic Agents 
 
The treatment of pediatric MB still remains a challenge in modern medicine.  Despite 
the knowledge of MB and its subtypes, a targeted chemotherapeutic treatment has not 
been clinically developed.  Treating MB presents many challenges including the 
average age of patients (7 years old) and the presence of the BBB.  Current treatment 
involves surgery followed by high-dose chemotherapy and radiation.  If the cancer does 
not spread, survival rates are generally between 70 and 80%.  However, this harsh 
treatment regimen results in long-term side effects in these young patents.33 It is 
necessary to develop a more targeted therapeutic for the treatment of pediatric MB.    
Due to MB subtypes, it is difficult to develop just one therapeutic and ultimately, 
each subtype will need to be treated in a different manner.  As SHH subtype MB is 
driven by aberrant Hh pathway activity, a viable strategy to treat this subtype is with Hh 
pathway inhibitors.33 FDA-approved Hh pathway inhibitors such as vismodegib often 
result in decreased activity due to conferred resistance; this was specifically seen in a 
clinical trial involving vismodegib and an MB patient.49,50,51  It would be advantageous to 
identify Hh pathway antagonists that do not lead to resistant forms of Smo.9,78 One way 
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to bypass this would be to identify Hh pathway inhibitors that target downstream of 
Smo.  ITZ serves as a promising scaffold due to its ability to inhibit the Hh pathway in 
the presence of both wild type Smo and mutant forms of Smo.  ITZ is already FDA-
approved and there is a good understanding of its overall safety and adverse side 
effects.  In addition, this antifungal agent is currently administered to and tolerated by 
children for the treatment of various fungal infections.176 Due to these reasons, ITZ 
serves as a promising starting point for targeted MB therapeutic development with an 
Hh pathway antagonist.  Treatment with an Hh pathway inhibitor such as ITZ may allow 
for cancer treatment without harsh life-changing side effects seen with current therapy. 
The blood brain barrier remains a large roadblock in the development of therapeutics 
to treat MB.  A very small percentage of compounds, regardless of physiochemical 
properties, are capable of penetrating the BBB.147 One efficient way to ensure BBB 
penetration is by using nanoparticles, such as liposomes, to ensure targeted drug 
delivery.  Liposomes can be formulated to contain certain characteristics that are 
optimal for BBB penetration.  In addition, liposomes serve as viable treatment options 
for patients suffering from brain or pediatric cancer as they have been proven to limit off 
target toxicities.137,154  Due to its large size, it is anticipated that ITZ will not be able to 
cross the BBB and reach the brain.  As a result, ITZ has been formulated into a 
preliminary liposome model that proves promising for Hh pathway inhibitory activity. 
This liposome formulation should be further explored to increase cell permeability and 
BBB penetration.  An ITZ-liposome formulation may prove advantageous for targeted 
drug delivery and may aid in the development of ITZ as an anticancer agent.  More 
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specifically, liposome formulations of Hh pathway inhibitors may prove to be a promising 
chemotherapeutic option for children suffering from SHH subtype MB.   
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APPENDIX A: Select 1H and 13C NMR Spectral Data 
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SYNTHETIC PROCEDURES 
Linker Region Intermediates 
1-(4-methoxyphenyl)-4-(4-nitrophenyl)piperazine (13). 1-(4-
methoxyphenyl)piperazine (11) (8.0 g, 41.6 mmol) and 1-chloro-4-nitrobenzene (12) 
(6.3 g, 40.0 mmol) were dissolved in anhydrous DMSO (80 mL).  K2CO3 (6.0 g, 43.5 
mmol) was added and the mixture refluxed at 160°C for 12 h.  The reaction was cooled 
to RT and a red solid precipitated. The red solid was filtered and washed with CHCl3. 
The filtrate was concentrated to afford 13, which was immediately utilized as the crude 
solid.  
4-(4-(4-methoxyphenyl)piperazin-1-yl)aniline (14). 10% palladium on carbon (0.88 g, 
5% mole ratio) was added to a dry 3-neck round bottom flask. Ethanol (200 mL) was 
added followed by slow addition of 13 (5.2 g, 16.59 mmol). Hydrazine monohydrate (5.2 
mL, 165.9 mmol) was added dropwise and the mixture was stirred at reflux for 3.5 h.  
Upon cooling to RT, the mixture was filtered through celite. The celite was washed with 
ethanol (250 mL) and chloroform (1000 mL) to ensure complete elution of the aniline. 
The filtrate was concentrated to afford 14, which was immediately utilized as the crude 
solid. 
Phenyl (4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)carbamate (15). A solution of 
aniline (14) (2.7 g, 9.51 mmol) and pyridine (12.8 mL, 158.8 mmol) in CHCl3 (100 mL) 
was cooled to 0°C.  Phenyl chloroformate (1.25 mL, 9.9 mmol) was added dropwise and 
the mixture stirred at RT for 3 h. Water and petroleum ether (50 mL: 50 mL) were added 
at which point an off-white precipitate formed.  The solid was washed with H2O and 
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isopropyl alcohol to provide the crude carbamate 15, which was immediately utilized 
without further purification. 
N-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)hydrazinecarboxamide (16). A 
solution of hydrazine hydrate (1.33 mL, 42.8 mmol) and 15 (3.2 g, 7.9 mmol) in 1.4-
dioxane (70 mL) was stirred at reflux for 3 h. The mixture was poured into H2O (250 
mL), and the resulting off-white solid was filtered and washed with H2O and isopropyl 
alcohol to give carboxamide 16, which was immediately utilized without further 
purification.  
4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
(17). A solution of formamidine acetate (2.86 g, 27.5 mmol), 16 (2.1 g, 6.15 mmol), and 
acetic acid (4 mL) in anhydrous DMF (30 mL) was stirred at 130°C for 3 h.  The mixture 
was cooled to room temperature and diluted with H2O (100 mL) at which point a light 
brown precipitate formed.  The solid was filtered and washed with CHCl3 to provide 
triazolone 17, which was immediately utilized without further purification.  
4-(4-(4-nitrophenyl)piperazin-1-yl)phenol (44). N-(4-hydroxyphenyl)-piperazine (5.3 g, 
29.7 mmol), 1-chloro-4-nitrobenzene (6.57 g, 41.7 mmol), and DIPEA (7.74 mL, 44.4 
mmol) were dissolved in 50 mL anhydrous NMP and heated to 125°C for 12 h.  The 
reaction was cooled to 80°C and isopropanol (250 mL) was added portion wise over 30 
mins.  The reaction mixture was cooled to room temperature and precipitate started to 
form.  The reaction was further cooled to -20°C and stirred for 30 mins.  The precipitate 
was vacuum filtered and washed with cold isopropanol to give the product, a brown 
powder, in quantitative yield.  Characterization matched that previously reported.1 
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Side Chain Intermediates  
(R)-sec-butyl 4-bromobenzenesulfonate (20). (R)-2-butanol (18) (3.0 g, 40.5 mmol), 
Et3N (12.0 mL, 13.5 mmol), and DMAP (5.0 g, 40.5 mmol) in DCM.  Cool the reaction to 
0°C and slowly add a solution of 4-bromobenzene-1-sulfonylchloride (22.7 g, 89.1 
mmol) in DCM.  The mixture was stirred at 0°C for 4h.  Dilute the reaction with H2O and 
extract with DCM.  Combine the organic layers, dry over sodium sulfate, filter, and 
concentrate.  The crude residue was purified by column chromatography (SiO2, 0-2% 
EtOAc in hexanes) to afford the product (37.9%, 4.5 g). 1H NMR (500 MHz, CDCl3) δ 
7.68 (m, 2H), 7.57 (m, 2H), 4.47 (m, 1H), 1.45 (m, 2H), 1.15 – 1.09 (m, 3H), 0.65 (m, 
3H). 13C NMR (126 MHz, CDCl3) δ 137.12, 132.83, 129.53, 128.95, 83.03, 31.99, 29.88, 
23.05, 20.76, 14.51, 9.71. DART-HRMS: m/z calcd. for C10H13BrO3S [MH]+, 294.9827; 
Found: 294.9822. IR (solid) vmax: 2954, 2930, 2869, 1588, 1463, 1376, 1364, 1313, 
1224, 1188, 1093, 1070, 1034, 942, 903, 821, 752. [α]D20 = -16.0 (c = 1.984, MeOH). 
(S)-sec-butyl 4-bromobenzenesulfonate (21). (S)-(+)-2-butanol (19) (3.0 g, 40.5 
mmol), Et3N (12.0 mL, 13.5 mmol), and DMAP (5.0 g, 40.5 mmol) in DCM.  Cool the 
reaction to 0°C and slowly add a solution of 4-bromobenzene-1-sulfonylchloride (22.7 g, 
89.1 mmol) in DCM.  The mixture was stirred at 0°C for 4h.  Dilute the reaction with H2O 
and extract with DCM.  Combine the organic layers, dry over sodium sulfate, filter, and 
concentrate.  The crude residue was purified by column chromatography (SiO2, 0-2% 
EtOAc in hexanes) to afford the product (53.9%, 6.4 g). 1H NMR (500 MHz, CDCl3) δ 
7.84 – 7.72 (m, 2H), 7.65 (m, 2H), 4.57 (m, 1H), 1.56 (m, 2H), 1.32 – 1.19 (m, 3H), 0.77 
(m, 3H). 13C NMR (126 MHz, CDCl3) δ 136.56, 132.31, 129.00, 128.40, 82.50, 60.22, 
31.43, 29.33, 20.21, 14.07, 9.16. DART-HRMS: m/z calcd. for C10H13BrO3S [MH]+, 
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294.9827; Found: 294.9856.  IR (solid) vmax: 3090, 2975, 2937, 2880, 1576, 1501, 
1471, 1389, 1361, 1226, 1185, 1112, 1090, 1068, 994, 895, 819, 751, 608. [α]D20 = 
+11.5 (c = 4.466, MeOH). 
Linker/Triazolone/Side Chain Intermediates. 
General Protocol for alkylation of triazolone (propyl- or sec-butyl-substitutions) 
(24-27).  To a suspension of triazolone 17 (1.0 g, 2.8 mmol) in anhydrous NMP (30 mL) 
was added Cs2CO3 (2.74 g, 8.4 mmol), and an alkylating agent (20-23) (8.4 - 14 mmol). 
The mixture was stirred at RT for 2 h, then warmed to 60º C for 12 h and finally to 110º 
C for 4h. The mixture was then cooled to RT, diluted with water (125 mL), and extracted 
with EtOAc (3 X 150 mL).   The organic layers were combined, dried (MgSO4), filtered, 
and concentrated. The crude residue was purified by column chromatography (SiO2, 0 
to 20% EtOAc in Hex) to afford 24-27 as off-white solids (45-88%).  Compounds were 
further purified as needed via recrystallization (EtOH) to remove a “grease-like” impurity 
(observed in 1H NMRs at 0.88, 1.31 ppm). 
(S)-2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-
1,2,4-triazol-3-one (24). 1H NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.46 – 7.40 (m, 2H), 
7.03 (d, J = 9.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 6.90 – 6.84 (m, 2H), 4.35 – 4.24 (m, 
1H), 3.78 (s, 3H), 3.37 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.78 – 1.66 (m, 1H), 1.39 (d, 
J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 154.24, 152.07, 
150.60, 145.53, 133.91, 125.96, 123.55, 118.63, 116.66, 114.57, 55.61, 52.72, 50.83, 
49.31, 28.47, 19.25, 10.80. DART-HRMS: m/z calcd. for C23H29N5O2 [MH]+, 408.2400; 
Found: 408.2368. IR (solid) vmax: 3120, 3053, 2967, 2935, 2877, 2821, 2765, 1686, 
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1549, 1507, 1446, 1388, 1240, 1222, 1154, 1117, 1030, 943, 823, 805, 720.  [α]D20 = + 
12.6 (c = 0.996, DMSO). 
(R)-2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-
1,2,4-triazol-3-one (25). 1H NMR (500 MHz, CHCl3) δ 7.61 (s, 1H), 7.47 – 7.40 (m, 2H), 
7.06 – 6.99 (m, 2H), 6.96 (m, 3H), 6.90 – 6.84 (m, 2H), 4.30 (m, 1H), 3.78 (d, J = 1.3 
Hz, 2H), 3.40 – 3.28 (m, 4H), 3.24 (m, 4H), 1.94 – 1.76 (m, 1H), 1.78 – 1.67 (m, 1H), 
1.39 (d, J = 6.7 Hz, 2H), 0.91 (t, J = 7.4 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 154.21, 
152.06, 150.58, 145.50, 133.94, 125.94, 123.54, 118.62, 116.65, 114.55, 55.60, 52.70, 
50.81, 49.29, 28.47, 19.29, 10.83. DART-HRMS: m/z calcd. for C23H29N5O2 [MH]+, 
408.2400; Found: 408.2430. IR (solid) vmax: 3120, 3052, 2967, 2821, 1686, 1549, 
1507, 1444, 1386, 1240, 1221, 1030, 943, 824, 805, 719, 530. [α]D20 = -12.2 (c = 0.873, 
DMSO). 
2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-
1,2,4-triazol-3-one (26). 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 0.6 Hz, 1H), 7.51 – 
7.43 (m, 2H), 7.11 – 7.04 (m, 2H), 7.04 – 6.97 (m, 2H), 6.96 – 6.88 (m, 2H), 4.34 (m, 
1H), 3.83 (s, 3H), 3.44 – 3.38 (m, 4H), 3.31 – 3.25 (m, 4H), 1.91 (m, 1H), 1.83 – 1.70 
(m, 1H), 1.44 (d, J = 6.8 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
154.22, 152.07, 150.60, 133.98, 125.92, 123.59, 118.66, 116.69, 114.54, 55.61, 52.69, 
50.85, 49.29, 32.36, 28.49, 19.33, 10.85. DART-HRMS: m/z calcd. for C23H29N5O2 
[MH]+, 408.2400; Found: 408.2388. IR (solid) vmax: 3120, 3053, 2970, 2877, 2818, 
2763, 1686, 1548, 1508, 1444, 1399, 1241, 1223, 1030, 943, 823, 805. 
4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-
triazol-3-one (27): 1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H), 7.50 – 7.43 (m, 2H), 7.04 
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– 6.97 (m, 2H), 6.96 – 6.88 (m, 2H), 3.86 (m, 2H), 3.83 (s, 3H), 3.44 – 3.38 (m, 4H), 
3.31 – 3.25 (m, 4H), 1.89 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
154.22, 152.22, 150.66, 145.51, 133.93, 125.87, 123.60, 118.64, 116.67, 114.55, 55.61, 
50.83, 49.28, 47.23, 22.06, 11.13. DART-HRMS: m/z calcd. for C22H27N5O2 [MH]+, 
394.2243; Found: 394.2265. IR (solid) vmax: 3122, 3053, 2956, 2873, 2830, 1686, 
1555, 1511, 1451, 1409, 1390, 1250, 1225, 1032, 942, 813, 733. 
General Protocol for phenol synthesis (demethylation protocol) (28-31).  Hydrogen 
bromide (48% aqueous solution, 10 mL) was added to a solution of methoxy-alkyl 
substituted triazolone 24-27 (500 mg, 1.2 mmol) in toluene (6 mL) was refluxed for 6-12 
h.  The reaction was cooled to RT and water (10 mL) was added.  The precipitate that 
formed was collected by filtration and washed with copious amounts of water.  1H NMR 
analysis indicated pure phenol in good yields (55-80%).  The filtrate was neutralized 
with saturated NaHCO3 and washed with EtOAc (2 X 150 mL).  The organic layers were 
dried (MgSO4), filtered, and concentrated to afford remaining phenol (28-31) in 
moderate purity that required chromatography. 
(S)-2-(sec-butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-
1,2,4-triazol-3-one (28).   1H NMR (500 MHz, DMSO) δ 8.38 (s, 1H), 7.58 (m, 2H), 7.53 
(s, 1H), 7.19 (m, 2H), 6.91 (d, J = 8.4 Hz, 2H), 4.13 (m, 1H), 3.67 (s, 8H), 1.71 (m, 2H), 
1.31 (d, J = 6.7 Hz, 3H), 0.81 (t, J = 6.6 Hz, 3H).  13C NMR (126 MHz, DMSO) δ 161.5, 
151.2, 148.5, 134.9, 126.4, 122.9, 122.0, 116.2, 116.1, 53.8, 51.7, 46.4, 27.8, 19.2, 
10.5.  DART-HRMS: m/z calcd. for C22H28N5O2 [MH]+, 394.2243; Found: 394.2216. IR 
(solid) vmax 3331, 2958, 2875, 2832, 2807, 1688, 1509, 1448, 1385, 1222, 1181, 1152, 
965, 824, 741, 729. [α]D20 = +13.0 (c = 0.994, DMSO).  
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(R)-2-(sec-butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-
1,2,4-triazol-3-one (29).  1H NMR (500 MHz, DMSO) δ 8.38 (s, 1H), 7.58 (d, J = 8.9 Hz, 
2H), 7.48 (s, 1H), 7.19 (d, J = 8.9 Hz, 2H), 6.89 (m, 2H), 4.14 (m, 1H), 3.62 (s, 8H), 1.70 
(m, 2H), 1.31 (d, J = 6.7 Hz, 3H), 0.82 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, DMSO) 
δ 157.2, 151.4, 148.6, 135.1, 126.4, 123.1, 122.1, 122.0, 116.4, 116.3, 53.9, 51.9, 46.6, 
28.0, 19.3, 10.7.  DART-HRMS: m/z calcd. for C22H28N5O2 [MH]+, 394.2243; Found: 
394.2212. IR (solid) vmax: 3241, 3055, 2965, 2928, 2855, 1670, 1509, 1451, 1378, 
1234, 1185, 1110, 967, 921, 832, 807, 746. [α]D20 = -13.7 (c = 1.254, DMSO).  
2-(sec-butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-
triazol-3-one (30). 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 0.6 Hz, 1H), 7.41 – 7.35 
(m, 2H), 7.00 – 6.94 (m, 2H), 6.86 – 6.80 (m, 2H), 6.72 – 6.67 (m, 2H), 4.31 (m, 1H), 
3.37 – 3.31 (m, 4H), 3.23 – 3.17 (m, 4H), 1.87 (m, 1H), 1.73 (m, 1H), 1.40 (d, J = 6.7 
Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.72, 151.21, 151.13, 
134.68, 125.80, 124.64, 119.18, 116.91, 116.38, 53.32, 51.44, 49.53, 28.85, 19.64, 
11.18. DART-HRMS: m/z calcd. for C22H27N5O2 [MH]+, 394.2243; Found: 394.2221. IR 
(solid) vmax: 3333, 3058, 2959, 2876, 2833, 2809, 1690, 1509, 1449, 1385, 1224, 
1182, 1153, 965, 825, 739. 
4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-
triazol-3-one (31): 1H NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.44 – 7.36 (m, 2H), 7.05 
– 6.98 (m, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.80 – 6.73 (m, 2H), 3.82 (m, 2H), 3.37 (t, J = 
5.0 Hz, 4H), 3.22 (m, 4H), 1.82 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 152.40, 150.78, 150.50, 134.14, 125.58, 124.03, 118.86, 116.60, 115.99, 
51.03, 49.16, 47.33, 22.05, 11.12. DART-HRMS: m/z calcd. for C21H25N5O2 [MH]+, 
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380.2087; Found: 380.2099.  IR (solid) vmax: 3344, 2969, 2934, 2893, 1466, 1378, 
1365, 1185, 1160, 1127, 1104, 950, 815. 
Dioxolane Region Intermediates. 
1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-one (38). A solution of 2-
chloro-2’,4’-dichlorophenylacetone (34) (10.0 g, 45.0 mmol), 1H-1,2,4-triazole (35) (6.2 
g, 89.0 mmol), NaHCO3 (6.1 g, 72.0 mmol), and toluene (100 mL) were heated to reflux 
(110-120°C) overnight.  The reaction vessel was then placed in the -20°C freezer for ~6 
h. The solid was filtered, dissolved in H2O, and extracted with ethyl acetate (~50 mL x 
3). The organic layer was collected, washed with brine, and dried over sodium sulfate. 
The solvent was evaporated and the remaining solid was washed with EtOAc/hexanes 
(1:1, 100 mL) resulting in a yellow solid (7.4 g, 64.2%). Characterization matched that 
previously reported.2 
(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate  (39a). DL-1,2-
isopropylideneglycerol (39) (25 g, 89 mmol) was added to 300 mL of DCM with 
molecular sieves.  Pyridine (30.5 g, 378 mmol) was then added to the mixture.  The 
solution was cooled to 0°C and TsCl (54 g, 283.5 mmol) was added portion wise over 
30 mins.  The reaction stirred overnight at room temperature.  The solution was washed 
with pH 2.0 H2O (6M HCl) and brine.  The organic layer was collected and 
concentrated. The crude product was purified via column chromatography (SiO2, 0 - 
25% EtOAc in hexanes) yielding a white solid in quantitative yield. Characterization 
matched that previously reported.3 
2,3-dihydroxypropyl 4-methylbenzenesulfonate (40). Tosylated dioxolane 39a (9.3 
g) was dissolved in 300 mL of MeOH and 30 mL of 0.5N HCl was added to the solution.  
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The reaction was stirred and heated to reflux for 5h.  The reaction was cooled to room 
temperature and neutralized to pH 7 with dropwise addition of saturated NaHCO3.  The 
solution was extracted (~150 mL x 1) with ethyl acetate and then washed with brine.  
The organic layers were collected, dried over sodium sulfate, filtered, and concentrated 
(7.7 g, 89.0%). Characterization matched that previously reported.4 
(2-((1H-1, 2,4-triazol-1-yl) methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl) methyl 
4-methylbenzenesulfonate (43). Ketone 38 (2.0 g, 7.8 mmol) and 40 (1.98 g, 8.03 
mmol) were added to a dry round bottom flask.  Anhydrous toluene (15 mL) was added 
to the reaction.  The reaction was cooled to 0°C and TfOH (2.8 mL, 31.9 mmol) was 
added dropwise with a glass syringe.  The reaction was stirred at room temperature for 
60 h.  The mixture was diluted with 50 mL of ethyl acetate and slowly dropped into a 
solution of K2CO3 (5 g) in water (40 mL).  The organic layer was separated with ethyl 
acetate (50 mL x 3).  The organic layers were combined, dried over sodium sulfate, 
filtered, and concentrated to ~70 mL EtOAc.  A solution of TsOH monohydrate (2.0 g) in 
EtOAc (13 mL) was slowly added at room temperature.  The product precipitated as the 
salt (3.6 g, 70.3%). Characterization matched that previously reported.5 
(S)-2,3-dihydroxypropyl 4-methylbenzenesulfonate. (S)-(+)-1,2-
isopropylideneglycerol was tosylated following the above procedure for 39a and was 
then subjected to the acid-mediated hydrolysis procedure for 40. Characterization 
matched that previously reported. 
(R)-2,3-dihydroxypropyl 4-methylbenzenesulfonate. (R)-(-)-1,2-
isopropylideneglycerol was tosylated following the above procedure for 39a and was 
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then subjected to the acid-mediated hydrolysis procedure for 40. Characterization 
matched that previously reported. 
Amide Region Intermediates 
General Preparation of Benzyl Protected Esters. To a solution of ester phenol (500 
mg, 3.2 mmol) in acetone (5 mL) was added potassium carbonate (anhydrous, 6 eq, 
19.2 mmol) followed by benzyl bromide (2.5 eq, 8.2 mmol).  The reaction was stirred for 
12h at room temperature.  The mixture was filtered over a celite pad, washed with 
EtOAc (30 mL), and concentrated under reduced pressure.  The crude residue was 
purified via column chromatography (SiO2, 5% EtOAc in hexanes) to afford benzyl 
protected esters. 
General Preparation of Benzyl Protected Acids. To a solution of ester (500 mg, 2.1 
mmol) in H2O: THF (3 mL: 9 mL) lithium hydroxide (monohydrate, 3 eq, 6.3 mmol) was 
added to the reaction.  The reaction mixture was refluxed for 12h at which time it was 
neutralized and then acidified with 1M HCl.  The aqueous mixture was extracted with 
EtOAc (3 x 50 mL).  The combined organic layers were dried, filtered, and concentrated 
under reduced pressure.  The crude residue was purified by column chromatography 
(SiO2, 30 – 50 % EtOAc in hexanes) to afford benzyl protected esters. 
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HSQC:	
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HSQC zoomed (3.2 to 4.8ppm): (1) HC4 (methine at C4 of dioxolane) direct correlation 
via HSQC experiment: 4.23à72.82ppm.  (2) Remaining 1H nuclei in the expanded 
region below are methylene, correlating to the diastereomeric pairs at C5 of dioxolane 
and α-carbon to tosyl group (not specified: 3.76à66.20ppm; 3.91à66.20ppm; 
4.08à69.37ppm; 4.13à69.37ppm). 
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NOESY: 
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NOESY zoomed (3.2 to 4.8ppm): (1) HC4 (methine at C4 of dioxolane) very weak to no 
NoE signal with methyl at C2 of dioxolane (2,4-correlation) in experiment: 
4.23à1.73ppm.   
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X-RAY: 
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HSQC: 
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HSQC zoomed (3.2 to 4.8ppm). (1) HC4 (methine at C4 of dioxolane) direct correlation 
via HSQC experiment: 4.50à73.73ppm.  (2) Remaining 1H nuclei in the expanded 
region below are methylene, correlating to the diastereomeric pairs at C5 of dioxolane 
and α-carbon to tosyl group (not specified: 3.61à66.56ppm; 3.85à68.62ppm; 
3.96à68.59ppm; 4.25à66.57ppm). 
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NOESY: 
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NOESY zoomed (3.2 to 4.8ppm): (1) HC4 (methine at C4 of dioxolane) moderate NoE 
signal with methyl at C2 of dioxolane (2,4-correlation) in experiment: 4.50à1.74ppm.   
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X-Ray: 
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X-RAY: 
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APPENDIX B: Selected ITZ Liposome Data 
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Encapsulation Efficiency 
 
ITZ Standard Curve + Raw Data (254 nm) 
 
 
µg/mL 250 200 150 100 50 25 20 10 5 
1 0.944 0.922 0.71 0.51 0.318 0.203 0.174 0.157 0.118 
2 0.986 1.067 0.79 0.515 0.327 0.199 0.186 0.14 0.116 
3 0.989 1.047 0.83 0.567 0.324 0.215 0.193 0.143 0.12 
 
 
 
 
 
 
 
 
 
 
 
 
y	=	0.0046x	+	0.0935	R²	=	0.9994	
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ITZ Liposomes Raw Data 
- Each liposome sample was centrifuged @ 13,000 rpm for 90 min to remove free 
drug 
- Each liposome sample (1 mL) was treated with 5% triton X-100 (1 mL), vortexed 
for 30 seconds, and heated at 60°C for 2-2.5 h 
- After heating, liposome samples were vortexed again for 30 seconds 
- Aliquot into UV-appropriate 384 well plate in triplicate 
- Read absorbance at 254 nm 
 
Sample 1 2 3 Average Normalized y = mx + b Final  
A 1.912 1.778 1.693 1.79433333 0.46666667 81.12318841 162.2463768 
B 1.776 1.772 1.729 1.759 0.43133333 73.44202899 146.884058 
C 1.922 1.412 1.725 1.68633333 0.35866667 57.64492754 115.2898551 
D 1.762 1.739 1.719 1.74 0.41233333 69.3115942 138.6231884 
E 1.656 1.73 1.738 1.708 0.38033333 62.35507246 124.7101449 
F 1.781 1.715 1.788 1.76133333 0.43366667 73.94927536 147.8985507 
G 1.648 1.743 1.732 1.70766667 0.38 62.2826087 124.5652174 
 
Controls Raw Data 
Control 1 2 3 Average 
EtOH 0.103 0.121 0.114 0.11266667 
5% Triton 2.614 2.646 2.629 2.62966667 
1:1 1.257 1.291 1.435 1.32766667 
 
Intact Liposomes 
Sample 1 2 3 
Intact empty-liposomes 0.136 0.142 0.139 
Intact ITZ-liposomes 0.311 0.403 0.364 
 
Trial 2: Concentration Confirmation for Drug Solution 
 
Sample 1 2 3 Average Normalized y = mx+b Final 
A 1.748 2.006 1.867 1.873 0.41 68.8 137.6 
B 1.872 1.912 1.807 1.863 0.4 66.6 133.3 
 
1:1 EtOH: 5% Triton Control à 1.46 
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Concentration Calculation Trial 1+ Trial 2+ Trial 3Total # of Trials = Average Absorbance 1.912+ 1.778+ 1.6933 = 1.794 Average Absorbance− Control = Noramlized Absorbance 1.794− 1.327 = 0.466 y = 0.0046x+ 0.0935 0.466 = 0.0046x+ 0.0935 0.466− 0.0935 = 0.0046x 0.372 = 0.0046x 0.3720.0046 = 80.07 = x 
x = 1 mL liposomes2 mL total volume 2x = Concentration of Drug 2 80.07 = 161.95 µg/mL 
Encapsulation Efficiency 
Original concentration 60 mg100 = 0.6 mg/mL 
Collected 7 tubes of ~50 mL of liposomes (350 mL total) 
New concentration 60 mg350 mL = 0.171 mg/mL 
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Free Drug Total Concentration µgmL− Experimental Concentration =   Free Drug 171 µgmL− 161µgmL = 8.8 µgmL 
 
Encapsulation Efficiency Total Drug− Free DrugTotal Drug  x 100% = Encapsulation Efficiency (EE) 171 µgmL− 8.8 µgmL171 µgmL =  161
µgmL171 µgmL = 0.941 x 100% = 94.2 % EE 
 
Drug Solution Concentrations 137.6 µgmL  x 1 g1,000,000 µg =  0.0001376 gmL  0.0001376 gmL  x 1,000 mL1 L = 0.1376 gL  0.1376 g1 L  x 1 mol705.6 g =  0.000195 molL =  0.195 mM 
